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ABSTRACT
COMPARISON OF THE EFFICACY OF ARV MEDICATIONS ALONE AND IN
COMBINATION WITH HERBAL MEDICATIONS IN THE TREATMENT OF HIV
AMONG NIGERIAN HIV+ PATIENTS
MAY 2017

ABDULFATTAH B. DUROJAIYE, BSN, UNIVERSITY OF MEDICINE &
DENTISTRY OF NJ (NOW RUTGERS UNIVERSITY)
BSc, UNIVESITY OF AGRICULTURE, ABEOKUTA, NIGERIA
MSc, UNIVERSITY OF IBADAN, NIGERIA
PhD, UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by Prof. Donna Zucker

Background/Purpose: There is disproportionate incidence of HIV in SubSaharan Africa in comparison to the rest of the world. Of the estimated 35.3 million
people living with HIV, Sub-Saharan Africa has the highest level of HIV infections,
accounting for 69% of global HIV infection in spite of having only 12% of the global
population. Nigeria, with over 3.2 million people living with HIV, has the second highest
HIV/AIDS burden in the world, next only to South Africa (5.6 million) whose population
is approximately one third of Nigeria’s population. According to the World Health
Organization (WHO) an estimated 80% of Africans reportedly use herbal therapies in the
treatment of many diseases (WHO, 2002). The use of herbal remedies in the treatment of
HIV has gained currency in Nigeria. The purpose of this study was to investigate the
efficacy of ARV- only therapy and a combined therapy of ARV and herbal medications
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and to also investigate the effect of these treatment modalities on HIV symptoms and
patients’ quality of life among HIV patients in Nigeria.
Methods: This is a comparative analysis study designed to compare the efficacy
of conventional antiretroviral (ART) medications with a combination therapy of ART and
herbal therapies as they are already used by Nigerian HIV patients. The World Health
Organization Quality of Life Instrument for HIV (WHOQOL-HIV BREF) and the Sign
and Symptom Check-List for persons with HIV disease (SSC-HIV BREF) questionnaires
were administered to 110 participants drawn from two groups of Nigerian HIV patients:
those using conventional antiretroviral medications only and those using a combination
of herbal remedies and conventional antiretroviral medications. Each group was
composed of 55 participants. Physiological data (CD4 counts) was also collected for the
two groups. Data generated from the study was analyzed using IBM SPSS Statistics 22
software. Both descriptive and inferential data analyses were used to analyze study
results. Descriptive statistics was used to analyze the demographic data (age, gender, and
ethnicity) while inferential statistics was used to draw conclusion from study data. Paired
Sample test was used to determine the differences between baseline CD4 counts and
post-treatment CD4 counts in both groups. Analysis of covariance (ANCOVA) was used
to statistically adjust and control the differences noted in baseline CD4 counts between
the two groups before comparative analyses of the two groups’ CD4 counts were done.
Independent t-test was used to compare the differences between ARV group and
combined group.
Findings: There was a statistically significant difference between baseline CD4
counts and post- treatment CD4 counts after treatment with ARV only and combined
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therapies. However, no statistically significant difference was noted in the overall quality
of life of patients receiving ARV only and those receiving combined therapies (p=.211).
Statistically significant difference was noted in social relationship domain (p=.028) and
health satisfaction domain (p=.049) of the WHOQOL BREF instruments. No statistically
significant difference was noted in all the sign and symptom factors evaluated except in
the fever factor (p=.003) and sore throat factor (p=.013).
Conclusion: Findings from this study have shown that a vast majority of patients
on combined therapy do so without disclosing the use of herbal remedies to their
physicians and care providers. It is expected that physicians and care providers would
incorporate this knowledge into their care model, build trusting and supportive
relationships with patients and specifically solicit information about the use of herbal
therapy in combination with ARV. This knowledge will enable physicians, nurses and
other care providers to explore possible side effects and cross reactions between ARV
and herbal remedies.
Keywords: HIV, ARV, Herbal Medications, Nigeria
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CHAPTER 1
INTRODUCTION
Background of the Study
With infection rates at an alarming level, especially in developing countries, the
HIV/AIDS epidemic is one of the greatest health challenges of our time (Short, 2006).
Globally, the United Nations estimated that 35.3 million people are living with HIV
(UNAIDS, 2013). Of this number, Sub-Saharan Africa has the highest level of HIV
infections, accounting for 69% of global HIV infection in spite of having only 12% of the
global population (UNAIDS, 2012). The global HIV epidemic has shown a decrease from
the peak record of 3.4 million new infections in 1997 to an estimated 2.7 million new
infections in 2010 (UNAIDS, 2011). This is a 21% decrease from the prevalent rate in
1997 (UNAIDS, 2011). Nigeria has a disproportionately high incidence of HIV infection
compared to other Sub-Saharan African countries (NACA, 2012).
The HIV infection has been recognized as one of the biggest challenges facing
humanity in this century (Durojaiye, 2009). The Nigerian census appears to be inaccurate
and varies widely. Nigeria, with an estimated population of 177,072,561, is the most
populated country in Sub-Saharan Africa (NACA, 2014). An estimated 3,229,757 people
are currently living with HIV in Nigeria, ranking Nigeria second among the countries
with the highest HIV/AIDS burden in the world, next only to South Africa (5.6 million)
whose population is approximately one third of Nigeria’s population (NACA, 2014). An
estimated 220,394 new infections occurred in 2013 alone (NACA, 2014).
The lacks of political will as well as the inadequate resources are factors that
continue to hamper the prevention of HIV infection in Sub-Saharan Africa (Uneke, Alo,
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Ogbu, & Ngwu, 2007). HIV infections continue to spread among highly marginalized
and stigmatized populations (Uneke et al., 2007). The first diagnosis of HIV in Nigeria
was in 1986 with the diagnosis of a 13-year-old hawker (Alubo, Zwandor, Jolayemi &
Omudu, 2002). HIV infections continue to decimate many communities in Nigeria
(Durojaiye, 2009). From the first HIV diagnosis in 1986 to year 2011, 3,459,363 HIV
infections have been recorded in Nigeria (NACA, 2012).
Nigerian women are disproportionately affected by the HIV epidemic. Over 55%
of HIV infections occur among the female population. HIV is the leading cause of death
and disease among women of reproductive age (15-49 years old) (NACA, 2012). HIV
prevalence among Nigerian women aged between 15 and 24 years is estimated to be three
times higher than among men of the same age (NACA, 2011a). In Nigeria, 58% of the
population of HIV-positive patients are women, with 55% of AIDS-related deaths
occurring among female patients (NACA, 2012).
The National HIV/AIDS and Reproductive Health Survey (NARHS) conducted in
2012 reported a national prevalence of 3.4% (NACA, 2014). There are an estimated 3.2
million HIV patients in Nigeria, which has a significant impact on the global HIV burden
(NACA, 2014). 58% of HIV-positive people in Nigeria are women (NACA, 2012). This
has resulted in a high population of pregnant HIV patients, showing a prevalence level of
4.1% infection rate among this population (pregnant women) (NACA, 2012). This has
translated into a staggering figure of 210,000 pregnant HIV patients (Afe, Adewumi,
Fagorala, Disu, Ganikale, & Audu, 2011; NACA, 2011). Annually, there are 56,000
births of HIV-positive babies in Nigeria (NACA, 2011). In 2011 the number of pregnant
women living with HIV was estimated to be 221,129 with about 17.1% (37,868) of these
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women receiving antiretroviral medications to prevent mother-to-child HIV transmission
(NACA, 2012).
Globally, Nigeria has the second largest population of HIV infection (NACA,
2014). Nigerian women are disproportionately affected with HIV infection. Nigeria still
lags behind in antiretroviral (ART) intervention and the country needs to scale up the
uptake of prevention of mother-to-child transmission (PMTCT ) in order to catch up with
global trend.
Problem Statement
With its physical and psychosocial aspects, HIV has been recognized as one of the
biggest challenges facing humanity in this century (Alubo, et al., 2002; Gilbert & Walker,
2010). The introduction of effective antiretroviral combination therapy (ART) in 1996
helped curtail the epidemic nature of HIV (CDC, 2013). ART is commonly known as
highly active antiretroviral therapy (HAART) or combination antiretroviral therapy
(cART) (Dieffenbach & Fauci, 2011). ART therapy, which involves the use of a
combination of three or more antiretroviral medications, brings a renewed hope of
effective management of HIV (Gulick et al., 1997). With the use of HAART/cART, HIV
is now considered a chronic disease with improved life expectancy (Dieffenbach &
Fauci, 2011; Palella et al., 1998). ART has revolutionized the management protocol of
HIV, increasing the hope of curtailing transmission of HIV to uninfected people. Results
from HIV Prevention Trial Network (HPTN) 052 study shows that early HIV treatment
with ART is capable of reducing HIV transmission to uninfected persons by 96% (Cohen
et al., 2011). In addition, ART is very helpful in preventing mother-to-child HIV
transmission by as high as 90% (CDC, 2006).

3

In Africa, the use of herbal remedies in treating many disease conditions is
astronomically high, with the World Health Organization (WHO, 2002) reporting the use
of herbal remedies among 80% of the population. Herbal remedies such as a-Zam have
shown significant promise in improving the CD4 and reducing viral load of HIV patients
in Nigeria. Studies have shown that a-Zam is an effective remedy in the management of
HIV symptoms such as fatigue, fever, oral thrush, weight loss, appetite, skin lesions,
malaise and diarrhea (Onifade, Jewell, & Okesina, 2011a).
Outside the conventional ART management of HIV, multiple claims of nonorthodox and traditional treatment have been made in different parts of the world
(Abalaka, 2004; Amzat & Abdullahi, 2008; Igoli, Ogaji, Tor-Anyiin & Igoli, 2005:
Kisangau, Lyaruu, Hosea, & Joseph, 2007; Oreagba, Oshikoya, & Amachree, 2011; Zou,
Liu, Wang, Li, & Liao, 2012). However, there is little evidence of the support of Nigerian
doctors and politicians for the use of herbal treatments for HIV that are prescribed by
traditional healers. If there is any alternative treatment that is effective in the treatment of
HIV/AIDS, it is imperative that the scientific world investigate such treatment protocols.
Purpose
With the increasing popularity of herbal remedies in the treatment of HIV in
Nigeria (Abalaka, 2004), nurse scientists must investigate the efficacy of herbal remedies
and compare the efficacy of herbal remedies with conventional anti-retroviral treatments.
It is important to continue to seek remedies to this deadly disease that is ravaging our
world and to seek better understanding of the experience of HIV patients using herbal
remedies in their treatment.
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Onifade et al (2011a) studied the effectiveness of a-Zam in HIV treatment by
measuring the changes in CD4 and viral load of patients during the course of a-Zam
treatment. However, Onifade et al. (2011a) did not compare outcomes of herbal treatment
with outcomes of antiretroviral medications. Additionally, the study did not seek deeper
understanding of the experience of patients during the course of the herbal therapy. The
present study is designed to bridge these identified gaps and to seek deeper understanding
of the experiences of Nigerian patients during treatment with ARV only and a combined
treatment of ARV and herbal medications.
The purpose of this study was to investigate the efficacy of ARV only therapy and
a combined therapy of ARV and herbal medications and to also investigate the effect of
these treatment modalities on HIV symptoms and patients’ quality of life among HIV
patients in Nigeria. This is a comparative analysis study designed to compare the
effectiveness of conventional antiretroviral (ARV) medications with a combination
therapy of ARV and herbal therapies as they are already used by Nigerian HIV patients.
The study consisted of two parts namely the pilot study and the actual study. The pilot
study was designed to test the reliability of the two instruments used in obtaining data
from the subjects. The actual study measured and compared the symptom experience and
quality of life of patients using ARV only and those using a combination of ARV and
herbal medications. Data collection was done using the Sign and Symptom Check-List
for persons with HIV disease (SSC-HIVrev) (Holzemer et al., 2001) and the brief version
of the World Health Organization Quality of Life instruments Instrument for HIV (WHO,
2012).
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Aims of Study
The aims of this study are:
1. To investigate the efficacy of antiretroviral (ARV) medications on the CD4 count
among Nigerian HIV patients.
2. To investigate the efficacy of a combination therapy of ARV and herbal
medications on the CD4 count among Nigerian HIV patients.
3. To investigate the difference in the CD4 counts of patients taking ARV only and
patients that take a combination of ARV and herbal medications.
4. To investigate the effects of ARV on patients’ quality of life.
5. To investigate the effects of ARV on HIV symptoms.
6. To investigate the effects of a combination of herbal therapies and ARV on
patients’ quality of life.
7. To investigate the effects of a combination of herbal therapies and ARV on HIV
symptoms.
Research Questions
The research questions for this study are:
1. How do CD4 counts differ after treatment with antiretroviral medications only?”
2. How do CD4 counts differ after treatment with a combined therapy of herbal
treatment and conventional antiretroviral medications?
3. What is the difference in CD4 counts of patient taking ARV only and those taking
a combination of herbal therapies and conventional antiretroviral medications?
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4. What is the difference in the symptom experience of patients taking ARV only
and those taking a combination of herbal therapies and conventional antiretroviral
medications?
5. What is the difference in the quality of life of patients taking only ARV, and those
taking a combination of herbal therapies and conventional antiretroviral
medications?
Significance of the Study
HIV/AIDS has reached an epidemic level, especially in developing countries
(Short, 2006). Nigeria, with a median age of 17 years, is a youthful nation of
approximately 177 million people. NACA (2012) estimates that the population of people
living with HIV/AIDS is 3.2 million. Globally, Nigeria is reported to have the second
highest incidence of new HIV infections (UNAIDS, 2012). Heterosexual relationships are
known to contribute to approximately 80 percent of new infections in Nigeria (UNAIDS,
2012), while blood transfusion and mother-to-child transmission accounts for
approximately 20% of infections. Multiple studies have shown that most pediatric HIV
infection is associated with mother-to-child transmission (MTCT), which occur during
childbearing, labor, delivery and breastfeeding (Buskens, Jaffe, & Mkhatshwa, 2007;
Coetzee, Hilderbrand, Boulle, Draper, Abdullah, & Goemaere, 2005; Futterman, Shea,
Besser, Stafford, Desmond, Comulada, & Greco, 2010; Hembah-Hilekaan, Swende, &
Bito, 2012). In 2011, the number of pregnant women living with HIV was estimated to be
221,129 with about 37,868 (17.1%) of these women receiving antiretroviral medications
to prevent mother-to-child HIV transmission (NACA, 2012). An estimated 26.5% of
HIV-infected pregnancies resulted in child infection in 2011 (NACA, 2012). The fact that
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HIV has no known cure at present and HAART is not readily available provides impetus
for people to seek cures outside the conventional health care model (Onifade, Jewel,
Okesina, Yong, Ojezele, Nwanze, Adejumo, Oladeinde, Osakue, & Uwaifo, 2011b).
UNAIDS (2012a) estimates that about 35.3 million people worldwide are living
with HIV, with over 3.2 million people living with the disease in Nigeria (NACA, 2014).
The prevalence of HIV in Nigeria has recorded a remarkable increase from the time of
the first infection in 1986. The prevalence of HIV infection among adults aged 15-49
years was reported to have increased from 1.8% in 1991 to 5.8% in 2005 (UNAIDS,
2007; USAIDS/PEPFAR, 2008). Although the trend decreased to 3.9% in year 2005
(UNAIDS, 2007), an estimated 3.2 million Nigerians are still living with HIV (NACA,
2014).
HIV infection continues to decimate many communities in Nigeria (Durojaiye,
2009). The number of weekly cases of HIV in many secondary health facilities in Nigeria
averages 20 per week, and AIDS-related disorders account for up to 40% of hospital
admission (Soyinka, 1998). The transmission of HIV continues to increase at an alarming
rate. According to Alubo et al (2002), up to 30% of the hospitalized patients in Otukpo
General Hospital (OGH) in Benué State, Nigeria were admitted with AIDS-related
conditions.
A similar trend was recorded in a Catholic-run diagnostic center, where 29 out of
250 voluntary blood donors tested positive for HIV in 1996, and AIDS-related deaths
averaged 2 per week (Alubo et al., 2002). There is high discrimination and stigma
attached to HIV infection in Nigeria. This is because the mode of transmission of HIV in
Nigeria is predominantly through heterosexual means (UNAIDS, 2012) and there is a
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general perception that people living with AIDS (PLWA) are people of low morals who
have brought HIV/AIDS upon themselves (Alubo et al., 2002). These people are
generally regarded as “loose” people who deserve neither sympathy nor empathy (Alubo
et al., 2002).
HIV infections have a multitude of symptoms that can manifest in different ways,
and in an extremely unpleasant manner. Symptoms associated with HIV include fatigue,
pain, fever, and memory problems (Siegel, Lekas, Schrimshaw, & Brown-Bradley,
2011). Other commonly reported HIV-related symptoms are headaches, herpes zoster,
throat pain, and arthralgia (Singer, Zorilla, Fahy-Chandon, Chi, Syndulko & Tourtellotte,
1993). A comprehensive HIV symptom list is adequately captured in the Sign and
Symptom Check-List for persons with HIV disease (SSC-HIVrev) (Holzemer, Hudson,
Kirksey, Hamilton & Bakken, 2001). The HIV symptoms cluster identified by Holzemer
et al (2001) in the instrument are: fatigue, fear, fever, GI upset, shortness of breath, sore
throat, numbness, headache, rectal itch, bruising/bleeding, body changes and
gynecological-related problems for women. Posttraumatic and depressive symptoms are
also known to be associated with diagnosis of HIV (Klis, Velding, Gidron, & Peterson,
2011).
The debilitating nature and multiplicity of HIV symptoms are known to impact
significantly on patients’ quality of health. According to Fatiregun, Mofolorunsho &
Osagbemi (2009) quality of life is a function of the overall well-being of patients, which
can foster happiness and contentment. The state of health could influence quality of
health. The WHO’s (2012) conceptualization of quality of life within the context of
individual culture and value system provides a unique definition of quality of life. Quality
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of life is individualistic in nature. Factors such as religion, financial need/status, culture,
educational level, culture and health will influence an individual’s perception of quality
of health. Health is a major determinant of quality of life. Because of the centrality of
health to quality of life, the quality of life of HIV patients could be used as a way to
evaluate the effectiveness of HIV treatment and/or management.
According to the World Health Organization (WHO) herbal remedies have been
used throughout the world to treat many ailments (WHO, 2002). An estimated 80% of
Africans reportedly use herbal therapies in the treatment of many diseases (WHO, 2002).
Herbal therapy is used either as a complementary treatment or as an alternative treatment
to conventional or orthodox medicine in treating different disease conditions (Onifade et
al., 2011a; Patel, Bessong & Liu, 2011). Herbal remedies have been found to inhibit
some steps associated with HIV replication (De Clereq, 2000; Kong, Goh, Chia, & Chia,
2003). Herbal remedies have shown to be effective in reducing viral load and increasing
CD4 counts (Onifade et al., 2011a). According to Matthee, Wright & Konig (1999)
alkaloid-derived herbal remedies such as Ancistrocladus korupensis, which is extracted
from the tropical liana plant, inhibit reverse transcriptase and HIV-induced cell fusion.
Dhamaratne, Tan, Marasinghe & Pezzuto (2002) reported that Coumarin herbal remedy
in the form of canolides extracted from a tropical forest tree, Calophyllum lanigerum,
was classified as a potent non-nucleoside reverse transcriptase inhibitor. Coumarin from
plant sources and their analogs (i.e. synthetic coumarins) have shown to be potent
nonnucleoside RT-inhibitors, or inhibitors of HIV-integrase, or HIV-protease (Kostova,
2006).
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Historically, herbal therapies have recorded groundbreaking successes, as in the
clinical success of quinine and quinidine isolated from the Cinchona tree bark, and
artemisinin from Artemisia annua, in the treatment of malaria (Igoli, Ogaji, Tor-Anyiin &
Igoli, 2005). Ufo opioko (Ageratum conyzoides Linn) is an herbal therapy that is
reportedly widely used in treating HIV in Nigeria (Igoli et al., 2005). The efficacy of Ufu
opioko (Ageratum conyzoides Linn) in the treatment of HIV is yet to be scientifically
established.
Onifade et al (2011a) studied the use of herbal therapy with a-Zam and showed
that a-Zam is an effective anti-HIV agent as it resulted in significant increase in CD4
counts and significant decrease in viral load. This study showed no remarkable harmful
drug interaction with Highly Active Anti-Retroviral Therapy (HAART). Onifade et al
(2011a) study did not carry out comparative analysis of the efficacy of a-Zam with the
efficacy of HAART. The study only investigated the efficacy of a-Zam on the
physiologic (CD4 and viral load) aspect of HIV management. The effects of a-Zam on
HIV symptoms were not investigated in detail. These obvious knowledge gaps
necessitate the investigation of the impact of herbal therapies and HAART on HIV
symptoms and patients’ quality of life.
Operational Definitions of Concepts or Terms
The meaning of Nigeria and Nigerians as used in this review need to be
operationally defined for proper understanding of these two concepts. Nigeria refers to
the geographical location of the country in West Africa. This excludes all the foreign
embassies and high commissions of the country that are located all over the world. Also,
the term Nigerians refers to those individuals that were born in Nigeria by Nigerian
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parents and are currently living permanently in Nigeria. For the purpose of this study, all
diasporic Nigerians were not classified as Nigerians. This differentiation is necessary
because residency abroad may introduce different dynamics that may not be prevalent in
Nigeria’s geographical space.
For the purpose of this study, WHO’s (2000) definition of herbal
medicines/therapies provided an operational definition. Herbal therapies are herbs, herbal
materials, herbal preparations and finished herbal products whose active ingredients
include plants parts or plant materials, or combination (WHO, 2000). For the purpose of
this study, herbal homes are local traditional healer homes where herbs, herbal materials,
herbal preparations and finished herbal products are used in treatment of different disease
conditions.
Theoretical Framework
The theory of symptom management (TSM) (Dodd, Miaskowski, & Lee, 2004;
Humphreys et al., 2008) provided the theoretical framework for this study. Symptom
management is central to the management and treatment of HIV. The TSM helped to
adequately conceptualize symptoms and helped to develop pragmatic means of
eliminating or ameliorating these symptoms.
Concepts of TSM
The three major concepts of the TSM are symptom experience, symptom
management strategies and symptom status outcomes. These concepts are embedded
within the nursing dimensions of person, environment and health and illness (Humphreys
et al., 2008).
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Symptom Experience
This is described as “a simultaneous perception, evaluation and response to a
change in one’s usual feeling” (Humphrey’s et al., 2008, p. 147). It is known that the
response to symptom experience is a function of the severity of the symptom as well as
the context (environment) of the experience (Humphreys et al., 2008).
Symptom Management Strategies
These are the pragmatic ways to reduce the frequency of the symptom experience
or minimize the severity of symptom or ameliorate the distress associated with the
symptom experience (Portenoy et al., 1994). Symptom management strategies require an
aggregate information on the who (i.e. the individual patients), how (dose), where
(whether home or health care setting), when (timing of intervention) and what (type of
intervention) are involved in the interventional protocols employed in symptom
management (Humphreys et al., 2008). The combination of these strategic management
approaches is capable of having profound effects on the management outcomes
(Humphreys et al., 2008).
Symptom Status Outcomes
These are objective, measurable outcomes resulting from symptom management
strategies. Outcomes could be reduction in the intensity, or frequency or distress level of
the symptom, resulting in improved physical and psychological well being. Other
possible outcomes could be early return to optimum functional level, cost containment
and/or early discharge from the healthcare setting (Humphreys et al., 2008).
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Relationships Between the Concepts of TSM
The three concepts of the TSM are known to have simultaneous interactions with
each other. The symptom experience is a function of the strategies employed in symptom
management and the outcomes of such management strategies. According to the authors
of the theory, “the symptom experience is conceptualized as influencing and being
influenced by both symptom management strategies and symptoms status outcomes. As
individuals become aware of symptoms, initiate strategies, and assess symptom
outcomes, their symptom perception is affected” (Humphreys et al., 2008, p. 147).
The reciprocal interaction between these three concepts is a continuous process
until the resolution or stabilization of symptoms. The effects of non-adherence to
management strategies are shown by the broken arrows between symptom management
strategies and symptom status outcomes components of the TSM (in Appendix 1). Nonadherence could adversely affect the symptom status outcome. Factors such as the
complexity or difficulty of symptom management strategies and the factors embedded in
the nursing dimension of person, environment and health and illness could impede
adherence to symptom management protocol (Humphreys et al., 2008). The bi-directional
arrows seen in Appendix 1 indicate a simultaneous interaction among the three concepts
of the TSM. Non-adherence to management strategies could result when treatments or
interventions are too challenging, are not followed, or are not followed consistently.
Adequacy of TSM for HIV Symptom Management
The TSM has shown great promise in explaining, conceptualizing and
contextualizing symptom experiences among HIV patients. The symptom experience is
conceptualized as affecting and being affected by both symptom management strategies
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and symptoms status outcomes (Humphreys et al., 2008). The theory was used to explore
the association between symptom experience and the use of behavioral response (prayer)
in the management of HIV-related symptoms of fatigue, nausea, depression and anxiety
among HIV-positive African American patients (Coleman et al., 2006). To investigate the
applicability of study results from the United States to Taiwan, Tsai, Hsiung, & Holzemer
(2002) used the TSM and concluded that symptom management strategies had not been
fully explored. The theory of symptom management has played a useful role in
explicating the experience of depressive symptoms among HIV-positive patients (Eller et
al., 2005) and in testing the effectiveness of symptom management information manuals
among Taiwanese patients (Tsai, Holzemer, & Leu, 2005). Voss, Dodd, Portillo, &
Holzemer (2006) were able to provide extensive explication of the symptom of fatigue in
HIV patients by clearly integrating the three components of the TSM: symptom impact,
symptom management & symptom outcomes. The TSM has been hailed as one of the
prominent theories for enhancing understanding in nursing research on fatigue associated
with HIV (Voss et al., 2006).
The central constructs of the TSM provided a suitable framework for this study.
Patients’ perception of their quality of life is a function of the effective symptom
management strategies employed. In the context of this study, symptom management
strategies are related to whether the patients are taking herbal remedies, or HAART, or a
combination of both. The symptom management strategies will also influence patients’
experience of the symptoms. Conversely, the symptom status outcomes will be dependent
on the combination of symptom management strategies used. Similarly, the experience of
symptom and the perception of symptoms will be dependent on the outcome of the
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management protocol. The three concepts of the TSM perfectly provide pragmatic
explanation for this study.

Hypothesis
This study seeks to compare the efficacy of conventional antiretroviral
medications with a combined therapy of ARV and herbal remedies in the treatment of
HIV among Nigerian HIV patients. This study is predicated on certain hypotheses. The
hypotheses for this study are as follows:
1. There is no significant difference in the quality of life of HIV patients using a
combined therapy of ARV and herbal medications and those using conventional
antiretroviral medications only,
2. There is no significant difference in the symptom improvement of HIV patients
using a combined therapy of ARV and herbal medications and those using
conventional antiretroviral medications only, and
3. There is no significant difference in the improvement in CD4 counts of HIV
patients using a combined therapy of ARV and herbal medications and those
using conventional antiretroviral medications only.
If these hypotheses are true, the use of a combined therapy of ARV and herbal
medications would hold great promise in HIV treatment in Nigeria and in other resource
constraint countries. It is known that accessibility to ARV medication is still grossly
limited in Nigeria. Likewise, in spite of the wide availability of ARV medications in
western countries, ARV is still not readily available in Nigeria and other Sub-Saharan
African countries. Also high proportions of patients are using herbal medications as
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complementary medication to ARV. A comparable treatment outcome between patients
using a combined therapy of ARV and herbal medications and those using ARV
medications only would mean that herbal remedies could be safely used concomitantly
with ARV. This would greatly help many HIV patients in Nigeria who use herbal
remedies. With this information, Nigerian authorities could concentrate efforts on
improving herbal treatment of HIV through research and appropriate data gathering to
continually evaluate herbal therapies.
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CHAPTER 2
LITERATURE REVIEW
Introduction
The purpose of this literature review is to seek insight into HIV and the use of
herbal remedies in the treatment of HIV in Nigeria. This review examines current trends
in the treatment of HIV and reviews the epidemiology of HIV in Sub-Saharan Africa and
Nigeria and the use of herbal therapies in the treatment of HIV. The review also
synthesizes information about the vertical transmission of HIV in Sub-Saharan Africa,
with special attention on the Nigerian situation. Stigmatization and discrimination of HIV
patients will also be discussed.
The literature review of HIV treatment modalities is conducted with special
emphasis on the use and safety of herbal remedies in HIV treatment. Many research
works have been carried out on the use of herbal remedies in the treatment of HIV
(Dhamaratne, Tan, Marasinghe & Pezzuto, 2002; Hodgson & Rachanis, 2002; Igoli,
Ogaji, Tor-Anyiin & Igoli, 2005; Kisangau, Lyaruu, Hosea, & Joseph, 2007; Kostova,
2006; Langlois-Klassen, Kipp, Jhangari, & Bubaale, 2007; Matthee, Wright & Konig,
1999; Mills, Cooper, Seely & Kanfer, 2005; Onifade, Jewell, & Okesina, 2011a;
Orisatoki & Oguntobeju, 2010; Patel, Bessong & Liu, 2011). Specifically, literature on
the use of the herbal remedy a-Zam in HIV treatment were reviewed.
Epidemiology of HIV
The advent of HIV in 1981 heralded the era of serious global health challenges.
The scourge of HIV was first noticed in a San -Francisco clinic when a group of
homosexual men presented with symptoms of rare opportunistic infections, which

18

included Pneumocystic carinii pneumonia, extensive mucosal candidiasis and multiple
viral infections (Gottlieb et al., 1981). The first presentations of HIV symptoms were
noted mainly in homosexual men and drug abusers (Masur et al., 1981). Subsequent
evaluations of these men revealed that they were suffering from severe immune
deficiency, which led to the tagging of the disease as acquired immune deficiency
syndrome (AIDS) (Costin, 2007), while the virus causing this syndrome was named
human immunodeficiency virus (HIV) in 1983 (Levy, 1993). At present, the majority of
people infected are between the ages of 15-40 and are the most productive, agile and
sexually active group in a society (Amzat & Abdullahi, 2008).
HIV infection is usually characterized by three distinct clinical stages: acute
viremia, a latency phase which could be of variable duration, and a classification of
clinical AIDS (Costin, 2007). During the acute viremia stage the virus can be detected in
the blood of patients (Daar, Moudgil, Meyer, & Ho, 1991; Zhu et al., 1993). Following
the initial viremia peaks, the level of virus in the blood declines to a very low to nondetectable level, signifying the latency phase (Coffin, 1995; Perelson, Newmann,
Markowitz, Leonard, & Ho, 1996; Wei et al., 1995). This stage is characterized by high
turnover of CD4+ T cells with accompanying HIV virion production (Ho et al., 1995;
Piatak et al.., 1993). During this stage the CD4+ T cells begin to decline (Costin, 2007;
Esbjournsson et al., 2012). Clinical diagnosis of AIDS occurs when the CD4+ T cell
count falls below 200cells/mm3, and when a patient presents with at least one
opportunistic infection such as Pneumocystic carinii (Costin, 2007). This is the final stage
of immune compromise leading to high susceptibility to secondary infections. This may
manifest as rare cancers such as Kaposi’s sarcoma and/or neuropathy (Costin, 2007;
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Esbjournsson et al., 2012). The progressive manifestation of opportunistic infection is a
result of the dysfunctional immune system (Esbjournsson et al., 2012)
HIV is known to contain reverse transcriptase and belongs to a subgroup of
retroviruses known as the lentiviridae (Arnaout et al.., 1999; Fahey et al.., 1998; Garry,
1989; Levy, 1993). The infection’s latency stage could last for a considerably long time,
sometimes more than 20 years (Costin, 2007). During the latency phase, HIV continues
to have destructive effects on immunological and neurological systems of the body
(Costin, 2007).
There are two types of retroviruses (lentiviruses) namely pandemic HIV type 1
(HIV-1) and HIV type 2 (HIV-2) (De Silva, Tienen, Rowland-Jones & Cotton, 2010;
Esbjornsson et al.., 2012; Nyamweya et al.., 2013). These retroviruses are closely related.
Both types are transmitted in similar ways, exhibit similar cellular targets and manifest
similar AIDS-related opportunistic infections (Di Silva, et al., 2010; Esbjornsson et al..,
2012). HIV-2 is predominantly restricted to West Africa, but an increasing number of
cases have been seen in the U.S, Europe and India (Campbell-Yesufu, & Gandhi, 2011;
Thiébaut et al., 2012). In comparison to HIV-1, the main characteristics of HIV-2 are that
it has lower transmission rates, a longer latency period, slower reduction in CD4+ T cell
count and lower mortality rates (De Silva et al., 2010; Esbjornsson et al., 2012). HIV-1 is
reported to have been introduced to human through multiple interspecies transmission
from simian immunodeficiency virus in chimpanzees, while HIV-2 is thought to have
been introduced to human through sooty mangabeys (De Silva et al., 2010; Esbjornsson
et al., 2012).
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Globally, there are approximately 34 million people living with HIV, the virus
which causes AIDS (UNAIDS, 2013). New cases of HIV infection continue to be
recorded in all regions of the world. However, 95% of new infections happen in
individuals that live in low-and middle-income countries, especially in Sub-Saharan
Africa (UNAIDS, 2013). Globally, there were over 700,000 fewer new HIV infections in
2011 compared to in 2001 (UNAIDS, 2012). Nonetheless, large improvements have been
recorded in different parts of the world, including Sub-Saharan Africa. Africa has
reduced AIDS-related death by one third in recent years (UNAIDS, 2012). The global
HIV epidemic appears to be in check, with a record 50% reduction in new HIV infection
in low-and middle-income countries between 2001 and 2011. However, there still exists
sharp disparities in the incidence of HIV infection in low-income countries as compared
with the industrialized nations of the world.
HIV in Sub-Saharan Africa
The United Nations estimated that 34 million people were living with HIV at the
end of 2011 (UNAIDS, 2012). Of this number, Sub-Saharan Africa has the highest level
of HIV infection, accounting for a disproportionate 69% of global HIV infection despite
having only 12% of the global population. On average, 1 in every 20 adults (amounting
to 4.9% of the population) in Sub-Sahara Africa live with HIV (UNAIDS, 2012).
There is a disproportionate impact of HIV on women and children, who continue
to experience high rates of new infection, with attendant HIV-related illness and death
(WHO, 2011). Sub-Saharan Africa has been greatly hit by the HIV epidemic. Of the
children who contracted HIV in 2011, 90% live in Sub-Saharan Africa. Also, 92% of the
global HIV-positive pregnant women live in Sub Saharan Africa (UNAIDS, 2012). In
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2011, 59% of women living with HIV in Sub-Saharan Africa received ART medication
during pregnancy and delivery (UNAIDS, 2012).
HIV in Nigeria
Nigeria, with an estimated population of 177,072,561, is the most populated
country in Sub-Saharan Africa (NACA, 2014). An estimated 3.4 million people are
infected with HIV in Nigeria, ranking Nigeria third among the countries with the highest
HIV/AIDS burden in the world, next only to India and South Africa (NACA, 2012). The
lack of political will and inadequate resources are factors that continue to hamper the
prevention of HIV infection in Sub-Saharan Africa (Uneke et al., 2007).
HIV was first noted in Nigeria in 1986 with the diagnosis of a 13-year-old hawker
(Alubo et al., 2002), and continues to decimate many communities in Nigeria (Durojaiye,
2009). From the first HIV diagnosis in 1986 to year 2011, 3,459,363 HIV infections have
been recorded in Nigeria (NACA, 2012), with 388,864 new infections recorded in 2011
alone (NACA, 2012). Despite declines in global HIV prevalence, incidence has increased
in Nigeria between 2008 and2012. Table 1 below shows the epidemiology of HIV in
Nigeria. Table 1 shows the overall HIV statistic while table 2 shows the HIV statistic for
year 2010 and 2011 alone. Although table 1 shows an increase in total HIV population,
there was actually a decrease in new infection rate in 2011 as shown in table 2. This
decline is a result of increase awareness and proactive efforts on the part of all the
stakeholders in the country.
HIV among Women in Nigeria
As shown in Table 2, Nigerian women are disproportionately affected by the HIV
epidemic. Over 55% of HIV infection occurs in female population. HIV is the leading
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cause of death and disease among women of reproductive age (15 and 49 years) (NACA,
2012). HIV prevalence among Nigerian women aged 15 and 24 is estimated to be three
times higher than among men of the same age (NACA, 2011a). In Nigeria, 58% of the
population of HIV-positive patients are women, with 55% of AIDS related deaths
occurring among female patients (NACA, 2012).
In 2011 the number of pregnant women living with HIV was estimated to be
221,129 with about 17.1% (37,868) of these women receiving antiretroviral medications
to prevent mother-to-child HIV transmission (NACA, 2012). This is a 45% increase in
ARV treatment for pregnant women from the 2010 figure. An estimated 26.5% of HIV
infected pregnancies resulted in child infection in 2011 (NACA, 2012). Only about 4.7%
of antenatal care (ANC) facilities in Nigeria provide prevention of mother-to-child
transmission (PMTCT) services (WHO, 2011). In 2011, less than 18% of pregnant HIV
infected women received ARVs for PMTCT while 11% of babies born in 2010 to HIV
infected mothers received ARVs for PMTCT (NACA, 2012). Only 4% of babies born to
HIV patients were tested for HIV within 2 months of life (WHO, 2011). In Nigeria
prophylactic maternal triple ARV is the treatment of choice for HIV-infected pregnant
women (NACA, 2012).
Mother-to-Child Transmission in Sub Saharan Africa
Multiple studies have shown that most pediatric HIV infection is associated with
mother-to-child transmission (MTCT), which occurs during childbearing, labor, delivery
and/or breastfeeding (Buskens, Jaffe, & Mkhatshwa, 2007; Coetzee, et al., 2005;
Futterman, et al.., 2010; Hembah-Hilekaan, Swende, & Bito, 2012). Pregnant women
living with HIV have a high risk of passing the infection to their babies if no intervention
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is initiated to prevent such transmission (De Cock et al., 2000). In the absence of any
intervention, the risk of transmission could be as high as 15-30% (Anoje et al., 2012).
However, a combination of approaches could help reduce the risk of MTCT of HIV to
less than 2% (De Cock et al., 2000). Interventions that could reduce incident of MTCT of
HIV include prophylactic administration of antiretroviral (ARV) during pregnancy and
labor and to the infant in the first few weeks of life, through an obstetrical intervention
which includes elective caesarean delivery of the baby before the onset of labor and
rupture of membranes. Safe infant feeding practices could help in the prevention of
mother-to-child infection (Hembah-Hilekaan et al., 2012).
Some of the interventions to prevent MTCT, such as the avoidance of breastfeeding, may have cultural implications that make its acceptance difficult in Sub Saharan
Africa. Similarly, the use of elective caesarean may not be safe nor available in resourceconstrained communities in Sub Saharan African (De Cock et al., 2000). Prevention
methods tend to focus on administration of ARV regimen from the third trimester of
pregnancy (Chabikuli et al., 2013), which is reported to reduce the risk of transmission
during pregnancy and childbirth to between 2-4% (Chabikuli et al., 2013). In response to
the need for effective prevention regimen, different countries in Sub Saharan Africa are
adopting different protocols to prevent MTCT.
Mother-to-child transmission is responsible for the high prevalence of pediatric
HIV in Sub-Saharan Africa (Coetzee et al., 2005; Koo, Makin, & Forsyth, 2013;
Kouanda et al., 2010). Of the two million global pediatric HIV infections, Sub-Saharan
Africa accounts for 90% of infections (Kouanda et al., 2010). A UNAIDS (2008)
estimate shows that over 90% of pediatric infections occur during pregnancy, birth or
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breastfeeding. As a result of effective medical intervention in most industrialized
countries, the rate of perinatal HIV transmission has decreased to 2% or less (Ghanotakis
et al., 2012; Kouanda et al., 2010). This level was achieved through a combination of
novel antiretroviral therapy, obstetrical intervention and re-definition of infant feeding
that emphasize the use of infant formula and exclusion of breastfeeding for HIV-positive
mothers (Cooper et al., 2002). However, the prevalence of MTCT in Sub-Saharan Africa
is still as high as 40% pediatric infection rate among HIV-positive women (Kouanda et
al., 2010).
Unlike the prevailing situation in high-income countries where the incidence of
mother-to-child transmission of HIV has been almost completely eliminated, there is still
high incidence of mother-to-child transmissions of HIV in Sub-Saharan Africa
(UNAIDS, 2006). The effective voluntary testing and counseling services, increased
access to antiretroviral medications, safe delivery practices and widespread availability
and safe use of breastfeeding substitute have reduced the incidence of MTCT of HIV in
high-income countries (UNAIDS, 2011). In spite of the improvement in the western
world in the prevention of mother-to-child transmission of HIV, Sub-Saharan African
countries still record high rates of pediatric HIV infection (Stringer et al., 2008). The lack
of medical infrastructure, shortage of PMTCT services and shortage of medical personnel
result in ineffective coordination of PMTCT services in Sub-Saharan African countries
(Stringer et al., 2008).
Contrary to what is obtainable in developed countries of the world, most SubSaharan African countries have limited access to ARV regimens. Similarly, there exists
scarce access to elective Caesareans or safe alternatives to breastfeeding (Stringer, et al..,
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2008). This situation is also compounded by a lack of evenly distributed basic antenatal
services. The resultant effect of this situation is the disproportionately high incidence of
mother-to-child transmission of HIV in Sub Saharan African.
The 2009 HIV estimate among pregnant women in eastern and southern Africa
was 750,000 (Kasenga et al., 2007). Sub-Saharan Africa accounts for about 90% of the
incidence of MTCT (UNAIDS, 2006). Figures 1 and 2 below show the number of adults
and children receiving and eligible for ARV therapy and estimated coverage in low-and
middle-income countries by region in December 2010.

Figure 1: Number of Adults and Children Receiving and Eligible for ARV Therapy and
Estimated Coverage in Low- and Middle-Income Countries by Region in December
2010.
Data Source: UNAIDS (2011). Retrived from www.unaids.org
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Figure 2: Number of Adults and Children Receiving and Eligible for ARV Therapy and
Estimated Coverage in Low- and Middle-Income Countries by Region in December
2010.
Data Source: UNAIDS (2011). Retrived from www.unaids.org
For both figures 1 and 2
Receive = Number of people receiving ARV therapy
Need = Estimated number of people in need of ARV therapy
The trend in the availability of PMTCT in low-and middle-income countries, by
geographical region in 2010 is depicted in figures 3 and 4.
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Figure 3: Estimated Number of Women Living with HIV Needing and Receiving ARV to
Prevent New Infection Among Children, and Excluding Single-Dose Nevirapine in Lowand Middle-Income Countries, by Geographical Region in 2010.
Data Source: UNAIDS (2011). Retrived from www.unaids.org
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Figure 4: Estimated Number of Women Living With HIV Needing and Receiving ARV
to Prevent New Infection Among Children, and Excluding Single-Dose Nevirapine in
Low-and Middle-Income Countries, by Geographical Region in 2010.
Data Source: UNAIDS (2011). Retrived from www.unaids.org
For both figures 3 and 4
A = Estimated number of pregnant HIV women in need of ARV
B = Number of pregnant HIV women on ARV
Figure 5 and Table 3 show the estimated prevalence of HIV among women and
the general population and PMTCT services in selected Sub-Saharan African countries.
As shown in Figure 6, PMTCT services in Nigeria were as low as 3.6% in 2010
(UNAIDS, 2011). The figure compares the HIV prevalence in the general population and
among pregnant women in 2009 with the percentage of PMTCT services in 2010. Nigeria
was seen to underperform at 4.7% in PMTCT services when compared with South Africa
(94%), Tanzania (90.4%), Kenya (92.5%), Mozambique (86%), Uganda (81%), and
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Zimbabwe (74%) (UNAIDS, 2010). This poor performance requires positive action on
the part of Nigerian authorities.

Figure 5: Estimated Prevalence of HIV Among Women and General Population and
PMTCT Services in Selected Sub-Saharan African Countries
Sources: UNAIDS (2010)-UNAIDS Report on the Global AIDS Epidemic; UNICEF
(2009). Prevention of Mother-to-Child Transmission (PMTCT) of HIV.

Figure 6 shows the percentage of women receiving ARV therapy to reduce HIV
transmission during pregnancy, percentage of eligible children younger than 15 years old
receiving ARV therapy in 2010 and the percentage of HIV testing among pregnant
women in 2010. From this figure it could be seen that South Africa (95%) is
outperforming other sub-Saharan African countries in the percentage of women receiving
ARV therapy to reduce HIV transmission during pregnancy (UNAIDS, 2010). Similarly,
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South Africa (95%), Zambia (94%), and Zimbabwe (90%) have a higher percentage of
HIV testing among pregnant women in 2010 (UNAIDS, 2010). South Africa (58%) also
has the highest number of eligible children younger than 15 years old receiving ARV
therapy in 2010 as shown in table 4.

Figure 6: Percentage of Women and Children Receiving Antiretroviral Therapy in
Selected Sub-Saharan African Countries for the Prevention of Mother-to-Child HIV
Transmission
Blue=% of eligible children younger than 15 years old receiving ARV therapy in
2010.
Red=% of women receiving ARV therapy to reduce HIV transmission during
pregnancy 2010.
Green=% of HIV testing among pregnant women in 2010.

31

MTCT in Nigeria
Data shows that among 388,864 new HIV infections which occurred in Nigeria in
2012, only about 56,000 new HIV clients were put on ARVs (NACA, 2013). Nigeria is
lagging behind countries such as South Africa and Ghana in ARV coverage. South
Africa, which has about 350,000 new HIV infections annually, puts about 277,000 HIVpositive persons on ARVs annually. In 2012 PMTCT coverage in Nigeria was about
18%, which was one of the lowest in Sub-Saharan Africa. In contrast, South Africa and
Ghana achieved over 95% and over 75% PMTCT coverage respectively (NACA, 2013).
About a quarter of all babies born with HIV in the world are Nigerians (NACA, 2013).
Pediatric ARV coverage and treatment is about 13% in Nigeria. This is considerably low
when compared with South Africa’s coverage of 88% (NACA, 2013). To improve on its
PMTCT coverage and ARV treatment, Nigeria is in the process of decentralizing its
PMTCT and ARV treatments to primary care centers (NACA, 2013).
In 2011, an estimated 210,000 pregnant women (15+) were living with HIV in
Nigeria. Only 13% of these women were tested for HIV. Only 22% of pregnant HIV
patients received ARV treatment in 2009. The estimated number of children (0-14) living
with HIV in 2009 was 360,000 and prophylactic ARV was given to only 8% of HIVexposed infants (UNICEF, 2010). The Global HIV/AIDS initiative, Nigeria (GHAIN) is
at the forefront in providing facilities for PMTCT services in Nigeria (Chabikuli et al.,
2013). GHAIN is supporting PMTCT programs in 157 sites across the 36 states of the
Federation. The primary focus of the government is to incorporate PMTCT treatment into
primary health care system in Nigeria (NACA, 2011).
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As a result of the emergence of the HIV epidemic in Nigeria, a national health
sector-based response was established in 1986 with the Federal, State and Local
Government Area structures driving the response (FMH, 2010). In 2000, a national
multisectoral response was put in place to combat HIV in Nigeria. This includes the
establishment of a Presidential Council on AIDS (PCA) and National Action Committee
on AIDS (NACA) to drive the response. Also, state Action Committees on AIDS
(SACA) and Local Government Action Committees on AIDS (LACA) were also
established (FMH, 2010). Several PMTCT sites were established in all major federal
health care facilities (Ugboaja, 2011). These interventions are guided by the appropriate
policies namely the National HIV/AIDS Policy, HIV and AIDS Emergency Action Plan
(HEAP) and National Strategic Framework (NSF).
Prophylactic treatment for HIV-positive women in Nigeria include:
•

Co-trimoxazole 960mg once daily or every three days given to women with CD4
cell counts below 200cells/ul,

•

Sulfadoxine-pyrimethamine for malaria and

•

Iron, folate and multivitamin supplement are given to HIV-positive patients.
All infants born to HIV-positive mothers are given post-exposure prophylaxis.

This includes a single dose of Nevirapine (NVP) of 2mg/kg within 72 hours and
Zidovudine (ZDV) 2mg/kg twice daily for one week. A single dose of NVP 2mg/kg stat
within 72 hours is given to infants where ZDV is not available (FMH, 2010).
In summary, Nigeria is reported to have 3.6% HIV prevalence. In Nigeria there is
an estimated 3.5 million HIV patients, which has a significant impact on the global HIV
burden (UNAIDS, 2010). 58% of HIV-positive people in Nigeria are women. This has
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resulted in a high population of pregnant HIV patients, showing a prevalence level of
4.1% infection among pregnant women. This has translated into a staggering figure of
210,000 pregnant HIV patients (Afe et al., 2011; NACA, 2011). Annually, there are
56,000 births of HIV-positive babies in Nigeria (Oliver, et al., 2012). The uptake of
interventions for preventing mother-to-child HIV transmission is low in Nigeria in spite
of the staggering prevalence of pediatric HIV infection (Olugbenga-Bello et al., 2012).
The national target in Nigeria is to achieve a 90% reduction in the mother-to-child HIV
transmission by 2015 (NACA, 2011).
PMTCT Services in Nigeria
Skilled personnel deliver only 39% of births in Nigeria. Traditional birth
attendants (TBAs) or relatives deliver 41% of births while the remaining 20% are
unassisted deliveries (FMOH, 2010). Nigerian health care system is organized under a
three-tier arrangement composed of primary, secondary and tertiary health facilities. In
2003 provision of PMTCT services were initially restricted to 11 tertiary health facilities
in the country (FMOH, 2010). The gradual scale-up of PMTCT services has brought the
availability of PMTCT services to 640 facilities. In all, the formal health sector has about
22,726 health care facilities. Grossly limited number of PMTCT or HCT (HIV counseling
and testing) services is available in these facilities. Of the 22,726 health care facilities,
only 63 tertiary, 482 secondary and 473 primary health facilities are providing PMTCT or
HCT services (FMOH, 2010). PMTCT services are available in tertiary, secondary,
primary, private and faith-based health facilities across the country while the government
is striving to achieve a target of at least 90% PMTCT uptake by 2015 (NACA, 2011a).
The policy thrust of the government is to decentralize PMTCT services from tertiary and
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secondary facilities to primary care facilities to ensure accelerated scale-up towards
elimination of mother-to-child transmission of HIV (FMOH, 2010).
In 2010 the Nigerian government set the following goals for PMTCT program;
•

At least 90% of all HIV-positive pregnant women and breastfeeding
infant-mother pairs receive ARV prophylaxis by 2015.

•

At least 90% of all HIV exposed infants have access to early infant
diagnosis services by 2015.

•

At least 90% of pregnant women requiring ART for their own health
receive life long ART.

•

At least 90% of all pregnant women have access to quality HIV
counseling and testing by 2015.

•

At least 90% reduction in unmet need for family planning among women
with HIV by 2015.

•

At least 50% reduction in HIV incidence among 15-49 years old women
by 2015.

(FMOH, 2010 P. 17)
Due to poor implementation, the ministry of health has unequivocally admitted that
Nigeria will not be able to achieve the above goals by 2015 (FMOH, 2012).
Stigmatization and Discrimination of HIV Patients
HIV infection has physical as well as psychosocial aspects. There is still a heavy
stigma associated with the diagnosis of HIV in Africa (Alubo, Zwandor, Jolayemi &
Omudu, 2002), with many consequences for HIV patients’ psychosocial well-being.
There is high discrimination and stigma attached to HIV infection in Nigeria. This is
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because the mode of transmission of HIV in Nigeria is predominantly through
heterosexual means and there is general perception that people living with AIDS (PLWA)
are people of low morals who have brought HIV/AIDS upon themselves (Alubo et al.,
2002). These people are generally regarded as “loose” people that deserve neither
sympathy nor empathy.
Research has shown that stigmatization and discrimination constitute major
challenges to HIV treatment and prevention efforts (Reis et al., 2005). Discrimination and
stigmatization associated with HIV constitute major barriers to HIV testing, counseling
and status disclosure (Rankin et al., 2005). In spite of gains recorded in curtailing new
infections and the treatment of HIV, the full benefit of national and the US Presidential
Emergency Plan For Aids Relief (PEPFAR) programs are hampered by discrimination
and stigmatization (Monjok, Smesny & Essien, 2010). Discrimination and stigmatization
associated with HIV are believed to emanate from a culture of fear, ignorance and a lack
of adequate information about HIV (Valdiserri, 2000).
A study by Uwakwe (2000) on the effectiveness of HIV/AIDS educational
program among BSc nursing students at the University of Ibadan revealed that 79% of
nurses expressed reservations about caring for HIV/AIDS patients at the beginning of the
study. After three months of intense instruction on HIV/AIDS, AIDS patient care and
compliance with universal precaution, 53% of the nurses still expressed reservations
about caring for HIV/AIDS patients. Similarly, Oyelese’s study on stigma, discrimination
and ostracization of HIV patients in Nigeria (2004) revealed that a significant
stigmatization and discrimination is still directed at HIV patients, albeit in subtle and
suppressed manners.
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Using a combination of semi-structured interview and focus group methodologies,
Alubo et al (2002) investigated the acceptance and stigmatization of people living with
HIV/AIDS (PLWA) in Benue state, Nigeria. A total of 40 PLWA and 10 family members
were interviewed for the study while focus group discussions were held with male and
female members of the community to assess their general perceptions of, acceptance of,
and reactions to PLWA. Findings from this study showed that the level of stigmatization
is high and the rate of acceptance is low. Fear of contracting this deadly disease and lack
of knowledge about mode of transmission of the disease were found to be responsible for
this trend, with some participants suggesting that PLWA be eliminated before they infect
the entire community.
Healthcare workers have also been found to discriminate against HIV patients
(Reis et al., 2005: Sadob et al., 2006). Such discrimination results in poor quality care,
breaches of confidentiality (Ehiri et al., 2005), and complete refusal to provide treatment
(Sadob et al., 2006). Multiple studies in Nigeria have shown that healthcare professionals,
including physicians, nurses and laboratory scientists in many cases have refused to treat
or been unwilling to care for HIV patients (Reis et al., 2005: Sadob et al., 2006). Refusal
to care for HIV patients is usually attributed to a lack of adequate knowledge about HIV.
However, studies have shown that significant acceptance of HIV patients is achievable
with adequate and continuous education (Ezedinachi et al., 2002; Fawole, Asuzu,
Oduntan, & Brieger, 1999).
The impact of stigmatization and discrimination on HIV patients may result in
social isolation, may foster low self-esteem (Valdiserri, 2000), and discourage adherence
to preventive practice (Nyblade, Stangle, Weiss, & Ashburn, 2009). Similarly,
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individuals are discouraged from checking their HIV status and subsequently prevent
sero-positive individuals from seeking treatment (Rankin et al., 2005). Vertical
transmission of HIV is also adversely affected by stigmatization and discrimination, as
many pregnant women may refuse or avoid voluntary counseling and testing which
would enable them to know their status and subsequently commence treatment to prevent
mother-to-child transmission of the infection (Odimegwu, Adedini, & Ononokpono,
2013). Also, stigmatization may prevent HIV patients from disclosing their status to
sexual partners and families. This could adversely affect the efforts to prevent the spread
of the disease (Ehiri et al., 2005). Breastfeeding is a common practice in Sub-Saharan
Africa, including Nigeria. Stigmatization and discrimination may prevent HIV-positive
nursing mothers from practicing alternative feeding techniques, thereby exposing their
babies to HIV infection, for fear of rejection or chastisement from the public (Okonkwo
et al., 2007) In a nutshell, stigmatization is known to promote fatalism, social isolation
and self-hate (Rankin et al., 2005).
Herbal Treatment of HIV
Herbal therapy includes the use of herbs, herbal materials, herbal preparations and
finished products in the treatment of different disease conditions (WHO, 2002). Herbal
therapy is used either as a complementary treatment or as an alternative treatment to
conventional or orthodox medicines in treating different disease conditions (Onifade et
al., 2011a; Patel, Bessong & Liu, 2011). Historically, herbal therapies have recorded
groundbreaking successe,s as in the clinical success of quinine and quinidine isolated
from the Cinchona tree bark and artemisinin from Artemisia annua used in the treatment
of malaria (Igoli, Ogaji, Tor-Anyiin & Igoli, 2005). Ufo opioko (Ageratum conyzoides
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Linn) is a herbal therapy that is reportedly widely used in treating HIV in Nigeria (Igoli et
al., 2005). The efficacy of Ufu opioko (Ageratum conyzoides Linn) in the treatment of
HIV is yet to be scientifically established.
It is estimated that about 80% of Africans reportedly use herbal therapies in the
treatment of many diseases (WHO, 2002). The inaccessibility and unavailability of
orthodox medical treatment, especially in rural communities in developing countries,
provides the impetus for the increased patronage of herbal therapies (Orisatoki &
Oguntobeju, 2010). However, the increasing acceptability and popularity of herbal
remedies is eliciting concern from orthodox health care professionals because of safety
issues (WHO, 2002). The use of herbal remedies is not restricted to developing countries.
Even in the United States, 35% of the American population is reported to use
complementary and alternative medicine (CAM) (Lee, Andrade, & Flexner, 2006).
Herbal medicine is reported to be the most commonly used CAM. 18.6% of adults in the
U.S. reported using herbal therapy in 2002 (Tindle et al., 2005).
The search for an HIV cure is currently assuming different dimensions. Apart
from the use of conventional antiretroviral medications, the use of herbal remedies is
growing in different parts of the world (Mills, Cooper, Seely & Kanfer, 2005; Orisatoki
& Oguntibeju, 2010; WHO, 2002). Herbal therapy is reported to be higher among HIV
patients even with the availability of ARV (Lee et al., 2006). The use of natural health
products (NHP) is reported to be as high as 67% among HIV patients receiving
conventional ARV (Gore-Felton et al., 2003). Among the NHP users, 63% reported the
use of vitamin C, 54% multivitamin, 53% vitamin E, 53% garlic and 20-50% of patients
reported using vitamin B12, vitamin B6, vitamin A, aloe, zinc, beta-carotene,
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acidophilus, ginseng, selenium, Echinacea species, folate, Chinese herbs, marijuana,
goldenseal and coenzyme Q10 (Standish et al., 2001).
Herbal remedies are largely used to treat fungal and bacterial opportunistic
infections that are associated with HIV infection (Kisangau, Lyaruu, Hosea, & Joseph,
2007). Similarly, herbal remedies have been used as primary treatment modalities for
HIV/AIDS and associated problems such as dermatological disorders, insomnia,
weakness, nausea and depression (Hodgson & Rachanis, 2002). Herbal remedies are
reported to have been used by individuals in different stages of HIV infection (LangloisKlassen, et al., 2007).
Studies have shown that herbal remedies are effective or helpful in HIV treatment
(De Clereq, 2000; Dharmaratne, Tan, Marasinghe & Pezzuto, 2002; Kong, Goh, Chia, &
Chia, 2003; Kostova, 2006; Matthee, Wright & Konig, 1999; Onifade et al., 2011a).
Different herbal remedies are currently used in the treatment of HIV in different parts of
the world. In Sub-Saharan Africa, two herbal remedies used for HIV treatment are
Hypoxis hemerocallidea (African potato – an immunostimulant) and Sutherlandia (Mills,
Cooper, Seely & Kanfer, 2005; Orisatoki & Oguntibeju, 2010).
The South African government has incorporated hypoxis into the primary health
care system and used it as an immunostimulant in the treatment of HIV/AIDS (Mills et
al., 2005). Hypoxis reportedly contains sterols and sterolins. These constituents of
Hypoxis are believed to act as immune boosters but concrete evidence of this is lacking
(Bouic et al., 2001). The corms of H. hemerocallidea are widely used in the treatment of
immunity-related illnesses such as cancer, HIV/AIDS and the common cold. Herbal

40

remedies have gained governmental acceptance in South Africa despite a lack of
empirical evidence of efficacy and safety (Mills et al., 2005).
Amzat and Abdullahi (2008) reported that a study in Senegal showed that a herbal
formulation known as METRAFAIDS was able to decrease viral load by more than 66%
in 54% of HIV patient population. This remarkable efficacy was achieved without any
adverse reaction during the course of this study. METRAFAIDS is now trademarked and
has been patented by the association for the promotion of traditional medicine
(PROMETRA) (Amzat & Abdullahi, 2008).
Another study by Tumbare et al. (2012) on the safety and efficacy of a
combination of three herbal drug preparations showed that 80% of the subjects achieved
viral load reduction below detection level and the remaining 20% recorded a reduction in
viral load. Included in this 80% was a patient with co-diagnosis of tuberculosis who was
receiving anti-tuberculosis medications in conjunction with his herbal treatment.
Tumbare et al. (2012) recorded no side effects in patients who were using both ARV and
herbal therapies together.
The Chinese government provided a dynamic response to combat HIV epidemic
with the formation of a National Free Antiretroviral Treatment Programme (NFATP),
which is also known as a comprehensive acquired immuno-deficiency syndrome (AIDS)
response program. A tripartite approach is used in Chinese communities in the treatment
of HIV. These approaches are:
(a). Conventional antiretroviral medications (HAART),
(b). Buyao which include tea, soups, tablets, herbal preparations and tonics, sold
over-the-counter, and
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(c). Traditional Chinese medicine (TCM) (Zou et al., 2012).
Traditional Chinese herbal medicine (TCHM) is widely used in China to treat
HIV. TCHM is used to enhance immunity, treat HIV symptoms, reduce medication side
effects and improve quality of life (Liu, 2007). Many studies have shown that TCHM is
effective in decreasing HIV RNA levels (Sangkitporn, 2005; Shi, & Peng, 2003), provide
significant increase in CD4 counts (Shao, 2008; Wang et al., 2006), provide significant
improvement of symptoms of oral candidiasis with no side effects (Jiang et al., 2009) and
improve the symptom of diarrhea (Wang et al., 2008; Xu et al., 2011). TCHM has proven
to significantly increase peripheral leukocytes with no serious adverse effects (Jiang et
al., 2011), resulting in improvement of symptoms of anepithymia (loss of natural
appetite) and nausea (Wang et al.., 2008) and improvement in overall life satisfaction
(Burack, Cohen, Hahn, & Abrams, 1996). However, some TCHM show no significant
difference in CD4 count and symptom severity (Burack, Cohen, Hahn, & Abrams, 1996)
and no significant difference in viral load (Wang et al., 2008; Wang et al., 2006) between
treatment groups and placebo groups. TCHM is known to have undesirable effects such
as gastroenterological adverse effects (Shi & Peng, 2003) and other adverse effects
(Weber et al., 1999).
An herbal formulation, known as SH, is reported to be effective in HIV treatment.
SH, which is widely used in China, is a formulation containing five herbs (Sangkitporn et
al., 2005). Each constituent of SH is reported to be an individually effective anti-HIV
agent, and the combined herbs are also reported to possess anti-retroviral activity
(Sangkitporn et al., 2005). A randomized, double blind placebo controlled clinical trial
was conducted to investigate the effectiveness of co-administration of SH with
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antiretroviral medications. Two groups of subjects were used. A group of 40 subjects
were given a combination of Zidovudine (ZDV) 200mg, Zalcitabine (ddC) 0.75mg and
SH herbs 2.5grams three times daily. A control group consisting of 20 subjects was
administered a combination of ZDV 20mg, ddC 0.75mg and placebo 2.5grams three
times daily for a period of 24 weeks. Findings from Sangkitporn et al. (2005) showed that
HIV RNA from week 4 and beyond significantly decreased from the baseline value in
both the experimental and control groups. But the SH group recorded a significantly
lower HIV RNA compared to the control group. Similarly, the CD4 counts after 12
weeks and beyond showed a significant increase in SH group from baseline value.
Finding from this study showed that a combination of SH herbs with two nucleoside
reverse transcriptase inhibitor has a greater antiviral ability than conventional
antiretroviral medications (Sangkitporn et al., 2005). The combination of SH with
conventional antiretroviral medications resulted in no serious adverse effects.
In a chemical study conducted by Onifade, Jewel & Okesina (2010) on the
efficacy of herbal remedies used to treat HIV in Zaria (Kaduna state, Nigeria) and
Osogbo (Osun state, Nigeria), it was found that about 20% of herbal homes have
potentially effective herbal remedies for HIV infection. Sixty percent of these herbal
homes were able to provide symptomatic treatment, but potentially toxic products were
noted in 20% of the herbal homes (Onifade et al., 2010).
Herbal remedies have been found to inhibit some steps associated with HIV
replication (De Clereq, 2000; Kong, Goh, Chia, & Chia, 2003). Herbal remedies have
shown to be effective in reducing viral load and increasing CD4 counts (Onifade et al.,
2011a). According to Matthee, Wright & Konig (1999) alkaloid-derived herbal remedies
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such as Ancistrocladus korupensis obtained from tropical liana plant inhibit reverse
transcriptase and HIV-induced cell fusion. Dharmaratne, Tan, Marasinghe & Pezzuto
(2002) reported that Coumarin herbal remedy in the form of canolides obtained from a
tropical forest tree, Calophyllum lanigerum, was classified as a potent non nucleoside
reverse transcriptase inhibitor. Coumarin from plant sources and their analogs (i.e.
synthetic coumarins) have shown to be potent nonnucleoside RT-inhibitors, or inhibitors
of HIV-integrase, or HIV-protease (Kostova, 2006).
Herbal Treatment of HIV in Nigeria
Nigeria has embraced ARV therapy in the treatment of HIV. However, herbal
remedies have also been used in HIV treatment in Nigeria since its discovery (Awodele et
al., 2012). A descriptive cross-sectional survey conducted in Lagos, Nigeria showed that
8.2% of respondents used herbal therapy as a complementary medicine with conventional
ARV therapy (Awodele et al., 2012). Herbal therapies reportedly used include jobelyn
(Sorghum bicolor plant leaves), garlic (Allicin, Y-glutamyl(s)-ally-L-Cysteine), ginger
(Essential oil) and aloe vera (Hydroxyanthracene derivatives expressed as Barbaloin)
(Awodele et al., 2012). Findings from Awodele et al. (2012) study showed marginal, but
not significant, improvement in CD4 counts and viral load of HIV patients using these
herbal therapies compared to those who do not use herbal therapies.
In Nigeria, many herbal remedies have proven to be effective in the treatment of
HIV (Elujoba, 2005). Mostly, herbal remedies have been effective in treating the
opportunistic infections associated with HIV (Abere & Agoreyo, 2006; Elujoba, 2005).
Findings from Mbah et al. (2007) showed that a widely used herbal medicine, neem
leaves, is effective in HIV management as it is found to bring about significant increase

44

in CD4 and improvement in general well-being of HIV patients. Similarly, Baissea
axillaries Hua is found to be effective in treating HIV opportunistic infections of bacteria
origin (Abere & Agoreyo, 2006).
Similarly, herbal remedies, such as a-Zam, which contain alkaloid have shown to
be effective in the treatment of HIV (Bringmann et al., 1999). A-Zam is a herbal remedy
used in HIV treatment in Nigeria. The exact components of a-Zam are not known.
However, disclosure by the herbal therapist revealed that the major constituents of a-Zam
are black seed (nigella sativa), honey and water (Onifade et al., 2011a). Phytochemical
analysis of a-Zam revealed further constituents such as alkaloids, saponins, tannins,
cardenolides and anthraquinones (Onifade et al.., 2011a).
Previous use of a-Zam in the treatment of disease conditions is not found in the
literature. However, the constituents of a-Zam are known to be used in treating different
disease conditions. For instance, alkaloids such as physostigmine that are isolated from
natural sources has gained acceptance as acetyl-and butyrylcholinesterase (BChE)
inhibitors and is being used in the treatment of Alzheimer’s disease (Konrath, Passos,
Klein-Junior & Henriques, 2013). Saponins are known to have direct beneficial effects on
the heart and are useful in the treatment of heart and circulatory-related ailments. Saponin
helps in reducing blood coagulation, cholesterol and sugar levels in blood while helping
to promote systemic immunity and enzymic functions (Purmova & Opletal, 1995). Plant
tannins are known to be useful in decreasing inflammation of ulcerative colitis (Clinton,
2009). Cardenolide is a class of cardiac glycosides. Cardiac glycosides have a long
history of use in the treatment of congestive heart failure (Schoner & Scheiner-Bobis,
2007). Cardenolides are known to bind to the sodium pump producing a resultant effect
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on multiple signaling pathways leading to remarkable anti-tumor effects (Mijatovic et al.,
2006). Anthraquinone is reported to have diverse pharmacologic potentials. It is known to
possess antiviral activities against HIV-1, human cytomegalovirus (HCMV), vesicular
stomatitis virus, herpe simplex virus type 1 and 2, parainfluenza virus and vaccinia virus
(Dave & Ledwani, 2012).
A clinical study conducted by Onifade et al. (2011a) on the effectiveness of aZam in HIV treatment show that a-Zam is effective in increasing the CD4 count and in
reducing the viral load of HIV patients. Findings from Onifade et al. (2011) show that
there was a statistical significance difference (p<0.05) between pre-treatment CD4 count
and post-treatment CD4 count. Also, a significant reduction in viral load was obtained
after treatment with a-Zam. Onifade et al. (2011a) study show no negative drug
interaction in patients that used both ARV and a-Zam.
Nigerian Government Policy on Herbal Medications
In spite of the astronomical usage of herbal remedies in the treatment of diseases
in Nigeria, the Nigerian government appears not to have a clearly defined policy on the
use of herbal remedies. The Nigerian government, through the National Agency for Food
and Drug Administration (NAFDAC) and Nigeria Institute of Pharmaceutical Research
and Development (NIPRID), was in the process of conducting limited clinical trial on
selected herbal medications used for HIV treatment (Obinna, 2013). One of the core
mandates of NAFDAC is to ensure that only high quality, safe, and effective herbal
medicines are released into the Nigerian market. Stemming from the proliferation of
claims of herbal cure, the NAFDAC had set up a National Expert Committee to work in
conjunction with NIPRID to verify claims of potency of herbal HIV medications. The
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expect committee was scheduled to commence evaluation of herbal medicine in the first
quarter of 2014 (Obinna, 2013). But as it is typical of Nigerian agencies, no information
is found on the activity of this committee, and it is not clear if the committee has
commenced work as scheduled.
Safety of Herbal Remedies Used in HIV Treatment
There is an erroneous belief that herbal remedies are harmless because they are
obtained from natural sources. However, health care professionals have always been
concerned about the risks associated with the use of herbal therapy (Corns, 2003).
Despite this, increasingly large numbers of patients continue to use herbal remedies to
treat minor and major infections (Gardiner, 2007; WHO, 2002) because of their
accessibility, availability, affordability and acceptability in many communities in
developing countries (Amzat & Abdullahi, 2008; Tamuno, 2011).
Possible interactions between herbal medicine and ARV could lead to therapeutic
failure (Awodele et al., 2012). Studies have shown that herbal therapies such as St. John’s
wort, herbally derived vitamins and garlic are capable of causing negative drug
interaction with antiretroviral medications (Dhalla et al., 2006; Nyika, 2007). Similarly,
Awodele et al. (2012) showed that concurrent use of herbal remedies with ARV could
result in potential adverse effects. Studies have shown that garlic has the potential to
reduce pharmacokinetic concentration of Saquinavir in plasma and cause a reduction in
the effectiveness of ARV (Borrelli, Capasso, & Izzo, 2007; Piscitelli, Burstein, Welden,
Gallicano, & Falloon, 2002).
Investigation of the toxicological profile of herbal remedies has largely been
carried out using animal populations. Onifade et al. (2011b) conducted a toxicological
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study of a-Zam using 20 rats that were subdivided into four different groups. Different
dosages of a-Zam (400mg/kg, 800mg/kg, 1600mg/kg and 3200mg/kg) were administered
daily to each group over a period of 84 days to test for chronic toxicity after the initial
acute toxicity test. A control group was administered rat chow and water only. Physical
examination and hematological studies were performed. Histological studies were done at
85th day of drug administration. Onifade et al. (2011b) found no physical or physiological
alteration in any group. Similarly, blood test and histological studies only showed mild to
moderate derangement. Renal function test (electrolytes, urea & creatinine) and liver
function test (high density lipoprotein, HDL, triglyceride, low density lipoprotein and
total cholesterol) were done. It was found that, even at a higher daily dose of 3200mg/kg,
a-Zam was safe, as it resulted in no severe injury in any of the groups.
The use of herbal remedies in conjuction with ARV is likely to produce beneficial
or detrimental effects. When St. John’s Wort, which is generally used by HIV patients, is
taken with protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor
(NRTI) can cause a reduction in PI and NRTI concentration leading to possible
therapeutic failure (Mannel, 2004). As a result of the possible safety issues associated
with herbal remedies when taken alone or with ARV, it is important that health care
professionals should always review herbal remedies that patients may be taking during
the course of treatment.
Conclusion
A-Zam is found to be beneficial in increasing the CD4 counts and in reducing the
viral load in Nigerian HIV patients (Onifade et al., 2011a). However, Onifade et al.
(2011a) study did not investigate in detail the experience of patients who used a-Zam.
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Also, the study did not compare the symptom and treatment outcome of patients using the
herbal remedy a-Zam with those patients using conventional antiretroviral medications.
As a result of these identified knowledge gaps, it is imperative to conduct study to further
our knowledge of the experience of HIV patients in Nigeria in the course of using herbal
remedies. Therefore, the goals of this study are to investigate the effectiveness of the
herbal remedy a-Zam and to investigate the impact of herbal remedies and HAART on
HIV symptoms and patients’ quality of life.
Table 1: Epidemiology of HIV in Nigeria: Key Facts

2008

2012

4.6%

4.1%

2,980,000

3,459,363

Annual AIDS Deaths

192,000

217,148

Number requiring Antiretroviral Therapy

857,455

1,449,166

New HIV infections

336,379

388,864

2,175,760

2,193,745

National Median HIV Prevalence

Estimated Number of PLWHIV

Total number of AIDS orphans

Source: National Agency for the control of AIDS (NACA, 2012). Federal Republic of
Nigeria Global AIDS Response Country progress report in 2012. Retrieved from
http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012co
untries/Nigeria%202012%20GARPR%20Report%20Revised.pdf
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Table 2: Trends in HIV incidence in Nigeria 2010 and 2011
2010

2011

Total population

319,322

310,322

Adult > 15 years

247,718

243,430

Children < 15 years

71,604

67,190

Male

144,258

140,169

Female

175,064

170,431

Source: National Agency for the control of AIDS (NACA, 2012). Federal Republic of
Nigeria Global AIDS Response Country progress report in 2012. Retrieved from
http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012co
untries/Nigeria%202012%20GARPR%20Report%20Revised.pdf
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Table 3: Estimated Prevalence of HIV among Women, Children and General Population
in Selected Sub-Saharan African Country and the Percentage of PMTCT Services.
Sub-Saharan
African
Countries

HIV
prevalence
in 2009 (%)

PMTCT
Services (%)
2010

Number of
Pediatric (014) HIV
2009

3.6

HIV
prevalence
among
pregnant
women 2009
3.6

4.7

360,000

Number of
pregnant
women
living with
HIV 2009
230,000

Nigeria
South Africa

17.8

25.6

94

330,000

330000

Tanzania

5.6

5.5

90.4

160,000

73,000

Kenya

6.3

5.6

92.5

180,000

87,000

Zimbabwe

14.3

14.3

74

150,000

62,000

Mozambique 11.5

10.4

86

130,000

98,300

Uganda

6.1

81

150,000

96,700

6.5

Sources:UNAIDS (2010)-UNAIDS Report on the Global AIDS Epidemic; UNICEF
(2009). Prevention of mother-to-child Transmission (PMTCT) of HIV.
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Table 4: Percentage of Women and Children receiving Antiretroviral Therapy in Selected
Sub-Saharan African Countries for the Prevention of Mother-to-Child HIV Transmission

Sub-Saharan
African Countries

% of eligible
children younger
than 15 years old
receiving ARV
therapy 2010

HIV Testing among
pregnant women
2010 (%)

Nigeria

% of women
receiving ARV
therapy to reduce
HIV transmission
during pregnancy
2011
18

13

14

South Africa

95

58

95

Tanzania

74

14

86

Kenya

67

31

83

Zimbabwe

54

34

90

Ghana

75

14

68

Mozambique

51

20

87

Uganda

45

22

63

Zambia

86

31

94

Lesotho

62

25

57

Sources:UNAIDS (2010)-UNAIDS Report on the Global AIDS Epidemic; UNICEF
(2009). Prevention of mother-to-child Transmission (PMTCT) of HIV.
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CHAPTER 3
RESEARCH METHOD AND DESIGN
Introduction
This chapter discusses the research design and methodological approaches used in
this study. In this chapter, the aspects of the study that will be discussed are research
design, research setting, gaining access, instrument/questionnaire, sample and sampling
plan, recruitment problems, inclusion and exclusion criteria, control of threats, protection
of human subjects, data collection, methods and procedures, data analysis and
management, methods used to analyze research questions, trustworthiness of research
data, eliminating confounding variables and summary statement.
This is a comparative analysis study designed to compare the effectiveness of
conventional antiretroviral (ART) medications with a combination therapy of ART and
herbal therapies as they are already used by Nigerian HIV patients. The study would
consist of two parts namely the pilot study and the actual study.
The Pilot Study
The pilot study was designed to test the reliability of the two instruments used in
obtaining data from the subjects. The two instruments used for data collection are the
brief version of the World Health Organization Quality of Life Instrument for HIV
(WHOQOL-HIV BREF) (WHO, 2012) and the Sign and Symptom Check-List for
persons with HIV disease (SSC-HIVrev) (Holzemer et al., 2001). Although these two
questionnaires have been widely tested among different populations, the instruments have
not been tested extensively among Nigerian HIV population. The integrity of the data
obtained from this study is a function of the reliability of the instruments used in data
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collection. The researcher considered it imperative to ascertain the reliability of the study
instruments before they are used in the main study. The pilot study also enables the
researcher to socialize into the research environment in Nigeria, to assess and identify
possible problems that could arise during questionnaire administration and strategize to
resolve any problem before the actual study.
Questionnaire Administration for Pilot Study
Before the actual study, a pilot study was carried out. This is a reliability pilot
test of the two instruments (SSC-HIVrev and WHOQOL-HIV BREF) used in this
study. Both questionnaires were administered to 20 randomly selected HIV patients
receiving treatment at the State Specialist Hospital Osun-State, Nigeria. Randomization
was done by flipping a coin. A coin was flipped for each subject that agrees to participate
in the study. If the coin comes up “heads”, the subject was included in the pilot study. If
the coin comes up “tails”, the subject was excluded from the pilot study. This method
provided equal opportunity for all participants to be included in the actual study,
irrespective of characteristics such as sex, age, tribe, or educational levels (Polit & Beck,
2012). The research assistant helped situate the patients for questionnaire administration.
Questionnaires were administered by the principal investigator via phone
and/or Skype. Each participant was required to put completed questionnaire in an
envelope provided for that purpose and sealed. The sealed envelope was given to the
research assistant. All sealed envelopes were sent to the researcher in the U.S. for
reliability test.
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Analysis of Pilot Study
Data obtained from the pilot study was analyzed using IBM SPSS Statistics 22
software. The Cronbach alpha reliability tests were carried out for both the SSC-HIVrev
and WHOQOOL-HIV Bref. Similarly, descriptive analyses were done to analyze the
demographic information of the pilot study participants. The pilot study helped the
researcher to determine if the two instruments are suitable for use in the actual study.
The Actual Study
The actual study is divided into two parts namely;
1. Collection and analysis of physiological data (CD4 counts) and
2. Collection of data about patients’ symptom experience and quality of life
during treatment with ARV only and combination of ARV and herbal
remedies.
Collection and Analysis of Physiological Data (CD4 Counts)
The first component of this study was the collection and analysis of the
physiological data. The CD4 was used as a biomarker of HIV treatment outcome. The
initial intention of this researcher was to obtain and analyze the CD4 counts and the viral
load of HIV patients during the course of treatment. But data regarding viral load was
not available in the Specialist Hospital and in many clinics in Nigeria. The CD4 counts
were obtained from patients’ medical records. The purpose of the quantitative
comparative analysis was to examine the impact of ARV only and combination of ARV
and herbal therapy on CD4 counts of HIV patients during treatment. This component
involved the analysis of the improvement in the CD4 counts of patients taking ARV only
and those using combination of ARV and herbal remedies during the course of treatment.
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Each participant’s CD4 counts were obtained from patients’ medical records by the
record staff. To ensure credibility of study results, only CD4 counts results obtained from
patients’ medical records were used. The CD4 counts that were measured before the
commencement of treatment were used as baseline CD4 counts. CD4 counts obtained at 6
months post treatment were used as post treatment CD4 counts. Six month duration was
used because CD4 count is typically expected to increase rapidly in the first few months
of ARV treatment, followed by a more gradual increase until an optimum count is
achieved (Gengis & Deeks, 2009).
Collection of Patients’ Symptom Experience and Quality of Life Data During
Treatment
The second part of the actual study included the administration of dual
questionnaires to Nigerian HIV patients who were taking conventional antiretroviral
medications only (ARV group) and those who were taking a combination of conventional
antiretroviral medications and herbal remedies (combined group). The focus of the
questionnaire was to compare the experience of these two groups in the course of their
respective therapies. The goal was to investigate the impact of treatment on relief of HIV
associated symptoms and the patients’ quality of life in the course of treatment. This was
done by administering questionnaires to obtain information about treatment experience
and patients’ quality of life during the course of their treatment with herbal remedies
and/or conventional antiretroviral medications.
Questionnaire administration for the actual study was done in a fashion similar to
that of the pilot study. Each participant enrolled in the actual study was given the two
questionnaires. The research assistant helped situate the patients for questionnaire
administration. Questionnaires were administered by the principal investigator via phone
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and/or Skype. After the completion of the questionnaires, participants were required to
put completed questionnaires in an envelope provided for that purpose. The envelopes
were sealed by each participant before handing it over to the research assistant. All sealed
envelopes were sent to the researcher in the U.S. for analyses.
Analysis of Actual Study
Data generated from the actual study was analyzed using IBM SPSS Statistics 22
software. Descriptive statistics was used to analyze the demographic data (age, gender,
and ethnicity) while inferential statistics was used to draw conclusion from study data.
Pair sample t-test was used to compare the difference between pre-treatment CD4 counts
and post treatment CD4 counts within each group. Independent t-test was used to
compare the difference between pre-treatment CD4 counts and post treatment CD4
counts across both groups (i.e. between the ARV group and the combined group).
Analysis of covariance (ANCOVA) was used to statistically control the effect of baseline
CD4 counts and to examine the difference between the baseline and post treatment CD4
counts.
Research Questions
This study was designed to answer the following questions:
1. How do CD4 counts differ after treatment with antiretroviral medications only?”
2. How do CD4 counts differ after treatment with a combined therapy of herbal
treatment and conventional antiretroviral medications?
3. What is the difference in CD4 counts of patient taking ARV only and those taking
a combination of herbal therapies and conventional antiretroviral medications?
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4. What is the difference in the symptom experience of patients taking ARV only
and those taking a combination of herbal therapies and conventional antiretroviral
medications?
5. What is the difference in the quality of life of patients taking only ARV, and those
taking a combination of herbal therapies and conventional antiretroviral
medications?
Research Design
This study is designed to start with a pilot test. This is a reliability test of the two
instruments (SSC-HIVrev and WHOQOL-HIV BREF) used in data collection. Both
questionnaires were administered to twenty randomly selected HIV patients receiving
treatment at the State Specialist Hospital Osun-State, Nigeria. The research assistant
helped situate the patients for questionnaire administration. The questionnaires were
administered via phone and/or Skype. Each participant was required to put completed
questionnaire in an envelope provided for that purpose and sealed. The sealed envelope
was given to the research assistant. All sealed envelopes were sent to the researcher in
the U.S. for reliability test.
After the reliability test, the actual study commenced. The actual study compared
the effectiveness of ARV only with combined therapy of ARV and herbal remedies
among Nigerian HIV patients. Using power calculation (Cohen, 1988), 110 participants
were drawn from Nigerian HIV patients using conventional antiretroviral medications
only and those using a combination of herbal remedies and conventional antiretroviral
medications. Two groups of matched randomly selected HIV participants were utilized.
Each group was composed of 55 participants. Group A participants were drawn from
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patients who were using conventional antiretroviral medications only. Group B
participants were drawn from patients who were using a combination of herbal therapies
and conventional antiretroviral medications for their treatment. Subjects were placed in a
group on the basis of the treatment protocol (medications) used in the management of
their HIV prior to contact for this study. No participants were required to change the kind
of medication he/she was taking prior to contact for this study.
Participants in each group were selected randomly from matched subjects that are
similar in terms of important extraneous variables. For each group, subjects with similar
treatment protocol, same treatment duration and same duration of HIV diagnosis were
included in the study. Subjects in each group have started their treatment about the same
time and taking the same antiretroviral medications. All participants were diagnosed
within the last two years and also commenced treatment in the last two years. All patients
receiving ARV treatment at Osun State Specialist hospital received first and second line
HAART. Specifically, a combination of AZT+3TC+NVP (300mg +150mg +200mg) bd
or AZT+3TC(FTC)+ EVF (300mg+150mg+600mg) or TDF+3TC+EVF ( 300mg
+150mg +600mg ) and 2nd line, 3TC+TDF+LPV/r or with ATV/r are the treatment of
choice at State Specialist Hospital, Osun. The herbal medications used by participants in
this group include a-zam, ufo-opioko and numerous herbal concoctions popularly known
as “agbo” in western part of Nigeria. The herbal medications were prescribed by nonorthodox traditional medical practitioners.
The methods described above helped to eliminate extraneous variables that could
affect study results. From the matched samples, participants in each group were selected
by flipping a coin. For each group, a coin was flipped for each subject who agreed to
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participate in the study. If the coin came up “heads”, the subject was included in the
actual study. If the coin came up “tails”, the subject was excluded from the study. This
method provided equal opportunity for all participants to be included in the actual study,
irrespective of characteristics such as sex, age, tribe, or educational levels (Polit & Beck,
2012).
Symptoms assessment was done using the Sign and Symptom Check-List for
persons with HIV disease (SSC-HIVrev) (Holzemer et al., 2001). The quality of life
assessment was done using the brief version of the World Health Organization Quality of
Life instrument for international assessment of HIV/AIDS (WHOQOL-HIV BREF)
(WHO, 2012). The physiologic assessment was done by collecting and analyzing CD4
counts obtained from patients’ medical records. To protect the integrity of the study,
questionnaire administration was conducted in the clinic during clinic hours.
Arrangements were made to provide transport assistance to all subjects that have
difficulty with transportation.
Research Setting
A designated area was provided for the purpose of data collection and
administration of questionnaires to patients. This space was used throughout the duration
of the study. To promote the integrity of data collection process and prevent the data from
being compromised, all questionnaires and interviews were carried out in this location. It
is necessary to dedicate a specific space for the administration of the questionnaire, as
this would ensure that questionnaires were administered under a controlled environment.
Trained research assistant was present at the time of the questionnaire administration.
The principal investigator administered the questionnaire over the phone.
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Gaining Access
In order to gain access to the subjects for this study, there was collaboration with
HIV specialist hospital in Osun State, Nigeria, as well as with physicians, scientists and
researchers in this center. Collaboration with these professionals helped to facilitate
necessary access to study subjects. The stigma and discrimination attached to HIV
infection initially made the recruitment of subjects extremely difficult. Many scientists
and researchers were contacted but many of them were unwilling to provide access to
their HIV patients. After extensive contacts, a seasoned HIV scientist and researcher
committed to helping provide access to potential subjects. Similarly, two medical doctors
agreed to help in the recruitment efforts. A lot of resistance was encountered from
subjects but the strong assurance of confidentiality eventually persuaded some of the
patients contacted to agree to participate in the study. Contact was established with the
patients with the help of the care providers who coordinated their treatment. Recruitment
fliers were distributed to patients receiving treatment at the hospital. The process of
establishing contact with the patients was done with strict adherence to confidentiality.
Only patients who consented to participating in the study were included in this study.
Instruments/Questionnaires
Data collection was done using two well-tested instruments. This study seeks to
gain insight into the changes that occur in symptoms and quality of life of HIV patients
during treatment with antiretroviral medications only and with a combination of herbal
therapies and conventional antiretroviral medications. Two instruments that
incorporate/embed these two constructs were used in data collection. The quality of life
of subjects was measured using the brief version of the World Health Organization
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Quality of Life Instrument for HIV (WHOQOL-HIV BREF) (WHO, 2012). The
symptom outcome was measured using the Sign and Symptom Check-List for persons
with HIV disease (SSC-HIVrev) (Holzemer et al., 2001).
WHOQOL-HIV BREF Instrument
Investigation of the quality of life of HIV patients was done using the brief
version of the World Health Organization Quality of Life Instrument for International
Assessment of HIV/AIDS (WHOQOL-HIV BREF). This instrument provides insight into
the quality of life of participants in the course of their treatment with herbal remedies
and/or conventional antiretroviral medications. This instrument also provided an
opportunity for patients to provide information on their experiences in the course of their
treatment. According to the World Health Organization, quality of health (QOL) is
defined as “an individual’s perception of their position in life in the context of the culture
and value system in which they live, and in relation to their goals, expectations, standards
and concerns” (WHO, 2012 p. 3). Looking beyond the mechanistic focus of medicine on
the treatment of the signs and symptoms of diseases, the WHO quality of life assessment
instrument provides a tool that extends beyond the traditionally used indicators of disease
morbidity and mortality (Sharpe, 1994).
The WHOQOL-HIV was developed from an extensive test of 115 questions that
incorporate the WHOQOL-100 in 10 centers around the world (WHO, 2012). The quality
of life assessment tool is a valuable instrument in understanding the impact of HIV
infection on individual lives (O’Connell, Skevington, Saxena, WHOQOL HIV Group,
2004). The WHOQOL instrument is individualized, as it measures the satisfaction of
individuals vis-a-vis the impact of disease condition on vital aspects of their lives and
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their interpretation of such experience (Skevington, Lotfy, O’Connell, 2004). The
WHOQOL-HIV BREF, used in this study, is an abridged version of the original
WHOQOL-HIV assessment instrument. The brief version became necessary because of
the cumbersome and time-consuming nature of the original version (WHOQOL-HIV),
which made it difficult to be used in large studies or in resource constraint regions like
sub-Saharan Africa.
The WHOQOL-100 assessment version is a cross-culturally valid assessment
instrument of wellness and well-being (Skevington, Lotfy, O’Connell, 2004). WHOQOL100 is operationalized through 100 items that denote 25 facets organized into six domains
(WHOQOL Group, 1998). The conceptualization of WHOQOL instrument is based on
the realization that the determinants of health status could not be completely understood
through the measure of disease alone. Progressively, health status measures have come to
be conceived as incorporating both the objective measures of final health status and
subjective measures of health and well-being (Muldoon, Barger, Flory, & Manuck, 1998;
Wood-Dauphine, 1999).
Although many instruments have been previously developed for measuring the
quality of life of HIV patients, the WHOQOL-HIV instrument provides a unique
opportunity for cross-cultural measurement of the quality of life of people living with
HIV/AIDS. Some of the previously developed quality of life assessment instruments for
HIV include the HIV overview of problems-evaluation system (HOPES) (O’Leary et al.,
1998) and the medical outcomes study-HIV (Smith et al., 1996). The WHOQOL-HIV has
shown a high level of adaptability, as its use has extended beyond HIV patients. The
instrument is suitable for assessing the quality of life outcomes resulting from multiple
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opportunistic infections associated with HIV infection such as tuberculosis (Deribew et
al., 2009), depression (Pereira, Martins, Alves, & Canavarro, 2014) and Hepatitis C
(Preau et al., 2008). The instrument can be used by a broad spectrum of HIV patients at
different stages of infection (O’Connell, Saxena, Skevington, for the WHOQOL-HIV
Group, 2004) and by specific subgroups such as sex workers, injecting drug users, and
homosexual males (O’Connell & Skevington, 2012).
The WHOQOL-HIV instruments have gained wide acceptance internationally,
and different versions have been used across nations to measure quality of life of
HIV/AIDS patients in Iran (Razavi et al., 2012), in Taiwan (Fang et al., 2002; Hsiung et
al., 2011), in India (Chandra et al., 2006) in Burkina Faso (Bakiono et al. 2014), in Italy
(Starace et al., 2002), in Rwanda (Mutimura, Stewart & Crowther, 2007), in Brazil
(Berlim, Pavanello, Caldieraro, & Fleck. 2005) and in Nigeria (Agu et al., 2012;
Fatiregun et al., 2009; Mofolorunsho et al., 2013; Odili et al., 2011).
The WHOQOL-HIV BREF instrument consists of 31 items using a five point
Likert-type scale. The items are distributed into the following six domains: physical
health domain, psychological health domain, level of independence domain, social
relationship domain, environmental domain and spirituality/religion/personal beliefs
domain. The physical health domain measures pain and discomfort, energy level, fatigue,
sleep and rest. The psychological health domain measures positive and negative feelings,
thinking, learning, memory and concentration, self-esteem, body image, and appearance.
The level of independence domain measures mobility, daily life activities, level of
dependence on medication or treatment and work capacity. The social relationship
domain measures personal relationship, social support and sexual activity. Environmental

64

domain measures physical safety and security, home environment, financial resources,
health and social care, accessibility and quality, opportunities for acquiring new
information and skills, participation in and opportunities for recreation and leisure
activities and physical environment. Spirituality/religion/personal beliefs domain
measures forgiveness and blame, as well as concerns about future and death and dying
(Odili, Ikhurionan, Usifoh, & Oparah, 2011).
Validity and Reliability of WHOQOL-HIV Instrument
The WHOQOL-HIV has been widely evaluated for reliability and validity in
different parts of the world. In Iran, Razavi et al. (2012) assessed the reliability of the
instrument using Cronbach’s α (alpha) for internal consistency and found the
Cronbach’s alpha for the six domain to be 0.8 (for spiritual/religion/personal beliefs
domain), 0.78 (level of independence domain), 0.72 (psychological domain), 0.65
(environmental domain), 0.63 (social relationships domain), and 0.61 (physical domain)
showing that the instrument has good reliability. The French version of WHOQOL-HIV
is reported to have high reliability with Cronbach’s alpha of 0.944 (for
spiritual/religion/personal beliefs domain), 0.94 (level of independence domain), 0.937
(psychological domain), 0.938 (environmental domain), 0.94 (social relationships
domain), and 0.942 (physical domain) (Reychler, Caty, Vincent, Billo, & Yombi, 2013).
Similarly, the Malay version was found to have internal consistency ranging from 0.60 to
0.87 across all the domains indicating that the Malay version of WHOQOL-HIV is a
valid and reliable instrument for measuring the quality of life of HIV patients (Saddki et
al., 2009). The Nigerian version of WHOQOL-HIV BREF has good internal consistency
and reliability with Cronbach’s alpha ranging between 0.81 and 0.85 (Akinboro et al.,
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2014). Akinboro et al. (2014) reported the Cronbach’s alpha for the six domains to be
0.81 (physical domain), 0.81 (psychological domain), 0.82 (level of independence
domain), 0.83 (social relationships domain), 0.83 (environmental domain), and 0.85 (for
spiritual/religion/personal beliefs domain).
SSC-HIVrev Instrument
The other information collected in this study was the participants’ symptom
experience in the course of their treatment with herbal remedies and conventional
antiretroviral medications. The Sign and Symptom Check-List for persons with HIV
disease (SSC-HIVrev) (Holzemer et al., 2001) was used to evaluate symptom experience
and/or improvement. This instrument consists of six symptom clusters, namely:
malaise/weakness/fatigue (consisting 6 items), confusion/distress (4 items), fever/chills (4
items), gastrointestinal discomfort (4 items), shortness of breath (3 items) and
nausea/vomiting (3 items). Specifically, the symptoms cluster to be evaluated are fatigue
(muscle aches, weakness, painful joint, fatigue), fear (difficulty concentrating,
depression, memory loss, fear/worries), fever (fever, chills, day sweats, night sweats), GI
upset (loose stool, diarrhea, gas/bloating, abdominal pain, nausea and vomiting),
shortness of breath (shortness of breath at rest, wheezing and shortness of breath with
activities), sore throat (sore throat, painful swallowing, mouth ulcers, and white spots in
mouth/thrush), numbness (numbness/tingling of arms, hands/fingers, legs, feet/toes),
headache (dizziness, headaches, heart racing, chest pain), rectal itch (rectal itching,
bleeding and discharge), and bruising/bleeding (sore/bleeding gums, nose bleeds, easy
bruising, blood in spit/sputum). Body changes (weight gain, concern over weight gain,
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hump on back of neck/shoulders) was omitted from this questionnaire because it was
culturally not considered to be an important factor for the population in this study.
Validity and Reliability of SSC-HIVrev Instrument
To control the threat to internal validity, extensively used and well-tested
instruments was used for data collection. The Sign and Symptom Check-List for persons
with HIV disease (SSC-HIVrev) (Holzemer et al., 2001) is a reliable and highly valid
instrument. This instrument is reported to have high internal validity. The six symptom
clusters, the number of items in the factor and the Cronbach’s alpha reliability estimates
for this instrument were Malaise/Weakness/Fatigue (six items with Cronbach alpha of
0.90), Confusion/Distress (four items with Cronbach alpha of 0.90), Fever/Chills (four
items with Cronbach alpha of 0.85), Gastrointestinal Discomfort (four items with
Cronbach alpha of 0.81), Shortness of Breath (three items with Cronbach alpha of 0.79)
and Nausea/Vomiting (three items with Cronbach alpha of 0.77 (Holzemer et al., 2001, p.
1041). The reliability estimate of the instrument ranges between 0.76 to 0.94, showing
strong reliability and validity for this instrument.
Sample and Sampling Plan
Using power analysis (Cohen, 1988), 110 subjects (each group was composed of
55 subjects) were drawn among HIV patients receiving treatment at the Specialist
Hospital, Osun- State, Nigeria. This hospital was chosen because of the cosmopolitan
nature and large population of Osogbo, the location of the hospital. Osogbo is the capital
city of Osun state. The city has a population of approximately 250,951. This site provided
access to different ethnic groups in Nigeria, which could provide a broad generalization
for the study findings. The sample size was based on .05 significance level with an effect
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size of 0.4 and power of 0.8. To account for attrition from the study, an additional 15
percent increase in sample size was factored in.
Recruitment Problems
Selection criteria were based on the diagnosis of HIV. For the purpose of this
study, patients who have used or were using only herbal remedies for their HIV treatment
were contacted for participation in this study. However, it was very difficult to recruit
into this group. It appears that patients using only herbal therapy were trying to hide their
HIV status from their families, friends, and orthodox health care providers. Several
attempts were made to enlist patients into this group. The identified patients in the herbal
group only stalled this study for several months, as they kept requesting for time to think
about their participation in the study. After prolonged wait, this group fell out of this
study because of insufficient enrollment.
Only two groups were used in this study. The two groups are;
➢ Group A which included patients who were using conventional
antiretroviral medications only (ARV group).
➢ Group B which included patients who were using a combination of herbal
therapies and conventional antiretroviral medications for their treatment
(combined group).
Patients that meet the inclusion criteria were randomly selected from matched
participants as previously described. Informed consent was obtained before the inclusion
of subjects in the study. Participants were given full disclosure about the nature of the
study, the extent of their participation and voluntary nature of their participation in the
study. Subjects were able to voluntarily discontinue participation in the study at any time.
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Disclosure was made to subjects that the study may involve minimal risks, and these risks
were fully disclosed to subjects. All subjects who agreed to participate in the study were
required to sign the informed consent form.
Inclusion Criteria
Inclusion criteria for this study are as follows;
•

Age between 18 and 65

•

Diagnosis of HIV

•

Nigerian citizenship and

•

Residency in Nigeria

•

Ability to read, write, speak and understand English

•

Subjects must be receiving either antiretroviral medications only or herbal
medications only or a combination of antiretroviral medications and herbal
medications.
Exclusion Criteria

For the purpose of this study, patients with full-blown AIDS were excluded from
the study, as the aim of this study was to investigate and compare the efficacy of different
treatment protocols on HIV infection. Determination of full blown AIDS status was
based on the physical health of the patients. Non-ambulatory and bed-ridden patients
were considered to be a function of disease progression to full blown AIDS status. Such
patients were excluded from this study. Similarly, non-English speaking subjects were
excluded from the study. Subjects included men and women and selection was done
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based on inclusion and exclusion criteria. Full disclosure was given to research subjects
and written informed consent was obtained from each participant.
Control of Threats
To control the threats to the internal validity of the study result, subjects were
randomly selected from matched samples. Matching is a useful method in eliminating
confounding variables, as it will eliminate the sources of bias in the treatment. Also
randomization is a useful method in assigning treatment or intervention to study
participants, as it eliminates the sources of bias in the treatment (Polit & Beck, 2012;
Vickers, 2003 and Wendler, 2009). Randomization will also enhance the external validity
of the study finding, as it will ensure representative sampling, thereby enhancing the
generalizability of study findings to bigger population. The use of matching and
randomization will enhance the internal validity of the study results. An important
extraneous variable is the differences noted in the baseline CD4 counts among patients.
Analysis of covariance (ANCOVA) was used to statistically control the effect of baseline
CD4 counts.
Protection of Human Subjects
In the process of carrying out this study, appropriate attention was given to ethical
issues in research. Research subjects’ confidentiality was protected. Detailed information
about the study was explained to subjects and full disclosure of risks associated with the
study was made. The subjects were informed of their right to discontinue participation in
the study at any point during its course. Each subject was required to sign an informed
consent paper. Because of the initial apprehension of participants and the dynamic nature
of this study, process consent was used in combination with informed consent (Munhall,
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2007). Process consent is a way to continuously renegotiate informed consent to meet the
changing situation in the process of a study (Munhall, 2007; Usher & Arthur, 1998).
Process consent enables the participants to opt out of the study at any point if he/she
becomes uncomfortable or unable to go on with the study for whatever reason.
Throughout the process of this study, participants received continuous explanations of
and information about the study, and their permissions were sought on a continual basis.
This approach guaranteed necessary ethical issues needed in this study.
Patient confidentiality was maintained and a commitment to this effect was
provided to subjects in writing. Trained research assistant was strictly requested to not
disclose subjects’ information to anyone outside the research group. The research
assistant was required to sign a written commitment to maintain subjects’ privacy and
confidentiality at all time. Patient information was electronically stored in a passwordprotected computer system. All paper copies were stored under lock and key in a
fireproof cabinet. The paper copies were shredded after information was stored
electronically.
These measures also mitigate the risks involved in this study. This study involves
minimal risks. The risks associated with this study include potential breaches of
confidentiality and deep emotional and psychological trauma that could be precipitated
by discussion of health issues. To prevent psychological trauma to participants during
this study, informed consent was continuously renegotiated at different time during the
study. Participants were free to withdraw from the study at any point during the study.
Before the commencement of this study, ethical approvals were obtained from
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appropriate and relevant authorities in Nigeria and the U.S. Ethical approvals for this
study were obtained from the following authorities;
➢ Osun State Ministry of Health, Health Planning, Research and Statistics
Departments.
➢ Osun State Specialist Hospital, Osogbo Health Research Ethics Committee
(SHOSREC) and
➢ University of Massachusetts, Amherst Institutional Review Board (UMASS IRB).
Data Collection Methods and Procedures
Data collection was done for a period of five months and a week from November
16, 2015 to March 23, 2016. The study started on November 16, 2015 with the
identification of subjects using conventional anti-retroviral medications and those using a
combination of ARV and herbal medications. Subjects that meet the inclusion criteria
were randomly chosen from each group. The study was comprised of two groups (Group
A comprised of subjects using antiretroviral medications only {ARV group}; Group B
comprised of subjects using both herbal therapies and conventional antiretroviral
medications {Combined group}). General demographic information about the research
subjects was collected. Both SSC-HIVrev and WHOQOL-HIV BREF questionnaires
were administered to both groups.
HIV symptom management outcome was measured using the revised edition of
the Sign and Symptom Check-List for persons with HIV disease (SSC-HIVrev)
(Holzemer, Hudson, Kirksey, Hamilton & Bakken, 1999). For this instrument, subjects in
each group were asked to rate each sign or symptom on a three-point Likert scale as mild,

72

moderate or severe. Subjects were asked to rate the symptoms as they experience them on
a daily basis. If a subject is not experiencing a symptom on the day of the assessment,
he/she was instructed to record “not applicable”. With this, each item was scored as no
symptom= 0; mild= 1; moderate= 2; and severe= 3. The items within a factor will be
summed for a scale score. The symptoms cluster to be evaluated are; fatigue, fear, fever,
GI upset, shortness of breath, numbness, headache, rectal itch, bruising/bleeding, body
changes and gynecological-related problems for women. Appendices A and B shows the
SSC-HIVrev instrument and demographic questionnaire respectively. The quality of life
of HIV subjects was measured using the brief version of the World Health Organization
Quality of Life for HIV (WHOQOL-HIV BREF) instrument. Appendix C shows
WHOQOL-HIV BREF instrument/questionnaire. The questionnaires were administered
to patients in Groups A and B.
Data Analysis and Management
Data generated from the pilot study was analyzed using IBM SPSS Statistics 22
software. The reliability of both the SSC-HIVrev and WHOQOOL-HIV BREF were
analyzed using IBM SPSS Statistics 22 software. Both descriptive and inferential data
analyses were used to analyze study results. Descriptive statistics was used to analyze the
demographic data (age, gender, and ethnicity) while inferential statistics was used to
draw conclusion from study data. Paired sample t-test was used to determine the
difference between baseline CD4 counts and post treatment CD4 counts in both groups.
Analysis of covariance (ANCOVA) was used to statistically control the effect of baseline
CD4 counts in both groups and to examine the difference between both groups. Also,
independent t-test was used to compare the differences between symptom cluster and

73

quality of life between both groups. With this, it was possible to determine if there was
significant difference in treatment outcomes between the groups using conventional
antiretroviral only (i.e. ARV group) and those using a combination of conventional
antiretroviral medications and herbal therapy (i.e. the combined group).
The focus of data analyses was on the following areas:
(1) The difference between pre-treatment (baseline) CD4 counts and post treatment
CD4 in group A (i.e. the difference in pre- and post-treatment CD4 counts in
ARV group).
(2) The difference between pre-treatment (baseline) CD4 counts and post treatment
CD4 in group B (i.e. the difference in pre- and post-treatment CD4 counts in
combined group).
(3) The difference in CD4 counts of patient taking ARV only and those taking a
combination of herbal therapies and conventional antiretroviral medications (i.e.
differences in CD4 counts between ARV group and combined group).
(4) The difference in the symptom experience of patient taking ARV only and those
taking a combination of herbal therapies and conventional antiretroviral
medications (i.e. differences in symptom experience between ARV groups and
combined group).
(5) The difference in the quality of life of patient taking ARV only and those taking a
combination of herbal therapies and conventional antiretroviral medications (i.e.
differences in quality of life between groups A and B).

74

Methods Used to Analyze Research Questions
This study is carried out to answer five research questions. Appropriate statistical
analytical methods were employed to investigate each of these research questions.
Research Question #1: How do CD4 counts differ after treatment with antiretroviral
medications only?
To answer this question a pair sample t-test was ran on IBM SPSS Statistics 22
software.
Research Question #2: How do CD4 counts differ after treatment with a combined
therapy of herbal treatment and conventional antiretroviral medications?
To answer this question pair sample t-test was ran on IBM SPSS Statistics 22
software.
Research Question #3: What is the difference in CD4 counts of patient taking ARV only
and those taking a combination of herbal therapies and conventional antiretroviral
medications?
To answer this question ANCOVA was run on IBM SPSS Statistics 22 software.
Research Question #4: What is the difference in the symptom experience of patient
taking ARV only and those taking a combination of herbal therapies and conventional
antiretroviral medications?
To answer this question independent t-test was ran on IBM SPSS Statistics 22
software.
Research Question #5: What is the difference in the quality of life of patient taking
ARV only and those taking a combination of herbal therapies and conventional
antiretroviral medications?
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To answer this question independent t-test was ran on IBM SPSS Statistics 22
software.
Trustworthiness of Research Data
To control the threats to external validity of the study result, randomization was
used in sample selection. All patients that consented to participate in the study were
screened for meeting the inclusion criteria. Among the patients that meet the inclusion
criteria, sample selection was done randomly from matched subjects that are similar in
terms of important extraneous variables. Randomization was done by flipping a coin for
each of the patient that met the inclusion criteria and agreed to participate in the study. If
the coin came up “heads” the subject was included in the actual study. If the coin came
up “tails” the subject was excluded from the study. This method provided equal
opportunity for all participants to be included in the actual study, irrespective of
characteristics such as sex, age, tribe, or educational levels (Polit & Beck, 2012).
Randomization is a useful method of assigning treatment or intervention to subjects or in
sample selection, as it eliminates the sources of bias in the treatment (Burns & Grove,
2009; Polit & Beck, 2012; Vickers, 2006; Wendler, 2009). Randomization enhanced the
external validity of the study finding, as it ensured a representative sample, thereby
enhancing the generalizability of study findings to overall Nigerian population. Matching
of samples for important extraneous variables helped eliminate confounding variables
that could affect study results.
To further control for extraneous variables, the pretreatment (baseline) CD4
counts were statistically adjusted and controlled using analysis of covariance
(ANCOVA). ANCOVA is an appropriate tool to evaluate whether population means of a
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dependent variable are equal across treatment, while statistically controlling for the
effects of other continuous variables that are not of primary interest or for nuisance
variables. The use of ANCOVA helped to ensure that the differences in the baseline CD4
counts between the two groups were controlled for before comparison of the baseline
CD4 counts with post treatment CD4.
To control the threat to internal validity, extensively used and well-tested
instruments were used for data collection. The Sign and Symptom Check-List for persons
with HIV disease (SSC-HIVrev) (Holzemer et al., 2001) was used to evaluate symptom
improvement. This instrument is reported to have high internal validity. “The six
symptom clusters, the number of items in the factor and the Cronbach’s alpha reliability
estimates for this instrument were Malaise/Weakness/Fatigue (six items with Cronbach
alpha of 0.90), Confusion/Distress (four items with Cronbach alpha of 0.90), Fever/Chills
(four items with Cronbach alpha of 0.85), Gastrointestinal Discomfort (four items with
Cronbach alpha of 0.81), Shortness of Breath (three items with Cronbach alpha of 0.79)
and Nausea/Vomiting (three items with Cronbach alpha of 0.77) (Holzemer et al., 2001,
p. 1041).
The World Health Organization Quality of Life (WHOQOL) instrument was
developed by a group of reputable experts from World Health Organization (WHO).
Using confirmatory factor analysis, Skevington et al. (2004) analyzed the internal
consistency, item-total correlations, discriminant validity and construct validity and
found that the instrument has good to excellent psychometric properties of reliability and
good validity. The WHOQOL-HIV instrument was found to be an excellent cross-
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cultural valid assessment tool for quality of life within the physical, psychological, social
and environmental domains (Skevington et al., 2004).
To further ensure the validity of this study, research assistant was given adequate
training about his role in situating patients for questionnaire administration and
maintaining confidentiality and patients’ rights. A scientist was recruited to serve as
research assistants for this study. Only physiological tests (CD4 counts) that were carried
out in conformity with Osun State Specialist Hospital standard were used for this study.
Although some of the subjects have information about their CD4 counts, only CD4
counts obtained from patients’ medical records by the hospital staff were used in this
study.
Eliminating Confounding Variables
To eliminate confounding variables meticulous approach was used in data
selection and treatment. Research subjects must have been on treatment for similar length
of time. It is necessary to only compare treatment outcome in subjects with similar length
of therapy because outcome may have direct correlation with treatment duration. Also,
subjects using similar ARV regime were used so as to be able to eliminate potential side
effects that could impact on quality of life of subjects. Variables such as time of
commencement of treatment, type of treatment and duration of treatment were similar for
all the study subjects. Another potential source of confounder is the source of physiologic
(CD4) data. CD4 counts were obtained from subjects’ medical records. The differences
noted in the baseline CD4 were statistically controlled and adjusted for using analysis of
covariance (ANCOVA) before the between group comparative analysis was done.
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Summary
The aim of this study was to seek better understanding of the impact of different
therapies on the management of HIV. To gain deep insight into the efficacy of different
HIV treatment modalities, two distinct, but interrelated measures were used to evaluate
the treatment outcomes. The symptom outcome and perception of quality of life (QOL)
were considered to be important in measuring the efficacy of different treatments. Since
ARV is the gold standard for HIV treatment, it becomes imperative to compare the
symptom outcomes and QOL in patients using combined treatment with patients using
only conventional antiretroviral medications.
The use of matching was useful in eliminating confounding variables and
randomization ensured sample representativeness by eliminating bias in sample selection.
Random sampling ensured that all subjects that met inclusion criteria have the same
chance of participating in the study irrespective of characteristics such as sex, educational
level, age, tribe or sexual orientations. Extraneous variables in the pre-treatment data
were also statistically controlled and adjusted for using analysis of covariance
(ANCOVA). Baseline CD4 data varies across patients and between the two groups. To
compare the baseline CD4 with the post-treatment CD4 counts, the baseline CD4 were
controlled and adjusted for using ANCOVA. This method helped to control for
extraneous variables in the baseline CD4 counts.
This study strictly adhered to ethical issues in research. The findings from this
study have the potential to revolutionize HIV treatment protocol and could help in
developing pragmatic treatment modalities for HIV, especially in resource-constrained
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regions such as Sub-Saharan Africa while opening further opportunities for future
studies.
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CHAPTER 4
RESULTS
The aim of this study was to compare the efficacy of ARV therapy only with that
of a combination therapy of ARV and herbal medications among Nigerian HIV patients.
The study compared the symptom outcome, quality of life and CD4 of patients taking
ARV with those patients taking a combination of ARV and herbal medications. This
study was divided into two parts. The first part was a pilot study designed to test the
reliability of the study instruments. The second part was the actual study. This study
involved the following two groups;
➢ Group A- Comprised of subjects drawn from patients who are using only ARV
for their treatment (ARV Group).
➢ Group B- Comprised of subjects drawn from patients who are using a
combination of herbal therapies and conventional antiretroviral medications for
their treatment (Combine Group).
Subjects were placed in a group on the basis of the treatment protocol (medications) used
in the management of their HIV prior to contact for this study. No participants were
required to change their treatment regimen.
The Statistical Package for Social Sciences Version 23 was used to determine the
reliability of the study instruments, to calculate the frequencies, and determine
differences between groups using independent t-tests. ANCOVA was used to control for
confounding variables. In this chapter, the aspects of the study that will be discussed are
the process of obtaining approval for the study, the pilot study, process of subject
recruitment, recruitment for reliability pilot study, process of questionnaire
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administration, and results of the pilot study. Also, the actual study, process of subject
recruitment and recruitment for the actual study, process of questionnaire administration
for the actual study, problems encountered during recruitment and results of the actual
study are discussed in this chapter.
Presentation of Findings
The results obtained from the pilot and actual studies are methodologically
presented for clarity. The results of the pilot study are presented under two sub-headings;
➢ The results of demographic data and
➢ Result of Cronbach’s alpha
For the actual study, the results of demographic information were presented first,
followed by the results of the five research questions. Demographic results from the
actual study are presented under three sub-headings as follows:
➢ Results of demographic information of all the participants in the actual study
(both groups A and B).
➢ Results of demographic information of participants in group A (ARV group).
➢ Results of demographic information of participants in group B (Combine group).
This chapter concludes with a summary of the findings of the pilot and actual study.
Process of Obtaining Approval for the Study
Because of the nature of this study, approval was obtained from three different
authorities in Nigeria and in the United States. Ethical approval was obtained from Osun
State Ministry of health, department of health planning, research and statistics.
Application for approval was submitted to the state authority in December 2014 and
approval was given on January 23, 2015. Because this study was carried out at the State
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Specialist Hospital, Asubiaro, Osogbo, Osun-State, another institutional approval was
obtained from the research and ethics committee of the Specialist Hospital. The State
Specialist Hospital’s approval was granted on September 18, 2015.
Following the approval of Osun State Ministry of Health and State Specialist Hospital
authorities, Institutional Review Board approval was obtained from the University of
Massachusetts, Amherst. It was after the necessary approvals were obtained that the pilot
study was started.
Pilot Study
The main purpose of the pilot study was to determine the validity and reliabilities
of the two instruments used in this study; the brief version of the World Health
Organization Quality of Life Instrument for HIV (WHOQOL-HIV BREF) and the Sign
and Symptom Check-List for persons with HIV disease (SSC-HIVrev). These are highly
reliable and valid instruments. However, there is no record of their use in Nigeria or
among Nigerian population. Determination of the study instruments’ reliability is very
important because the reliability of these instruments will have a strong impact on the
results of the final study. The pilot study also helped this researcher to test the process of
conducting the final study, to test study design and navigate possible logistic issues that
could come up during the actual study.
To test the validity and reliability of these instruments, face validity and internal
consistency of both instruments were evaluated. The face validity was done by the
researcher. This researcher is an expert in Nigerian culture being originally from Nigeria
and fluent in one of the Nigerian major languages. The researcher meticulously reviewed
both questionnaires to determine if each item in both instruments is relevant to the
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Nigerian population. Only the weight factor (in the SSC-HIVrev) was considered to be
unimportant to the Nigerian population. Cronbach’s alpha was used to determine the
internal consistency of both questionnaires.
Process of Subject Recruitment
A Nigerian scientist served as the research assistant for this study. The research
assistant helped situate the subjects for the researcher to be able to communicate with
them via telephone or Skype. The research assistant gave the informed consent form to
each patient that meet the inclusion criteria and volunteered to participate in this study.
Over the phone or via Skype, the researcher provided information about the study to the
subjects. Subjects were given the opportunity to ask questions and the researcher clarified
subjects' questions and concerns. Subjects were expressly told over the phone or Skype
that they can opt out of the study at any time during the study. A few days after the initial
information session, another telephone conversation was had with the subjects for a
second time to identify those who still wanted to participate in the study. Only those
patients that met the inclusion criteria and signified their willingness by signing the
consent form were included in the reliability pilot study.
Recruitment for Reliability Pilot Study
Before the commencement of the actual study, the two instruments used for data
collection were subjected to reliability testing. Twenty subjects were randomly selected
from patients that meet the inclusion criteria for this study. Inclusion criteria for this
study were as follows:
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1.

Subjects must be between 18 years and 65 years.

2.

Subject must have diagnosis of HIV

3.

Subject must be a Nigerian citizen

4.

Subject must reside in Nigeria

5.

Subject must be able to read, write, speak and understand English.

6.

Subjects must be receiving either antiretroviral medications only, or herbal

medications only, or a combination of antiretroviral and herbal medications.
For the pilot study, twenty subjects were randomly selected among HIV patients
receiving treatment at the State Specialist Hospital, Asubiaro, Osun-State, Nigeria.
Randomization was done by flipping of coins. This method helped to eliminate
extraneous variables that could affect study results. A coin was flipped for each subject
who agreed to participate in the study. If the coin came up “heads”, the subject was
included in the pilot study. If the coin came up “tails”, the subject was excluded from the
study. This method provided equal opportunity for all participants to be included in the
actual study, irrespective of characteristics such as sex, age, tribe, or educational levels
(Polit & Beck, 2012).
The two questionnaires were administered to the 20 randomly selected subjects.
The two questionnaires administered were;
(a). The brief version of the World Health Organization Quality of Life Instrument for
HIV (WHOQOL-HIV BREF) and
(b). The Sign and Symptom Check-List for persons with HIV disease (SSC-HIVrev).
The reliability pilot study was carried out between October 12, 2015 and October 28,
2015. Study recruitment was done via a flyer.
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Process of Questionnaire Administration
Identification of subjects was done with the help of the Nigerian medical doctors
and the research assistant. The Nigerian doctors and research assistant provided access to
the patients but did not participate in the study, review the study nor were they
involved in providing explanation to the subjects. Also, they did not play any role
in obtaining informed consent from the subjects. Instead the Nigerian doctors were taking
care of the patients and assisted in the distribution of recruitment flyer to potential
subjects. The Nigerian doctors and scientist also helped situate the subjects for
questionnaire administration. Informed consent and questionnaire administration were
done via Skype and/or telephone after the researcher had provided information to study
participants and clarified patients concerns and questions. After completion of the
questionnaire, subjects were instructed to put their completed questionnaires in an
envelope, sealed the envelope and asked to give the sealed envelope to the research
assistant. All sealed envelope were sent to the researcher in the U.S. via courier service
for reliability test.
Results of Pilot Study
The pilot study was conducted for many reasons. The primary reason was to
determine the reliability of the two instruments used in this study. The other reasons were
to use the pilot study to test-run the actual study, to become familiar with the Nigerian
terrain, to identify possible problems that might occur during the actual study and to
navigate a way toward resolving such problems. During the pilot study, questionnaires
were administered to 30 participants. Out of this number, 6 (20%) did not complete the
questionnaires in full and 4 (13%) participants changed their mind about participation and
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dropped out of the study. Only fully completed questionnaires were included in the
reliability analysis. Descriptive data obtained from the pilot study is presented in Table 5
below.
The results of the demographic data obtained from the Pilot study are presented in
the Tables 5 to 13 below. 90% of the participants in the pilot study were women and 80%
of the participants were below 49 years old. As shown in Table 8, less than 40% of the
participants in the pilot study had secondary education, while 20% had university degrees
and 10% had a post graduate education. 30% of the participants reported having more
than elementary education but less than secondary education. 55% of the participants
were married. The participants were predominantly from Yoruba tribe (85%). This is
because the site of the study is located in Yoruba territory. The other Nigerian major
tribes, Igbo and Hausa, constituted 5% each while the remaining 5% cut across other
Nigerian tribes. Christians and Muslims constituted 55% and 45% of the participants
respectively. 60% of the participants in the pilot study reported working full-time while
20% work on a part-time basis. 15% of the participants were unemployed. Most of the
participants were low-income earners with 85% of the participants having an annual
income of less than N100,000 Nigerian Naira (approximately US$312 yearly income).
Cronbach’s Alpha
From the pilot data, the two instruments were analyzed for reliability. In the SSCHIVrev questionnaire one factor (the body changes) was omitted because it was not
considered to be an important factor among the population of study. Five items are
embedded in the omitted factor (body changes). The omitted items under the body
changes are;
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➢ weight gain in stomach area
➢ concern over weight gain
➢ hump on back of neck/shoulders
➢ skinny arms and legs and
➢ prominent leg veins
With the omitted factor, the Cronbach’s alpha for the SSC-HIVrev instrument was .915.
Cronbach’s alpha for each factor of the SSC-HIVrev instrument is presented in Table 14.
The Cronbach’s alpha for the World Health Organization Quality of Life instrument
(WHOQOL-HIV BREF) was found to be .840. Overall, both the SSC-HIVrev and
WHOQOL-HIV BREF were found to be highly reliable instruments among Nigerian
population.
Actual Study
The purpose of the actual study was to compare the efficacy of HIV treatment in
patients using only ARV with those patients who are using a combined therapy of ARV
and herbal medications. In doing this, this study was designed to compare symptom
experience and quality of life of patients taking ARV with those patients using
combination of ARV and herbal remedies. Physiological data (specifically CD4 counts)
obtained from these two groups was also compared.
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Process of Subject Recruitment
A process similar to the approach used in the recruitment of subjects for the pilot
study was used to recruit subjects for the final study. After the pilot study had been
carried out and the reliability of the two study instruments determined, recruitment
process for the actual study began. Recruitment poster and fliers were distributed to HIV
patients receiving treatment at the State Specialist Hospital, Osun-State, Nigeria. Consent
was properly obtained from all patients that signify interest in participating in the study.
Detailed explanation of the study and potential risks associated with the study were
disclosed to potential subjects. Subjects were given the opportunity to ask questions and
the researcher clarified subjects' concerns. All potential subjects were told of the
voluntary nature of the study and were told that they could discontinue their participation
in the study at any time without any repercussion. Two days after the initial discussion
with each subject, another conversation was held with each subject to ask if they were
still willing to participate in the study. Only those patients that met the inclusion criteria
and signified willingness by signing the consent form were enrolled in the actual
study. The actual study commenced only after each subject had given consent for the
study. During administration of the informed consent, the research assistant helped
situate the subjects for the researcher to be able to communicate with them via telephone
or Skype.
Recruitment for Actual Study
After data from the pilot study had been analyzed and the reliability of the two
instruments had been determined, recruitment for the final study commenced. Fliers were
distributed to patients receiving treatment at State Specialist Hospital, Osun-State,
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Nigeria. 150 patients initially consented to participate in this study; however, 22 patients
withdrew midway into the study. Questionnaires from 18 subjects were discarded
because of incomplete filing. Inclusion criteria for this study were as follows:
1.

Subjects must be between 18 years and 65 years old.

2.

Subject must have diagnosis of HIV

3.

Subject must be a Nigerian citizen

4.

Subject must reside in Nigeria

5.

Subject must be able to read, write, speak and understand English.

6.

Subjects must be receiving either antiretroviral medications only, or herbal

medications only or a combination of antiretroviral and herbal medications.
Participants were put in a group on the basis of the medications they were taking at the
time of contact for this study. For each group, participants were selected randomly from
matched subjects that have similarity in terms of important extraneous variables. Subjects
with similar treatment protocol, same treatment duration, and same duration of HIV
diagnosis were included in the study. Subjects in each group had started their treatment at
about the same time and were taking the same antiretroviral medications. From the
matched samples, participants in each group were selected by flipping a coin. For each
group, a coin was flipped for each subject who agreed to participate in the study. If the
coin came up “heads”, the subject was included in the actual study. If the coin came up
“tails”, the subject was excluded from the study. This method provided equal opportunity
for all participants to be included in the actual study, irrespective of characteristics such
as sex, age, tribe, or educational levels (Polit & Beck, 2012).
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Process of Questionnaire Administration
The process of administering study questionnaires was similar to the method used
in the pilot study. Identification of subjects was done with the help of the Nigerian
medical doctors and a research assistant. The Nigerian doctors and the research assistant
provided access to the subjects but did not participate in the study (they did not review
the study, were not involved in providing explanation to subjects, and did not play any
role in obtaining informed consent from the subjects). These Nigerian doctors were
currently taking care of HIV patients and assisted in the distribution of recruitment flyers
to potential subjects. The research assistant helped situate the subjects for questionnaire
administration. Informed consent and questionnaire administration were done via Skype
and/or telephone after the researcher had provided information to study participants and
clarified patients concerns and questions. The two questionnaires administered were;
➢ The brief version of the World Health Organization Quality of Life Instrument for
HIV (WHOQOL-HIV BREF) and
➢ The Sign and Symptom Check-List for persons with HIV disease (SSC-HIVrev).
The actual study was carried out between November 16, 2015 and March 23,
2016. After completion of the questionnaire, each subject put their completed
questionnaire in an envelope, sealed the envelope and gave the sealed envelope to the
research assistant. All sealed envelopes were sent to the researcher in the U.S. via courier
service for evaluation.
Problems Encountered During Recruitment
The process of recruiting subjects into this study was very tedious. Although the
physicians that were primarily taking care of HIV patients in the Specialist Hospital,
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Osun-State provided access to the patients, they played no role in explaining the study to
the patients, nor did they help in the recruitment process. At the initial stage of the
recruitment exercise, most of the patients contacted were very concerned about the
breach of confidentiality. Many of the patients expressed fears that their video could
secretly be taken and published in Nigeria and outside Nigeria. Discussions were held
about the ethics of conducting research and the grave consequences of any breach of
confidentiality or research ethics. It took concrete assurances from the principal
investigator for the patients to feel comfortable. Strong assurance was given to subjects
about maintaining confidentiality.
This study was initially designed to include three groups namely:
➢ Group A: Subjects drawn from patients using herbal therapies only.
➢ Group B: Subjects drawn from patients using conventional antiretroviral
medications (ARV) only and
➢ Group C: Subjects drawn from patients using a combination of herbal therapies
and conventional antiretroviral medications.
However, in the course of this study, the herbal-only group fell out because the
study could not recruit enough subjects from this group. At a point it became apparent
that patients using herbal therapy only were basically trying to go under the radar and
avoid their status from becoming known to anybody. Several attempts were made to
enlist patients in this group. The identified patients in the herbal group only stalled this
study for several months, as they kept requesting for time to think about their
participation in the study. Contacts were made to this group through their care providers.
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During the course of questionnaire administration it was discovered that the
combined group was covertly using herbal therapy in conjunction with the conventional
ARV. In fact the patients using combined therapy were making concerted effort to avoid
disclosure of their dual therapies to their care providers. These patients disclosed the use
of dual therapy under strict assurance of confidentiality. However, the patients were
encouraged to disclose all their co-concomitant medications to their care providers so that
they could be better cared for. The reluctance of the patients to disclose dual therapy to
physicians was attributed to the patients’ conviction that the physicians would stop them
from continued use of the herbal medications. All the patients in this group believe that
the improvement noted in their symptoms and quality of life was a result of the herbal
remedies they were taking.
Results of Actual Study
The demographic information for all the participants in the actual study is
presented below, followed by the demographic data for the ARV group and the combined
group respectively. The results of the five research questions are presented after the
demographic data. The results of the demographic data obtained from the actual study are
presented in Tables 15-27.
Results of Demographic Information for all Participants in the Actual Study
The actual study was conducted to determine the effect of both treatment
modalities on HIV symptoms and on the quality of life of HIV patients and to determine
if there is any difference in treatment outcomes among the two groups. During the actual
study, questionnaires were administered to 150 participants. Out of this number, 25
(17%) did not complete the questionnaires in full and 15 (10%) participants changed their
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minds about their participation and dropped out of the study. Only 110 participants that
fully completed the questionnaires were considered in the final analysis. To obtain
descriptive data for the actual study the frequency, mean and standard deviation were
calculated (Table 15).
The results of the demographic data obtained from the actual study are presented
in Tables 15 to 23. 76.4% of the participants in the actual study were women and 23.6%
were male. 63.6% of the participants were 45 years old or younger. As shown in Table
18, 53.6% of the participants in the actual study had secondary education, 18.2% had
university degrees, and 1.8% had a post graduate education. 72.7% of the participants
were married while 4.5% were single. The participants were predominantly from Yoruba
tribe (71.8%). This is because the site of the study is located in Yoruba territory. The
other Nigerian two major tribes, namely Igbo and Hausa, constituted 10% and 10.9%
respectively while the remaining 7.2% cut across other Nigerian tribes. Christians and
Muslims constituted 43.6% and 56.4% of the participants respectively. 86.4% of the
participants in the actual study reported working full time, while 3.6% reported working
on a part-time basis. 7.3% of the participants were unemployed. Most of the participants
were low income earners, with 84.6% of the participants having annual income of less
than N200,000 Nigerian Naira (approximately US$624 yearly income).

Results of Demographic Data for Participants in ARV Group and Combined Group
The results of the demographic data obtained from the ARV group are presented
in Table 24 and Tables 25-27. 80 percent of the participants in the ARV group were
women and 20 percent were male. 61.8% of the participants were 45 years old or
younger. As shown in Table 26, 61.8% of the participants in the ARV group had a
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secondary education while 14.5% had university degrees. 78.2% of the participants were
married while 1.8% of the participants were single. The participants were predominantly
from Yoruba tribe (70.9%). This is because the site of the study is located in the western
part of the country (Yoruba territory). The other two Nigerian major tribes, namely Igbo
and Hausa, constituted 10.9% each while the remaining 7.2% cut across other Nigerian
tribes. Christians and Muslims constituted 45.5% and 54.5% of the participants
respectively in the ARV group. 85.5% of the participants in the ARV group reported
working full-time, while 3.6% reported working on a part-time basis. 9.1% of the
participants were unemployed. Most of the participants were low income earners with
83.7% of the participants reporting an annual income less than N200,000 Nigerian Naira
(approximately US$624 yearly income). The results of the demographic data obtained
from the ARV group are presented in Table 24 and tables 25-27.

The results of the demographic data obtained from the combine group are
presented in Table 24 and tables 25-27. 72.7% of the participants in the combined group
were women and 27.3% were male. 65.5% of the participants were 45 years old or
younger. As shown in Table 26 below, 45.5% of the participants in the combine group
had a secondary education while 21.8% had university degrees and 3.6 percent had
postgraduate degrees. 67.3% of the participants were married while 7.3% of the
participants were single. The participants were predominantly from Yoruba tribe
(72.7%). This is because the site of the study is located in the western part of the country
(Yoruba territory). The other two Nigerian major tribes, namely Igbo and Hausa,
constituted 9.1% and 10.9% respectively. The remaining 7.3% cut across other Nigerian
tribes. Christians and Muslims constituted 41.8% and 58.2% of the participants
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respectively in the combine group. 87.3% of the participants in the combine group
reported working full time, while 3.6% reported working on a part-time basis. 5.5% of
the participants were unemployed. Most of the participants were low-income earners with
85.5% of the participants reporting an annual income of less than N200,000 Nigerian
Naira (approximately US$624 yearly income). The results of the demographic data
obtained from the combine group are presented in Table 24 and tables 25-27.

Results for Research Question 1
Research Question #1: How do CD4 counts differ after treatment with antiretroviral
medications only?
To evaluate the difference between pre-treatment (baseline) and post-treatment
CD4 counts among patient taking only ARV (ARV group), a pair sample t-test was run
on IBM SPSS Statistics 22 software. Results show that there is a significant difference
between the pre- and post-treatment CD4 counts among subjects taking ARV
medications only with t-value=-6.713, sig. (2-tailed)=.000 and df=39 as shown in Table
29. The paired sample statistics for ARV group is shown in Table 28.

Results for Research Question 2
Research Question #2: How do CD4 counts differ after treatment with combined
therapy of herbal treatment and conventional antiretroviral medications?
To evaluate the difference between pre-treatment (baseline) and post-treatment
CD4 counts among patient taking a combination of ARV medications and herbal
medications (combined group), a pair sample t-test was run on IBM SPSS Statistics 22
software. Results show that there is a significant difference between the pre- and post96

treatment CD4 counts among subjects taking a combination of ARV and herbal
medications (t-value=-6.080, sig. (2-tailed)=.000 and df=39 as shown in Table 31. The
paired sample statistics for combined group is shown in Table 30.

Results for Research Question 3
Research Question #3: What is the difference in CD4 counts of patient taking ARV only
and those taking combination of herbal therapies and conventional antiretroviral
medications?
To determine if there is a difference in pre- and post-treatment CD4 counts
between patient taking ARV only (ARV group) and patients taking combination of ARV
medications and herbal medications (combined group), independent t-test was run on
IBM SPSS Statistics 22 software. Results show that there is a significant difference in
baseline CD4 counts between the two groups (p-value=.002). After statistically
controlling the baseline CD4 counts with analysis of covariance (ANCOVA), results
show that there is no significant difference between the two groups post-treatment CD4
(p-value=.832) as shown in Table 32.
Results for Research Question 4
Research Question #4: What is the difference in the symptom experience of patient
taking ARV only and those taking a combination of herbal therapies and conventional
antiretroviral medications?
To determine if there is a difference in symptom experience between patients
taking ARV only (ARV group) and patients taking a combination of ARV medications
and herbal medications (combined group), an independent t-test was run on IBM SPSS
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Statistics 22 software. Results show that there is no significant difference between the
two groups in many of the factors; fatigue factor (p=.229), fear factor (p=.471), GI upset
factor (p=.891), SOB factor (p=.651), numbness factor (p=.597), headache factor
(p=.314), rectal itch factor (p=.538), bruising factor (p=.497) as shown in Table 33.
However, a significant difference was noted in fever (p=.003) and sore throat (p=.013)
factors between the ARV group and combined groups. The fever factor mean scores for
ARV group and combined group were .3045 and .6045 respectively. This signifies that
the patients in ARV group recorded a significantly better outcome in fever factor
compared to patients in the combined group. The intensity of fever episodes in the ARV
group was significantly lower than the fever intensity among patients in combined group.
Similarly, a significant difference was noted in sore throat factor (p=.013) among
the ARV group and combined groups. The sore throat factor mean scores for ARV group
and combined groups are .0273 and .1636 respectively. This signifies that the patients in
ARV group recorded significantly better outcome in sore throat factor compared to
patients in combined group. The intensity of sore throat in ARV group is significantly
lower than the sore throat intensity among patients in the combined group.

Results for Research Question 5
Research Question #5: What is the difference in the quality of life of patient taking
ARV only and those taking a combination of herbal therapies and conventional
antiretroviral medications?
To determine if there is a difference in the quality of life between patient taking
ARV only (ARV group) and patients taking a combination of ARV and herbal
medications (combined group), an independent t-test was run on IBM SPSS Statistics 22
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software. Findings show that there is no significant difference in many domains such as
physical domain (p=.183), psychological domain (p=.486), independence domain
(p=.689), environment domain (p=.119), personal belief domain (p=.703), QOL (p=.670).
Similarly, results show that there is no significant difference in overall quality of life
between the two groups (p=.211) as shown in Table 34. However, a significant difference
was noted in two domains-social relationship (p=.028) and health satisfy domains
(p=.049) between the ARV group and combined groups. The health satisfaction mean
scores for ARV group and combined groups were 4.1273 and 3.6545 respectively. This
signifies that patients in ARV group reported significantly better satisfaction in their
health compared to the combined group. A similar trend was noted in social relationship
domain. The social relationship domain mean scores for ARV group and combined group
are 16.2364 and 14.6364 respectively. This signifies that patients using ARV alone
recorded significantly higher improvement in their social relationship as compared with
patients using combination of ARV and herbal medications.

Table 5: Descriptive Statistics for Pilot Study Participants (n=20)
Number

Minimum

Maximum

Mean

Gender

20

1

2

1.90

Standard
Deviation
.308

Age
Education
Marital Status
Ethnicity
Religion
Employment
Income

20
20
20
20
20
20
20

30
2
1
1.00
1.00
.00
1.00

63
5
6
6.00
2.00
3.00
13.00

43.40
3.10
3.15
1.4000
1.4500
1.1500
10.900

9.773
.968
1.694
1.18766
.51042
.74516
4.01182
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Table 6: Gender of Pilot Study Participants (n=20)

Frequency

Percent

Valid
Percent

Cumulative
Percent

Male
Female

2
18

10.0
90.0

10.0
90.0

10.0
100.0

Total

20

100.0

100.0

Table 7: Age of Pilot Study Participants (n=20)

Age

Frequency

Percent
5.0
15.0
5.0
5.0
10.0

Valid
Percent
5.0
15.0
5.0
5.0
10.0

Cumulative
Percent
5.0
20.0
25.0
30.0
40.0

30
32
36
37
40

1
3
1
1
2

41
42

2
2

10.0
10.0

10.0
10.0

50.0
60.0

44
45

1
1

5.0
5.0

5.0
5.0

65.0
70.0

48
49

1
1

5.0
5.0

5.0
5.0

75.0
80.0

54
58
62
63

1
1
1
1

5.0
5.0
5.0
5.0

5.0
5.0
5.0
5.0

85.0
90.0
95.0
100.0

Total

20

100.0

100.0

100

Table 8: Level of Education of Pilot Study Participants (n=20)

Primary
Secondary
University
Postgraduate
Total

Frequency

Percent

6
8
4
2
20

30.0
40.0
20.0
10.0
100.0

Valid
Percent
30.0
40.0
20.0
10.0
100.0

Cumulative
Percent
30.0
70.0
90.0
100.0

Table 9: Marital Status of Pilot Study Participants (n=20)

Frequency

Percent

Valid Percent

Single

1

5.0

5.0

Cumulative
Percent
5.0

Married

11

55.0

55.0

60.0

Living as
Married
Separated

1

5.0

5.0

65.0

1

5.0

5.0

70.0

Divorced

3

15.0

15.0

85.0

Widowed

3

15.0

15.0

100.0

Total

20

100.0

100.0
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Table 10: Ethnicity of Pilot Study Participants (n=20)
Frequency

Percent

Valid
Percent

Cumulative
Percent

Yoruba
Hausa

17
1

85.0
5.0

85.0
5.0

85.0
90.0

Igbo
Other

1
1

5.0
5.0

5.0
5.0

95.0
100.0

Total

20

100.0

100.0

Table 11: Religion of Pilot Study Participants (n=20)

Frequency

Percent
55.0

Valid
Percent
55.0

Cumulative
Percent
55.0

Christian

11

Muslim
Total

9
20

45.0
100.0

45.0
100.0

100.0

Table 12: Employment Status of Pilot Study Participants (n=20)
Frequency

Percent
15.0

Valid
Percent
15.0

Cumulative
Percent
15.0

Not
Working
Full time
Employment
Part Time
Employment
Retired

3
12

60.0

60.0

75.0

4

20.0

20.0

95.0

1

5.0

5.0

100.0

Total

20

100.0

100.0
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Table 13: Income of Pilot Study Participants (n=20)
Frequency

Percent

Valid
Percent

Cumulative
Percent

>N1.2M

1

5.0

5.0

5.0

N1m to less
than N1.2m
N37K to less
than N100K
0 to less than
N37K
Total

2

10.0

10.0

15.0

8

40.0

40.0

55.0

9

45.0

45.0

100.0

20

100.0

100.0

Table 14: Cronbach Alpha for Each Factor in SSC-HIVrev
FACTORS
Fatigue Factor
Fear Factor
Fever Factor
GI Factor
Shortness of breath Factor
Sore-throat Factor
Numbness Factor
Headache Factor
Rectal Itch Factor
Bruising Factor

CRONBACH’S ALPHA
.83
.716
.698
.536
0
.647
.844
.570
.977
-.202
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Table 15: Descriptive Statistics for Actual Study Participants (n=110)
N
Gender

110

Minimu
m
1.00

Maximu
m
2.00

1.7636

Std.
Deviation
.42679

Age

110

22.0

65.0

42.9636

10.40371

Education

110

2.00

5.00

2.9545

.72170

Marital
Status
Ethnicity

110

1.00

6.00

2.6636

1.44804

110

1.00

6.00

1.6273

1.25515

Religion

110

1.00

2.00

1.5636

.49820

Employment

110

.00

3.00

1.0182

.46888

Income

110

1.00

13.00

11.4545

2.59370
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Mean

Table 16: Gender of Actual Study Participants (n=110)
Frequency

Percent

Valid
Percent

Cumulative Percent

Male
Female

26
84

23.6
76.4

23.6
76.4

23.6
100.0

Total

110

100.0

100.0

Table 17: Age of Actual Study Participants (n=110)

Age
(Year)
20-25
26-30
31-35
36-40
41-45
46-50
51-55
56-60
61-65
Total

Frequency

Percent

1
12
23
13
21
13
12
10
5
110

.9
10.9
20.9
11.7
19.1
11.7
10.8
9.0
4.5
100

Valid
Percent
.9
10.9
20.9
11.7
19.1
11.7
10.8
9.0
4.5
100

Cumulativ
e Percent
.9
11.8
32.7
44.4
63.5
75.2
86.0
95.0
100.0

Table 18: Education of Actual Study Participants (n=110)

Primary
Education
Secondary
Education
University
Education
Postgraduate
Education
Total

Frequency

Percent

Valid Percent

26

26.4

26.4

Cumulative
Percent
26.4

59

53.6

53.6

80.0

20

18.2

18.2

98.2

2

1.8

1.8

100.0

100

100.0

100.0
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Table 19: Marital Status of Actual Study Participants (n=110)

Frequency

Percent

Valid
Percent

Cumulative
Percent

Single

5

4.5

4.5

4.5

Married

80

72.7

72.7

77.3

Living as
Married
Separated

2

1.8

1.8

79.1

7

6.4

6.4

85.5

Divorced

2

1.8

1.8

87.3

Widowed

14

12.7

12.7

100.0

Total

100

100.0

100.0

Table 20: Ethnicity of Actual Study Participants (n=110)
Frequency

Percent
71.8

Valid
Percent
71.8

Cumulative
Percent
71.8

Yoruba

79

Hausa
Igbo

12
11

10.9
10.0

10.9
10.0

82.7
92.7

TIV/Idoma
Ijaw

2
1

1.8
.9

1.8
.9

94.5
95.5

Other
Total

5
100

4.5
100.0

4.5
100.0

100.0
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Table 21: Religion of Actual Study Participants (n=110)
Frequency

Percent

Valid
Percent

Cumulative
Percent

Christian
Muslim

48
62

43.6
56.4

43.6
56.4

43.6
100.0

Total

110

100.0

100.0

Table 22: Employment of Actual Study Participants (n=110)
Frequency

Percent
7.3

Valid
Percent
7.3

Cumulative
Percent
7.3

Not
Working
Full time
Employment
Part Time
Employment
Retired

8
95

86.4

86.4

93.6

4

3.6

3.6

97.3

3

2.7

2.7

100.0

Total

110

100.0

100.0

Table 23: Income of Actual Study Participants (n=110)

>N1.2m
N1m to less
than N1.2m
N900K to less
than N1m
N400K to less
than N500K
N300K to less
than N400K
N200K to less
than N300K

Frequency

Percent
1.8
2.7

Valid
Percent
1.8
2.7

Cumulative
Percent
1.8
4.5

2
3
1

.9

.9

5.5

3

2.7

2.7

8.2

2

1.8

1.8

10.0

6

5.5

5.5

15.5
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N100K to less
than N200K
N37K to less
than N100K

11

10.0

10.0

25.5

40

36.4

36.4

61.8

0 to less than
N37K

42

38.2

38.2

100.0

Total

110

100.0

100.0

Table 24: Age of Participants in ARV and Combined Groups in Actual Study

Age
(Year)

ARV

COMBINED

Frequency Percent

Valid
Percent

Cumulative
Percent

Frequency

Percent

Valid
Percent

Cumulative
Percent

20-25

1

1.8

1.8

1.8

0

0

0

0

26-30

5

9.1

9.1

10.9

7

12.7

12.7

12.7

31-35

10

18.2

18.2

29.1

13

23.7

23.7

36.4

36-40

7

12.7

12.7

41.8

6

10.8

10.8

47.2

41-45

11

20

20

61.8

10

18.2

18.2

65.4

46-50

8

14.5

14.5

76.3

5

9.1

9.1

74.5

51-55

8

14.5

14.5

90.8

4

7.2

7.2

81.7

56-60

3

5.5

5.5

96.3

7

12.7

12.7

94.4

61-65

2

3.6

3.6

100.0

3

5.4

5.4

100.0

Total

55

100.0

100.0

55

100.0

100.0
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Table 25: Descriptive Statistics for Participants in ARV and Combined Groups
ARV

Combined
N Minimum

Maximum

Mean

N

Minimum

Maximum

Mean

Std.
Deviation

Gender

55

1.00

2.00

1.8000

.40369

55

1.00

2.00

1.7273

Std.
Deviatio
n
.44947

Age

55

22.00

65.00

43.0364

10.09210

55

27.00

65.00

42.8909

10.79896

Educati
on
Marital
Status
Ethnicit
y
Religio
n
Employ
ment
Income

55

2.0000

4.0000

2.90909
1

.6168236

55

2.0000

5.0000

3.00000

.8164966

55

1.00

6.00

2.6000

1.38245

55

1.00

6.00

2.7273

1.52090

55

1.00

6.00

1.6364

1.23773

55

1.00

6.00

1.6182

1.28367

55

1.00

2.00

1.5455

.50252

55

1.00

2.00

1.5818

.49781

55

.00

3.00

.9818

.45096

55

.00

3.00

1.0545

.48756

55

1.00

13.00

11.1636

3.09578

55

1.00

13.00

11.7455

1.95522

Table 26: Demographics of Participants in ARV and Combined Groups
ARV
Frequ Perc
ency ent

Gender

Education

Male

11

20.0

Female

44

80.0

total

55

Primar
y
Second
ary
Univer

13

100.
0
23.6
4
61.8
1
14.5

34
8

Combined
Valid Cum Freq Perc
Perce ulati uenc ent
nt
ve
y
Perc
ent
20.0 20.
15
27.3
0
80.0 100 40
72.7
.0
100.
55
100.
0
0
23.6 23.
16
29.1
4
64
61.8 85.
25
45.5
1
45
14.5 100 12
21.8
109

Valid Cumulati
Percen ve
t
Percent

27.3

27.3

72.7

100.0

100.0
29.1

29.1

45.5

74.5

21.8

96.4

sity
Postgr
aduate
Total
Marital
status

Ethnicity

Religion

0
55

5
0

5
0
100.
0
1.8

Single

1

100.
0
1.8

Marrie
d
Living
as
marrie
d
Separa
ted
Widow
ed
Total

43

78.2

78.2

2

3.6

3.6

2

3.6

3.6

7

12.7

12.7

55

Yorub
a
Hausa

39

100.
0
70.9

100.
0
70.9

6

10.9

10.9

Igbo

6

10.9

10.9

TIV/Id
oma
Ijaw

1

1.8

1.8

1

1.8

1.8

Others

2

3.6

3.6

Total

55

Christi
an
Musli
m
Total

25

100.
0
45.5

100.
0
45.5

30

54.5

54.5

55

100.
0

100.
0

.0
100
.0

2

3.6

3.6

100.0

55

100.0
7.3

7.3

1.8

4

100.
0
7.3

80.
0
83.
6

37

67.3

67.3

74.5

5

9.1

9.1

83.6

87.
3
100
.0

2

3.6

3.6

87.3

7

12.7

12.7

100.0

55

100.0

40

100.
0
72.7

72.7

72.7

6

10.9

10.9

83.6

5

9.1

9.1

92.7

1

1.8

1.8

94.5

0

0

0

94.5

3

5.5

5.5

100.0

55

100.0

23

100.
0
41.8

41.8

41.8

32

58.2

58.2

100.0

55

100

100.0

70.
9
81.
8
92.
7
94.
5
96.
4
100
.0

45.
5
100
.0

110

Employme
nt

Unemp
loyed
FullTime
PartTime
Retired

5

9.1

9.1

9.1

3

5.5

5.5

5.5

47

85.5

85.5

48

87.3

87.3

92.7

2

3.6

3.6

2

3.6

3.6

96.4

1

1.8

1.8

94.
5
98.
2
100
.0

2

3.6

3.6

100.0

Total

55

100.
0

100.
0

55

100.
0

100.0

Table 27: Income of Participants in ARV and Combined Groups
ARV
Freque Percen
ncy
t

Valid
Percen
t
1.8

Cumulativ
e Percent

1.8

Combined
Cumula Freque Percent
tive
ncy
Percent
1.8
1
1.8

Valid
Percent

>N1,200,000

1

1.8

N1,000,000 to
less than
N1,200,000
N900,000 to less
than N1,000,000
N400,000 to less
than N500,000
N300,000 to less
than N400,000
N200,000 to less
than N300,000
N100,000 to less
than N200,000
N37,000 to less
than N100,000
0 to less than
N37,000
Total

3

5.5

5.5

7.3

0

0

0

1.8

1

1.8

1.8

9.1

0

0

0

1.8

1

1.8

1.8

10.9

2

3.6

3.6

5.5

0

0

0

10.9

2

3.6

3.6

9.1

3

5.5

5.5

16.4

3

5.5

5.5

14.5

6

10.9

10.9

27.3

5

9.1

9.1

23.6

20

36.4

36.4

63.6

20

36.4

36.4

60.0

20

36.4

36.4

100

22

40.0

40.0

100.0

55

100

100

55

100.0

100.0

111

1.8

Table 28: Paired Sample Statistics for ARV Group (n=40)

Pair 1
BaselineCD4

Mean
298.6750
567.4500

N
40
40

Std. Deviation
139.06987
272.07276

PostTXCD4

Table 29: Paired Sample t-test for ARV Group (n=40)

Paired Differences
Mean
Pair 1 BaselineCD4PostTXCD4

268.77500

Std.
Deviation
253.22661

t
-6.713

Table 30: Paired Sample Statistics for Combined Group (n=39)

Pair 1
BaselineCD4

Mean
378.3333
598.5641

N
39
39

PostTXCD4

112

Std. Deviation
177.97018
210.81568

df
39

Sig (2tailed)
.000

Table 31: Paired Sample t-test for Combined Group (n=39)

Paired Differences

Pair 1 BaselineCD4 PostTXCD4

t

df

Mean

Std.
Deviation

Sig. (2tailed)

220.23077

226.19803

-6.080

38

.000

Table 32: ANCOVA table for CD4 Count

Group 1 ARV(n=)

Baseline
CD4
Post CD4

Mean

SD

Group 2 COMBINED
GROUP(n=)
Mean
SD

567.4500

272.07276

598.5641

113

210.81568

F
10.533

p
.002

.045

.832

Table 33: Independent t-test for SSC-HIVrev

Variable

Group 1 ARV
(n=55)
Mean

Group 2 COMBINED
(n=55)

(SD)

Mean

(SD)

t

p

Fatigue Factor

.5273

.68663

.7318

1.04622

-1.212

.229

Fear Factor

.5773

.5773

.4909

.52916

.723

.471

Fever Factor
GI Upset Factor

.3045
.2455

.40737
.35840

.6045
.2545

.59840
.33771

-3.073
-.137

.003
.891

SOB Factor

.0545

.24649

.0364

.16571

.454

.651

Sore Throat Factor

.0273

.09220

.1636

.38556

-2.551

.013

Numbness Factor

.6091

.82332

.6909

.79635

-.530

.597

Headache Factor

.3909

.43238

.4727

.41576

-1.012

.314

Rectal Itch Factor

.1333

.44721

.1879

.47904

-.617

.538

.15380

.0864

.19376

-.681

.497

Bruising Factor

.0636

Table 34: Independent t-test for WHOQOL-HIV BREF

Variable (Domain)

Group 1 ARV (n=55)
Mean

(SD)

Physical Domain
Psychological
Domain
Independence
Domain
Social relationship
Domain
Environment
Domain
Personal belief
Domain

16.2545

2.56918

Group 2 COMBINED
(n=55)
Mean

(SD)

t

p

15.5818

2.69218

1.341

.183

16.9455

2.45416

16.3491

5.82564

.700

.486

14.3091

2.11584

14.8182

9.16938

-.401

.689

16.2364

3.27145

14.6364

4.18712

2.233

.028

16.0182

2.40170

15.2182

2.91033

1.572

.119

13.3638

3.77302

13.0909

3.70322

.383

.703

QOL

4.4364

.71398

4.3818

.62334

.427

.670

Health satisfy

4.1273

1.10645

3.6545

1.36379

.1.996

.049

Sum WHOQOL

93.1273

10.31684

89.6945

17.38157

1.259

.211

114

CHAPTER 5
DISCUSSION
The purpose of this study was to investigate HIV treatment outcomes among
patients using only antiretroviral medications (ARV) and among those using a combined
therapy of ARV and herbal medications. This study also compares treatment outcomes in
these two groups. Two instruments, namely the SSC-HIVrev and the WHOQOL-HIV
BREF, were used to evaluate and compare treatment outcomes in these two groups.
Novel findings were obtained from this study. Many of the findings of this study are
consistent with findings from previous studies. In this section, findings of this study will
be discussed, as well as its strengths, limitations, and implications. This chapter
concludes with recommendations and a summary statement.
Discussions of the findings focus on the validity and reliability of the study
instruments, discussion of demographic information, discussion of the findings of each
research question, and discussion of treatment outcomes in the patients taking only ARV
and patients taking a combination of ARV and herbal remedies.
Reliability of Instruments
To ascertain the suitability of the study instruments, a reliability test was done
with a pilot sample. The two study instruments were administered to twenty subjects. The
subjects were selected randomly among HIV patients receiving treatment at the State
Specialist Hospital, Osun-State, Nigeria.
WHOQOL-HIV BREF
The Cronbach’s alpha for the WHOQOL-HIV BREF among Nigerian patients
was found to be .84. This indicated that this instrument has good reliability among
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Nigerian patients. This finding is consistent with findings from previous studies among
different populations (Akinboro et al., 2014; Razavi et al., 2012; Reychler, Caty, Vincent,
Billo, & Yombi, 2013; Saddki et al., 2009). Akinboro et al. (2014) reported Cronbach’s
alpha ranging between .81 and .85. A similar trend was reported by Saddki et al. (2009)
with Malay’s version of WHOQOL-HIV having Cronbach’s alpha values ranging from
0.60 to 0.87 across all domains. Also, in consistency with this study, the French version
of WHOQOL-HIV was reported to have high reliability with Cronbach’s alpha of 0.944
(for spiritual/religion/personal beliefs domain), 0.94 (level of independence domain),
0.937 (psychological domain), 0.938 (environmental domain), 0.94 (social relationships
domain), and 0.942 (physical domain) (Reychler, Caty, Vincent, Billo, & Yombi, 2013).
Razavi et al. (2012) reported that the reliability alpha among Iranian populations ranges
between 0.61 and 0.8. Based on the reliability findings for this instrument in the pilot
study, it is evident that the WHOQOL-HIV BREF is a suitable and highly reliable
instrument for this study.
SSC-HIVrev
Similarly, a very high reliability was obtained for the SSC-HIVrev among
Nigerian patients. This instrument is composed of six factors. However, a factor (i.e. the
body changes) was omitted in the SSC-HIVrev questionnaire because it was not
considered to be an important factor among the population of study. With the omitted
factor, the Cronbach’s Alpha for the SSC-HIVrev instrument was .915. A factor (i.e.
shortness of breath factor) was found to be negative. This indicates that there was no
variation among the participants’ responses to the question. The negative and low alpha
scores seen in some factors may indicate mixed understanding of the way the participants
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understood the item and items’ response options. The low alpha scores mean that items
are not highly correlated. There may be a need to refine the wording of this questionnaire
to be consistent with Nigerian cultural interpretation.
Fundamental assumptions of this instrument might need to be refined as well.
Records of reliability of this instrument among Nigerian population were not found in the
literature. However, the high reliability found in this study is consistent with findings
from Holzemer et al. (2001). The reliability Cronbach’s alpha obtained by Holzemer et
al. (2001) ranges between 0.76 to 0.94. “The six symptom clusters, the number of items
in the factor and the Cronbach’s alpha reliability estimates for this instrument were
Malaise/Weakness/Fatigue (six items with Cronbach alpha of 0.90), Confusion/Distress
(four items with Cronbach alpha of 0.90), Fever/Chills (four items with Cronbach alpha
of 0.85), Gastrointestinal Discomfort (four items with Cronbach alpha of 0.81), Shortness
of Breath (three items with Cronbach alpha of 0.79) and Nausea/Vomiting (three items
with Cronbach alpha of 0.77” (Holzemer et al., 2001, p. 1041). This shows strong
reliability and validity for this instrument.
Face validity of both instruments was also evaluated by the researcher. Face
validity was done to see if the items are culturally relevant to Nigerian population. Being
originally from Nigeria and fluent in one of the dominant Nigerian languages, the
researcher is an expert in Nigerian culture. Evaluating both the face validity and internal
consistency of both questionnaires showed that the instruments were highly valid and
culturally relevant to Nigerian population. Only the weight factor in the SSC-HIVrev was
considered to be unimportant to the Nigerian population.
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Trends from Demographic Data
Findings from this study show that there is a disparity in the population of male
patients seeking and receiving treatment for HIV. Over three quarter (76.4%) of
participants in this study were females with only 23.6% male participants. Even in both
the ARV group (80% females and 20% males) and the combined group (72.7% females
and 27.3% males) more females were receiving treatments. The high population of
female participants is a reflection of the large population of female patients receiving
treatment in the clinic. Significantly lower numbers of male patients were receiving
treatment at the clinic. The disproportionally large female population noted in this study
is consistent with findings from Bello and Bello (2013). In Bello and Bello’s (2013)
evaluation of the quality of life of HIV/AIDS patients in a secondary health care facility
in the Nigerian city of Ilorin. 70% of the participants were female. Similarly, participants
in Onyebuchi-Iwudibia & Brown (2014) and Ahmed et al. (2013) were 72.4% and 62.4%
females respectively. Ahmed et al. (2013) reported the HIV testing rate among females
(62.4%) to be significantly higher than that of male (37.6%) at facilities in Nigeria.
Takarinda et al. (2016) also found that females in Zimbabwe tend to make themselves
available for HIV testing. In determining the HIV testing rates among Zimbabwean males
and females, Takarinda et al. (2016) reported testing rates of 61% among Zimbabwean
females as compared to 39% males. The implication of this is that there is a high
population of HIV-positive men that are not diagnosed. This translates into fewer males
eventually entering into treatment, as noted in Egbe, Omoregie & Alex-Ighodalo (2015).
The lower testing rates noted in males could have large negative public health
consequences. It is likely that the male sense of invincibility is partially responsible for
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the low testing and low treatment rates. Studies have shown that there is a high
population of male HIV patients in Nigeria. According to the National HIV/AIDS and
Reproductive Health Survey (NARHS) conducted in 2012, there is a national HIV
prevalence of 3.4% (NACA, 2014). 58% of HIV-positive people in Nigeria are women,
and 42% of HIV patients are men (NACA, 2012). This translates into over 1.4 million
HIV positive males. This is an astonishingly high HIV population among Nigerian men.
In the light of Smith’s (2007) assertion that sexual and economic disparities and
contradictory moralities could contribute to an HIV epidemic in Nigeria, the Nigerian
male population need to be encouraged to seek testing and treatment for HIV. If most of
these male patients are not entering into treatment, this may portend grave public health
issues particularly in society where polygamy is a generally acceptable and widely
practiced cultural norm (Lawan, Envuladu & Abubakar, 2016). This becomes all the
more serious, considering prevailing gender inequality and the inability of females to
negotiate sexual relationships in many Nigerian cultures. It is necessary for coordinated
efforts to pull male HIV patients into treatment in conventional HIV clinics.
This study revealed that a majority of study participants (80%) had secondary
education or lower. Only 1.8% were found to have a postgraduate education and 18.2%
were found to have a bachelor’s degree. This shows that highly educated Nigerians are
not participating in treatment. A consistent finding by Suleiman & Momo (2015) found
that 65.3% of HIV patients receiving antiretroviral therapy in two hospitals in Bayelsa
state, Nigeria had secondary (high school) education or below. Similarly, Lubinga, Kintu,
Atuhaire, & Asiimwe (2012) also found that 96.1% of patients in a western Uganda study
had a secondary education or below. According to the United Nations Human
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Development Report, Nigeria has a 62.6% poverty rate in 2016
(http://www.ng.undp.org/content/nigeria/en/home/library/poverty/national-humandevelopment-report-2016.html). With the poverty index of Nigeria at all time high,
highly educated HIV positive individuals have the financial advantage to attract
individuals with less education into unprotected sex. This could lead to a higher incidence
of HIV among Nigerians. Strategic approaches need to be adopted to encourage highly
educated Nigerian professionals to seek treatment from orthodox HIV clinics and/or
hospitals. It appears that a higher number of poor and economically disadvantaged people
tend to seek treatment for HIV.
The majority of patients (72.7%) who were receiving treatment in both groups
were married, with an additional 1.8% living as married. 78.2% of subjects in the ARV
group and 67.3% of subjects in the combined group were in a legal relationship.
However, a majority of the married participants disclosed to the researcher that their
spouses were not aware of their HIV status. Reasons given for non-disclosure include the
stigma attached to HIV and the fear of being rejected by their spouses and family
members. Although tremendous improvements have been made to reduce the
stigmatization of HIV patients, a substantial stigma is still attached to the infection in
Nigeria. Onyebuchi-Iwudibia & Brown (2014) reported a high level of HIV-related
stigma among HIV patients in the eastern part of Nigeria, noting a strong association
between stigma and depression. A similarly high level of stigmatization against HIV
patients was reported by Downshen, Binns & Garofolo (2009) and Simbayi et al. (2007).
Stigmatization is known to have a significant impact on the physical health and the
overall quality of health of HIV patients. As a result, more efforts have to be channeled
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into education and increasing acceptance and support for HIV patients. Non-disclosure of
HIV status to spouses is very dangerous, as this could put spouses of HIV patients at risk
of contracting the disease. It is necessary that concerted efforts should be directed at
encouraging disclosure of HIV status to spouse and family members.
Findings from this study show that although over 86% of participants are engaged
in full time employment, a significantly high number of this population (90.1%) are low
income earners with an annual income of less than N300,000 (three hundred thousand
Nigerian Naira). This translates into an annual income of US$700 (seven hundred
American dollars). This trend is indicative of poor financial status of most of the
participants receiving treatment. Since HIV prevalence cuts across different income strata
of the Nigerian population, it could be assumed that high income earners are not entering
conventional treatment in comparable numbers to low-income earners. Also, it is possible
that high-income earners could be avoiding treatment in conventional HIV clinics or
going “under the radar” to source for alternative treatments which may include herbal
remedies. During the initial but failed recruitment efforts into the herbal-only group, all
the patients contacted for enrollment into the herbal group were in highbrow locations
and working in top private and government establishments. Although their identities were
essentially concealed, their care provider disclosed that they were not willing to be
identified because of their prominent status in the society.
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Research Questions
This study was carried out to seek answers to five research questions. These
research questions could provide great insight into treatment outcomes in patients taking
only ARV and in patients taking a combined therapy of ARV and herbal medications.
Research Question 1
The first research question for this study was, “How do CD4 counts differ after
treatment with antiretroviral medications only?”. Findings from this study show that there
is a significant difference between pre- (baseline) and post-treatment CD4 counts among
subjects taking ARV medications only (t=-6.713, sig (2-tailed)=.00 and df=39). CD4
count is a good biomarker of HIV treatment outcome. This study shows that ARV
resulted in significant improvements in CD4 counts after less than six months of ARV
therapy. The difference noted in the post CD4 counts is consistent with findings from
previous studies (Coetzee et al.,2004; Fairall et al., 2008; Idigbe et al., 2005). Fairall et al.
(2008) also reported an increase of 15.1cells/μL in CD4 cell counts with each month of
highly active anti-retroviral therapy (HAART) administration among South African
patients, while Coetzee et al. (2004) reported good clinical outcomes among patients
receiving ARV in Khayelitsha, South Africa. Among Nigerian patients, Idigbe et al.
(2005) found that ARV led to an increase in CD4 counts and improvement in the overall
physical wellness of Nigerian patients receiving a combination of Nevirapine, Stavudine
and Lamivudine. The finding of this study supports the fact that ARV is currently the
gold standard in the management of HIV infection. This could be noted in the significant
increase in baseline CD4 counts from 298.6750 to 567.4500 post-ARV treatment across a
six-month treatment period.
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Research Question 2
The second research question for his study was, “How do CD4 counts differ after
treatment with a combined therapy of herbal treatment and conventional antiretroviral
medications?” Findings from this study show that there is a significant difference
between the pre- and post-treatment CD4 counts among subjects taking a combination of
ARV and herbal medications (t=-6.080, sig. (2-tailed)=.00 and df=38. CD4 count is a
good biomarker of HIV treatment outcomes. CD4 counts increased from 378.3333
baseline to 598.5641 post-treatment with a combined therapy of ARV and herbal
medications.
The significant difference noted in CD4 counts in this group is consistent with
findings from Ayuba et al. (2014). Ayuba et al. (2014) investigated the efficacy of a West
African bicolor-based traditional herbal preparation (Jobelyn) used in combination with
ARV among Nigerian patients. Consistent with findings of this study, Ayuba et al.
(2014) reported improvement in CD4 counts of patients receiving ARV only and those
patients taking a combination of Jobelyn and ARV. However, Ayuba et al. (2014) found
that patients that received a combination of ARV and Jobelyn recorded faster
improvement in CD4 counts with a higher level of statistical significance at 6 weeks and
12 weeks when compared with patients that received only ARV. Awodele et al. (2012)
reported a marginal improvement in the CD4 counts and viral load of HIV patients using
herbal medications when compared with those patients who are not in herbal therapy.
However, the improvement noted between the herbal group and non-herbal group was
found not to be statistically significant (Awodele et al., 2012). No side effects or cross
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reactions were reported by patients taking combined therapy. Reasons given for taking
herbal therapy include to improve general health and immune systems, to reduce pain,
and to ameliorate symptoms of opportunistic infection.
Research Question 3
The third research question for this study was “What is the difference in CD4
counts of patient taking ARV only and those taking a combination of herbal therapies and
conventional antiretroviral medications?” This study compared the efficacy of ARV only
therapy with a combined therapy of ARV and herbal remedies. Results show that there is
no significant difference in the post treatment CD4 counts between the ARV group and
the combined group. This result shows that when CD4 counts are used as biomarkers to
evaluate treatment outcome between these two groups, there was no difference in
treatment outcome. This finding is in contrast to findings by Ayuba et al. (2014) which
found a significantly higher statistical difference in the treatment outcomes between
patients receiving ARV only and patients that received a combination of ARV and herbal
remedy with Jobelyn. Although Ayuba et al. (2014) found improvements in both the
ARV only group and the combined group, the study found that the combined group
achieved faster improvement in CD4 counts with a higher level of statistical significance
at 6 weeks and 12 weeks when compared with the ARV only group. It could be assumed
that herbal remedies produced no significant effect in treatment outcomes when used in
combination with ARV. If herbal remedies contributed in any significant way, it is
expected that the use of herbal remedies concomitantly with ARV should produce
treatment outcome that will significant improve the post-treatment CD4 counts in the
combined group when compared with ARV only group. If herbal medications produced
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an additive therapeutic role to ARV when they were used concomitantly with ARV, the
combined therapy is expected to result in better treatment outcomes and significant
improvement in physiological factors such as CD4 counts. Although the mean CD4 count
in combined group (598.5641) is higher than the CD4 counts in the ARV-only group
(567.4500), the slight increase noted in the combined group is not statistically significant
to confer superiority of treatment outcome on the combined group.
Unlike the findings from Ayuba et al. (2014), the “no difference” noted between
these groups may be because of the ineffective therapeutic nature of the specific herbal
medications taken by the combined group. The therapeutic, pharmacodynamics and
pharmacokinetics of the herbal medications used in this study were not known. Hence,
the lack of difference seen in this study may show that the types of herbal medications
used by participants of this study did not produce any therapeutic effects. While some
herbal medications have shown superior efficacy (Ayuba et al., 2014; Onifade et al.,
2011a; Sangkitporn et al., 2005; Sugimoto et al., 2005) it could be assumed that not all
herbal medications are resulting in similar treatment outcomes. The herbal medications
used in this current study probably helped to reduce some side effects and reduced the
incident of opportunistic infections.
A very important finding of this study was that the use of herbal medications did
not produce any undesirable outcome in CD4 counts. Since herbal remedies are widely
used, widely available and easily accessible in Nigeria, it is important to note that the use
of herbal medications with ARV did not result in any undesirable outcome. In the ARV
group, mean baseline CD4 counts increased from 298.6750 to 567.4500 after treatment.
Similarly, in the combined group, the baseline CD4 counts increased from 378.3333 to
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598.5641 post-treatment. The initial statistical difference noted between the baseline CD4
of the ARV group and combined group was statistically adjusted for using analysis of
covariance (ANCOVA).
A striking finding was obtained from this study. This study showed that 100% of
patients taking herbal medications concomitantly with ARV reported that their care
providers were not aware of their use of herbal remedies. Reasons given for nondisclosure include the fear of possible treatment denial and reproach from their
physicians and care providers. Similar finding were recorded by Lubinga, Kintu,
Atuhaire, & Asiimwe (2012) among HIV patients in Western Uganda where 92.3% of
patients reported that their physicians were not aware of their concomitant use of herbal
medications with ARV. Similarly, Peltzer, Preez, Ramlagan, & Fomundam (2008) also
reported that 90% of HIV patients in KwaZulu-Natal, South Africa did not disclose
concomitant use of herbal medications with ARV to their physicians. In addition, in a
study among patients in Kumasi metropolis in Ghana, Gyasi, Tagoe-Darko, & Mensah
(2013) found that 70% of patients used herbal medications. However, Gyasi, TagoeDarko, & Mensah (2013) found that 93.9% of HIV patients did not disclose their use of
herbal medications to their physicians. This pattern of non-disclosure was also reported
by Shedlin et al. (2013) among Mexican-origin patients in a U.S.-Mexico border HIV
clinic. Many reasons were given for the use of herbal medications. As also noted by
Shedlin et al. (2013) patients using herbal medications reported using it to help their
general health, improve their immune systems, and ameliorate symptoms of opportunistic
infection and side-effects related to ARV use. This is consistent with the reported use of
herbal medications in pain management (Gyasi, Tagoe-Darko, & Mensah, 2013; Peltzer,
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Preez, Ramlagan, Fomundam, 2008), stress relief, appetite stimulation and to promote
general physical well-being (Gyasi, Tagoe-Darko, & Mensah, 2013).
Research Question 4
The fourth research question for this study was, “What is the difference in the
symptom experience of patient taking ARV only and those taking a combination of
herbal therapies and conventional antiretroviral medications?”. The difference in
symptom experience between the two groups was measured using the SSC-HIVrev
instrument. A comparative analysis of overall symptom experience of patients in the
ARV-only group and combined group shows that there is no significant difference
between the two groups. Although no significant difference was noted in overall
symptom experience in both groups, significant difference was noted in some factors of
the symptom cluster. Specifically, significant differences were noted in fever (p=.003)
and sore throat factors (p=.013). The fever factor mean scores for ARV group and
combined group were .3045 and .6045 respectively. This signifies that the patients in the
ARV group recorded significantly better outcomes in fever factor compared to patients in
the combined group. The intensity of fever episode in ARV group was significantly lower
than the fever intensity among patients in combined group.
Similarly, a significant difference was noted in sore throat factors (p=.013)
between the ARV group and combined groups. The sore throat factor mean scores for
ARV group and combined group were .0273 and .1636 respectively. This signifies that
the patients in ARV group recorded significantly better outcome in sore throat factor
compared with patients in the combined group. The intensity or seriousness of sore throat
in ARV group is significantly lower than the sore throat intensity among patients in the
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combined group. This shows a consistently better treatment outcome in ARV group when
compared with the combined group.
Research Question 5
The fifth research question for this study was, “What is the difference in the
quality of life of patients taking only ARV, and those taking a combination of herbal
therapies and conventional antiretroviral medications? This study compared the quality of
life between patients taking ARV only (ARV only group) and patients taking
combination of ARV and herbal medications (combined group). This comparison was
done using the WHOQOL-HIV BREF instrument. Results show that there is no
significant difference in the overall quality of life of both groups. This finding is
consistent with findings from Bepe et al. (2011) among Zimbabwean HIV patients.
Similar to this study, Bepe et al.’s (2011) study among Zimbabwean HIV patients
showed that the use of herbal medications concomitantly with ARV did not produce
significant improvement in the quality of life index when compared to patients using only
ARV. Although in this study no significant difference was noted between both groups, a
significant difference was noted in two domains (social relationship and health
satisfaction domains) between the ARV group and combined groups. The health
satisfaction mean scores for ARV group and combined group were 4.1273 and 3.6545
respectively. This signifies that patients in ARV-only group reported significantly better
satisfaction in their health compared to the combined group.
A similar trend was noted in social relationship domain. The social relationship
domain mean scores for ARV group and combined group were 16.2364 and 14.6364
respectively. This signifies that patients using ARV only recorded significantly higher
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improvement in their social relationship compared to patients using a combination of
ARV and herbal medications. It is evident that there is a direct relationship between the
social relationship and health satisfaction domains. It appears that patients with a good
social relationship tend to enjoy better health satisfaction. It could be that the support
from family members, friends, and significant others plays an important role in patients’
perception of wellness, and helps patients to navigate and better cope with diagnosis and
treatment for HIV.
As seen in the findings from research questions 4 and 5, some factors and
domains in the SSC-HIVrev and WHOQOL-HIV BREF revealed that there are
consistently better treatment outcomes in ARV group when compared with the combined
group. The significantly better treatment outcomes noted in the ARV group in the two
domains and factors explained above may translate into better quality of life for patients
in the ARV group. It is doubtful if herbal medications play any significant additive role to
justify impact in the overall quality of life of patients. It appears that the use of herbal
medications play little role in the quality of life of patients when used concomitantly with
ARV. It is important to know if the used of only herbal medications would produce
significant treatment outcomes that is comparable or superior to ARV-only therapy group
or to combined group.
Several studies have shown that the use of herbal remedies only can be effective
in the treatment of HIV (Onifade et al., 2011a; Sangkitporn et al., 2005; Sugimoto et al.,
2005). Among people living with HIV/AIDS in northeastern Thailand, Sugimoto et al.
(2005) reported significantly better mental health scores in patients using herbal
medications than non-users of herbal medications. Onifade et al. (2011a) found that
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herbal therapy with a-Zam was an effective anti-HIV agent resulting in significant
increase in CD4 counts and significant decrease in viral load after treatment with a-Zam
from four months after initiation of herbal therapy. Onifade et al. (2016) reported no
remarkable harmful drug interaction between a-Zam and Highly Active Anti-Retroviral
Therapy (HAART). Another widely used herbal formulation in China, SH, was reported
to be effective in HIV treatment. Each of the five constituents of SH was reported to be
an individually effective anti-HIV agent, and the combined herbs are also reported to
possess anti-retroviral activity (Sangkitporn et al., 2005). Findings from Sangkitporn et
al. (2005) showed that HIV RNA decreased significantly from the baseline value in both
the experimental and control groups from week 4 of treatment. SH group was found to
have a significantly lower HIV RNA compared to the control group. The CD4 counts
after 12 weeks and beyond showed a significant increase in SH group from baseline
value. Sangkitporn et al. (2005) found that a combination of SH herbs with two
nucleoside reverse transcriptase inhibitor has a greater antiviral ability than conventional
antiretroviral medications. It will be interesting to compare treatment outcomes in herbal
only group, ARV only group, and with combined therapy. Like in this study no serious
adverse effect was reported with concomitant use of SH with conventional antiretroviral
medications.
Implications of this Study
This study has provided expanded insight into the treatment outcomes in patients
using different treatment modalities in the management of HIV infection. Although the
use of antiretroviral medications are generally and widely accepted as gold standard for
HIV management, it was seen from this study that a large proportion of HIV patients also
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use herbal medications concomitantly with ARV. While some used herbal medications as
complimentary medications, many reportedly used them as alternatives to conventional
antiretroviral medications. Many patients using herbal mediations reportedly did not
disclose its use to their physicians and care providers for the fear of being refused
treatment by their orthodox physicians and care providers.
Awareness about HIV is very high among Nigerian populace. However, large
scale discrimination and stigmatization are still prevalent, especially in non-official
interactions. There is a large effort on the part of government to provide appropriate
education and reduce stigmatization. However, it appears that the ignorance of the
common people is still largely high. The hyperactive enlightenment program initiated by
governmental and private agencies at the beginning of HIV epidemic in the early 90s
seems to be now dormant. This is mainly because of the perceived belief that people are
now well informed about the disease. The fight against HIV needs to be sustained at all
levels of Nigerian social classes/strata.
Equally important is the level of funding directed toward treatment, counseling
and education of HIV. Nigeria as a country relies heavily on foreign sponsorship and
donations in the war against HIV. Nigeria, being one of the largest economies in Africa,
needs to show more commitment in taking control of its future and channel more of its
own resources towards education and eradication of HIV. Indigenous researchers and
scientists should be supported to devote their energies to fighting and finding a cure for
HIV. Various claims of HIV cure that are rampant in Nigeria need to be scientifically
investigated to protect the innocent citizen from depending on and patronizing ineffective
treatment modalities. It is obvious that the patronage of non-conventional medications is
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very high in Nigeria. The current over reliance on foreign governments and donors
cannot be to the best advantage of the Nigerian nation.
The aim of this study was to compare treatment outcomes in two groups of
patients that were taking ARV only and those that were taking a combined therapy of
ARV and herbal medications. Findings from this study have implications in nursing
practice, research and education.
Nursing Practice
It is important to note that during data collection for this study that all the subjects
in the combined group verbalized a desire not to disclose their dual therapy to their
caregivers. Patients only disclosed that they were taking herbal medications after the
researcher had gained their confidence and assured that confidentiality of subjects’
information would be protected and would not be disclosed to individuals outside the
study group. However, the researchers strongly advised and counselled subjects to
disclose their dual therapy to their caregivers so that they could be adequately cared for.
Most of the subjects verbalized the fear that their caregivers would not take care of them
if they disclose that they were taking herbal medications. Similarly, many of the subjects
did not disclose their HIV status to their spouses and family members for the fear of
rejection. In nursing practice it is important that nurses establish a professional and
trusting relationship with patients so that patients can confide in them and disclose
treatment information that is necessary for better outcome. Knowledge of this
information will enable nurses and physicians to consider possible side effects and
interactions that could occur between the conventional ARV and herbal remedies. Nondisclosure of HIV status to spouses and significant others is a very big problem. In
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practice, nursing staff could play an important role in providing sufficient education,
encouragement, and support to HIV patients and facilitate voluntary disclosure of status
by the patients to their loved ones. Knowledge gained from this study should guide
nurses in professional interactions with patients. Nurses should specifically ask about
dual therapy, and holistically look into issues relating to disclosure of HIV status.
Nursing Research
Through this study a comparative analysis of two different treatment methods,
ARV-only therapy and combined therapy, was carried out. This study is a precursor to
other new nursing research on HIV treatment modalities. This study did not investigate
the lived experience of HIV patients during the course of treatment with either ARV only
or with a combination of ARV and herbal medications. Since nursing is essentially a
caring and nurturing profession, nursing concentrates on holistic care. As a result of this,
nursing care tends to foster healthy, nurturing and therapeutic relationship with patients.
Findings from this study show that there was a disconnect between the patients and their
care providers, at least in the population under investigation. This disconnection is
apparent in the patients’ non-disclosure of their dual therapy. All subjects that were
taking a combination of ARV and herbal medications reported non-disclosure of the use
of herbal medications to their care providers. Nursing should be at the fore front of
empirical research into reasons behind non-disclosure by carrying out studies to
understand the different methods and approaches that could be used to foster trusting
relationships between patients and their care providers. The profession of nursing is
fundamentally equipped to investigate this essential phenomenon.
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In the course of recruitment for this study, it was discovered that many patients
were using only herbal medications to treat HIV. This situation is very dire, as the
effectiveness of only herbal therapy in the treatment of HIV is still not widely reported.
This has great implications in nursing research. Nursing research need to focus
investigation on the lived experience of HIV patients using herbal medications only. The
use of qualitative methodology in the investigation of the experience of this group would
provide valuable insight. This could enable us to gain a rich understanding of the reasons
for using herbal medications. It will enable us to investigate the impacts of herbal therapy
on HIV. This will help our understanding of the perception of patients in this group on
their quality of life and on their symptom modifications.
Nursing Education
Evidence-based practice (EBP) is a cornerstone of nursing education. The focus
of nursing education in the 21st century is to promote and incorporate evidence-based
research findings into education. Transformation of practice environment is only possible
when quality research findings are incorporated into education of nursing students and
also into continuous in-service education of qualified nurses. Nursing education needs to
emphasize the role of nursing in building therapeutic and trusting relationships with
patients. The disconnection and distrust noted between patients in the combined group
and the care providers could be prevented if the nursing staff in the hospital used their
professional skills to foster trusting relationship with the patients in this group. With
appropriate evidence-based practice, nurses could develop efficient pragmatic approaches
to nursing care.
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Strengths of this Study
This study was meticulously designed to ensure strict adherence to ethical issues.
Patients’ confidentiality was maintained and protected throughout the duration of this
study. No subjects’ identifiable data were collected or stored in any research documents.
While this study possesses no direct risk to patients’ physical health, it is possible that
psychological and mental trauma may result if confidentiality of patients’ information is
breached. Only a randomly assigned patient number was used in all research documents.
No recording or videotaping was used during this study. Patient information was
electronically stored in a password-protected computer system. All paper copies were
stored under lock and key in a fireproof cabinet. The paper copies were shredded after
information was stored electronically.
Each subject was given extensive explanation about the study. Subjects were
given the opportunity to ask questions. Patients’ were given full disclosure of possible
risks associated with the study. In addition to obtaining informed consent from each
patient, a continuous re-negotiation of consent was maintained through process consent.
This provided opportunity to provide continuous clarification and opportunity for
questions. Process consent provided the opportunity for subjects to discontinue
participation from the study at any time should they choose to do so.
Particular attention was paid to trustworthiness of data obtained from this study.
The strength of the funding of this study is a function of the reliability of the study
instruments. Instruments used for data collection were carefully selected to achieve high
quality data. Two extensively used and well-tested instruments were used for data
collection. The SSC-HIVrev was developed by renowned nurse scientists while the
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WHOQOL-HIV BREF was developed by a group of reputable experts from World
Health Organization (WHO). The two instruments used for data collection have been
confirmed to have high reliability and validity. In spite of the documented reliability of
these instruments, a pilot study was done at the beginning of this study. The pilot study
was carried out prior to the main study to measure the Cronbach alpha reliability and face
validity of the study instruments. The two instruments were found to be highly reliable in
the population of study. Also, face validity of the instruments was determined by the
researcher, and both instruments were considered to have high validity and high
reliability. This high reliability was obtained even with the omission of the weight factor
from the SSC-HIVrev instrument.
The differences noted in baseline CD4 counts between ARV group and combined
group were statistically adjusted and controlled using analysis of covariance (ANCOVA).
ANCOVA statistically controlled the effect of continuous variables that are not of
primary interest in this study. The use of ANCOVA helped to statistically adjust and
control the differences noted in baseline CD4 counts between the two groups before
comparative analyses of the two groups were done.
The source of data used in this study was considered to be an important
determinant of data quality. Hence, only data obtained from credible, verifiable sources
was used in this study. The source of CD4 counts could be a potential source of
confounding variable. Patients’ CD4 counts could be obtained from different sources or
directly from the patients. However, to ensure credible data, only CD4 counts obtained
directly from patients’ medical records were used in this study. CD4 count records given
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by the patients were not used. This approach ensured that only quality and credible data
sets were used for this study.
In selecting a sample for this study, a random assignment technique was used.
Sampling was done randomly from matched subjects that are similar in terms of
important extraneous variables. Randomization eliminated the sources of bias in the
treatment, enhanced the external validity of the study finding, and ensured
representativeness of sampling. This enhanced the generalizability of the study findings
to the larger Nigerian population. The matching of samples for important extraneous
variables helped to eliminate confounding variables that could adversely affect study
findings. The study design and implementation, analytical procedure and reporting
process for this study followed a high standard expected of sound scientific study.

Limitations of this Study
This study was initially designed to have three groups namely;
➢ Group A: Participants were to be drawn from patients who were using only herbal
therapies for their treatment.
➢ Group B: Participants were to be drawn from patients who were using only
conventional antiretroviral medications.
➢ Group C: Participants were to be drawn from patients who were using a
combination of herbal therapies and conventional antiretroviral medications for
their treatment.
It was presumed that the inclusion of herbal group only would help the researcher
to determine the impact of using only herbal medications on HIV treatment outcome and
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to evaluate the efficacy of herbal therapy only. However, recruitment of subjects into this
group was very difficult, as it was hampered by multiple factors. The first major factor
was the stigmatization associated with HIV in Nigeria. During recruitment efforts for this
group, it was found that patients using only herbal medications were trying to hide their
status by not seeking treatment in conventional HIV clinics and hospitals. The second
factor that hampered recruitment efforts for this group was the condition that needed to
be met before recruitment into this group. Recruitment for this group could only be done
if the researcher committed to funding the cost of herbal treatment for patients in this
group. The budget for this study could not fund such treatment. Also, ethical issues may
arise as a result of this undertaking, as it may appear that the researcher influenced the
treatment choice of the patients. This study was designed to study treatment outcomes in
patients already receiving a specific treatment but not to influence patients’ treatment
choice. The inability to enroll into this group was a very important deviation from the
initial plan of this research. It is the hope of this researcher that future studies will
compare treatment outcomes in these three groups.
Also, this study was initially designed to use CD4 counts and viral load as
biomarkers of physiological treatment outcomes. However, the state specialist hospital
has no viral load records for any of the patients receiving treatment in the hospital. In
fact, viral load was not available in many clinics contacted in Nigeria. The only available
option for getting patients’ viral load was for the researcher to fund the test. However,
this study lacked the funding for such an expensive laboratory test. Information about
viral load could, in conjunction with CD4 counts, help determine the efficacy of different
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treatment options. It is important that future studies should obtain viral load in addition to
CD4 counts.
HIV infection is a debilitating health problem that requires holistic treatment
approach. It is important to evaluate the lived experience of Nigerian HIV patient in the
course of their daily life and treatment regime. This study did not investigate the lived
experience of the patients during their treatment regimens. It is recommended that future
studies should employ qualitative methods to evaluate the lived experience of HIV
patients during the course of their different treatments. In spite of the identified
limitations of this study, the study provided findings that could shape future studies and
improve treatment and care of HIV patients.
Recommendations
This study is considered to be the beginning of exploration of the vast area of
herbal therapy in the treatment of HIV. Further studies are necessary to provide expanded
insight into the use of herbal remedies in HIV treatment. Similarly, further study is
necessary to evaluate and compare different HIV treatment protocols. This study was
unable to recruit and enroll sufficient number of patients taking herbal medications only.
However, a lesson learned from the recruitment efforts for this group revealed that
patients in this group could easily be enrolled into future studies if the researcher could
provide partial or full funding of herbal treatment. Because of insufficient funds and
possible ethical issues, this researcher was unable to enroll patients taking herbal
medications only. It is therefore recommended that future studies should focus on
comparing treatment outcomes in those patients taking ARV only, herbal medications
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only and combined therapy. Findings from these studies would enable us to determine
and compare efficacy of these treatment protocols.
Similarly, there is a need to evaluate the lived experience of patients in each
treatment group. It is recommended that future studies explore qualitative methods to
investigate the lived experience of patients receiving ARV only, combined therapy and
herbal medications only. The use of qualitative methodology will show the richness of
the experiences of individuals during the course of their respective therapies.
Findings from this study show that stigmatization is still very high in Nigeria. The
quality of life of HIV patients is a function of social factors such as stigmatization. The
quality of life of HIV patients could be better enhanced if stigmatization attached to HIV
is adequately addressed. Efforts should be increased by the government and other
stakeholders to reduce stigmatization of HIV patients. To prevent targeting of HIV
patients, efforts should be made to provide privacy for patients during treatment. This
will make it possible for HIV patients to be cared for without compromising patients’
identity. There should be an interplay of community action and political initiatives to
combat stigmatization and foster acceptance of HIV patients.
Also, this study was initially designed to use CD4 counts and viral load as
biomarkers of physiological treatment outcomes. However, records of viral loads of
patients were not available in the State Specialist Hospital. As a result of this, the study
could not compare the viral load of patients in each group. It is recommended that future
studies should use both CD4 counts and viral load as biomarkers of physiological
treatment outcomes.
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A frightening trend was noted during this study. Finding from this study show that
majority of people seeking treatment were disproportionately female, low-income earners
and poor individuals. The question that arises is “Where are the men of affluence and
elites seeking treatment?” Since HIV infection cut across social strata, it is important that
educational efforts be designed to target Nigerian elites and the well-to-do members of
the society. This will prevent a public health epidemic. In light of Smith’s (2007)
assertion that sexual and economic disparities and contradictory moralities could
contribute to HIV epidemic in Nigeria, Nigerian male populations need to be encouraged
to seek testing and treatment for HIV. Any strategic efforts to combat the spread of HIV
that exclude this group of Nigerians might be counterproductive because of their social
power to negotiate sexual relationship with the poor members of the society. It is
expected that future studies will look into ways and strategies to bring many well-to-do
Nigerians into testing and treatment in conventional clinics and hospitals.
Findings from this study revealed that100% of the participants did not disclose
use of herbal medication to their primary physicians and care providers. Reasons given
for non-disclosure include fear of being refused treatment, admonition by their
physicians, and fear of incurring their displeasure. This disconnection and lack of
disclosure could affect the overall health outcome of patients. Physicians and care
providers need to have the totality of information needed to efficiently care for the
patients. Also, there is a possibility of cross-reaction or possible interaction between the
ARV and herbal medications that physicians might not be aware of. It is recommended
that future studies look into strategic interventions and approaches that could foster trust
and enhance disclosure on the part of the patients.
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A trend similar to the above was also seen to be prevalent among many of the
subjects of this study. It was found that majority of the patients did not disclose their HIV
status to their spouses and loved ones. Reasons for non-disclosure include fear of
rejection by their spouses and family members, fear of ostracization by the community
and consequences of stigmatization. It is very sad to imagine the difficulty of facing HIV
infection without the support of loved ones. Efforts need to be increased to encourage
disclosure of HIV status to family members, especially to spouses of HIV patients. The
patients need to be empowered to make the disclosure and there should be a continuous
system to support patients and families throughout their journey. Extensive efforts and
resources have been deployed toward HIV education. However, efforts should be
increased to provide more education for the general public. Stigmatization stems from
lack of education about HIV. Our generation needs to defeat HIV. However, nondisclosure of HIV status to spouses will only take our generation further away from
effective prevention of the disease. Health care providers need to encourage patients to
disclose status to their partners and family members. It is also recommended that nurse
scientists and researchers investigate methods and approaches that can foster disclosure
of status without jeopardizing the right, confidentiality, and wellbeing of the patients.
There is documented evidence of the efficacy of herbal medications in the
treatment of HIV. However, there are many herbal medications with a similarly large
number of claims of efficacy. Scientific efforts should be directed at investigating the
potency and efficacy of different herbal medications. Specifically, herbal medications
should be isolated and the safety and efficacy of each medication should be evaluated. It
is also necessary to thoroughly investigate the pharmacodynamics and pharmacokinetics
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of each herbal medication. This way, only herbal medications that can withstand sound
scientific scrutiny will be available for patients’ use.
Conclusion
This study has provided expanded insight and understanding into the treatment
outcome during HIV treatment with different protocols. The study compared the
treatment outcomes in patients using only ARV and patients using a combined therapy of
ARV and herbal medications. CD4 count was used as a biomarker of treatment outcome
in the two groups. Outcome comparison was also done using quality of life index and
symptom experience. Two highly reliable and well-tested instruments were used to
evaluate patients’ quality of life and symptom improvement. In spite of the high quality
of this study, it has its limitations as described above.
This study has enriched our understanding of the treatment outcomes in patients
using only ARV and patients using a combination of ARV and herbal medications. The
study has revealed salient points and issues that require further exploration and
appropriate interventions. Findings from this study have shown that a vast majority of
patients on combined therapy do so without disclosing the use of herbal remedies to their
physicians and care providers. It is expected that physicians and care providers would
incorporate this knowledge into their care model, build trusting and supportive
relationships with patients and specifically solicit information about the use of herbal
therapy in combination with ARV. This knowledge will enable physicians, nurses and
other care providers to explore possible side effects and cross reactions between ARV
and herbal remedies. Since herbal therapies are widely used in Sub-Saharan Africa and
since access to ARV is still largely and comparatively difficult, further studies need to be
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done, particularly in the group of patients using herbal remedies only. Incorporation of
this group in future comparative study would enable researchers and scientists to
determine the efficacy of herbal medications in comparison to ARV only and combined
therapy.
It is important that the Nigerian government and all other stakeholders negotiate
social policies to empower the female population and enhance the ability of Nigerian
females to negotiate social relationships. Health care professionals, especially nurses
should play pivotal roles in empowering Nigerian females with education and resources
to engage in safe sexual relationships. Extensive education and support systems should be
given to HIV patients to facilitate voluntary disclosure of their HIV status to their spouses
and family members. Such support systems and education should be sustained and
extended to family members of HIV patients after disclosure is made to them. Universal
acceptance, reduced stigmatization, and continuous therapeutic support are important
factors that can impact positively on the quality of life of HIV patients.
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APPENDICES
APPENDIX A
SIGN AND SYMPTOM CHECK-LIST FOR PERSONS WITH HIV DISEASE
(SSC-HIVrev)
Below is a list of potential problems that you may experience today. If you have
the problem, rate the degree of INTENSITY that best describe the extent of the problem.
If you do not have the problem, do not check a box.

INTENSITY
Mild
Moderate
FATIGUE
____
_____
____
_____
____
_____
____
_____
FEAR
____
_____
____
_____
____
_____
____
_____
FEVER
____
_____
____
_____
____
_____
____
_____
GI UPSET
____
_____
____
_____
____
_____
____
_____
____
_____
____
_____
SOB
____
_____
____
_____
____
_____
SORE THROAT
____
_____
____
_____

Severe

Problem

_____
_____
_____
_____

Muscle aches
Weakness
Painful joint
Fatigue

_____
_____
_____
_____

Difficulty Concentrating
Depression
Memory loss
Fear/worries

_____
_____
_____
_____

Fever
Chills
Day sweats
Night sweats

_____
_____
_____
_____
_____
_____

loose stools
Diarrhea
Gas/bloating
Abdominal pain
Nausea
Vomiting

_____
_____
_____

Shortness of breath at rest
Wheezing
Shortness of breath with activity

_____
_____

Sore throat
Painful swallowing
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____
_____
_____
____
_____
_____
NUMBNESS
____
_____
_____
____
_____
_____
____
_____
_____
____
_____
_____
HEADACHE
____
_____
_____
____
_____
_____
____
_____
_____
____
_____
_____
RECTAL ITCH
____
_____
_____
____
_____
_____
____
_____
_____
BRUISING/BLEEDING
____
_____
_____
____
_____
_____
____
_____
_____
____
_____
_____
Items that did not load on factor scores
____
_____
_____
____
_____
_____

Mouth ulcers
White spots in mouth/thrush

____
____
____

_____
_____
_____

_____
_____
_____

Dry mouth
Thirst
Coughing

____
____
____
____

_____
_____
_____
_____

_____
_____
_____
_____

Lack of appetite
Constipation
Concern over weight loss
Flushing

____
____

_____
_____

_____
_____

Rash
Itchy skin

____
____
____
____

_____
_____
_____
_____

_____
_____
_____
_____

Insomnia/can’t sleep
Anxious
Blurred vision
Seizure/tremors

____
____
____
____

_____
_____
_____
_____

_____
_____
_____
_____

Nipple discharge
Breast pain/changes
Sores or lumps on genitals
Burning with urination
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Numbness/tingling of arms
Numbness/tingling of hands/fingers
Numbness/tingling of legs
Numbness/tingling of feet/toes
Dizziness
Headache
Heart racing
Chest pain
Rectal Itching
Rectal bleeding
Rectal discharge
Sore/bleeding gums
Nose bleeds
Easy bruising
Blood in spit/sputum
Swollen glands
Swollen feet

GYN-RELATED PROBLEMS
For women only
____
_____
____
_____
____
_____
____
_____
____
_____
____
_____
____
_____
____
_____

_____
_____
_____
_____
_____
_____
_____
_____

Vaginal discharge
Irregular period
Heavy period
Bad cramps
Vaginal itching
Vaginal odor
Bleeding between periods
Pelvic pain

SCORING:
1. Scaling: 0= not present today; 1= mild; 2= moderate; 3= severe
2. Factor scores: Sum the item scores (0-3) for each item in a factor and divided by
the number of items.
3. Total score: Sum the item scores (0-3) for each of the 45 items from the factor
scores.
Sources: Holzemer, W.L., Hudson, A., Kirksey, K.M., Hamilton, M.J., & Bakken, S.
(2001).
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APPENDIX B
DEMOGRAPHIC QUESTIONNAIRE
Check the appropriate box
Age
18-19 ______
35-39 ______
>54 ______

20-24 _______
40-44 _______

25-29 _______
45-49 _______

30-34 ______
50-54 ______

Gender
Male ______

Female _______

Ethnicity
Yoruba _______
Ijaw
_______

Hausa _______
Igbo ______ Tiv/Idoma _______
Others _______ (Please specify)

Religion
Christain ________ Muslim ________
Others __________ (Please, specify)

Traditionalist ________

Marital Status
Single ______
Married Polygamous _________
Living with a partner _________

Married Monogamous ________
Divorced/Separated __________

Education
None _______
Some High School ________
Some College ____________
Graduate ________________

Elementary ________
High School ________
College_____________

Employment
Full-time ________
Part-time ________
Retired _________
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Income Level
Which annual income bracket best describes your household?
>N1,200,000
_______
N1,000,000 to less than N1,200,000
_______
N9000,000 to less than N1,000,000
_______
N800,000 to less than N900,000
_______
N700,000 to less than N800,000
_______
N600,000 to less than N700,000
_______
N500,000 to less than N600,000
_______
N400,000 to less than N500,000
_______
N300,000 to less than N400,000
_______
N200,000 to less than N300,000
_______
N100,000 to less than N200,000
_______
N37,000 to less than N100,000
_______
0 to less than N370,000
_______
HIV Medication
Do you take antiretroviral Medications?
Yes______ No _______
Do you take herbal medication?
Yes_______ (Please list all herbal medications including vitamins)
No _______

Adapted from Sunmola, A. (2005). Sexual practices, barriers to condom use and its
consistent use among long distance truck drivers in Nigeria. AIDS Care, 17(2), 208-221.
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APPENDIX C
WHOQOL-HIV BREF INSTRUMENT
ABOUT YOU
Before you begin we would like to ask you to answer a few general questions about
yourself: by circling the correct answer of by filling in the space provided.
What is your gender
How old are you? (age in years)
What is the highest education you received?

Male / Female
_____________
None at all / Primary /
Secondary /
University/Postgraduate
Single/ Married/ Living as
married/
Separated/
Divorced/Widowed

What is your marital status?

How is your health? (G1.2)
Very poor
good
1

Poor

Neither poor nor good

2

3

Do you consider yourself currently ill?
If something is wrong with your health what do you think it
is?___________________________

Good
4

Very
5

Yes / No

Please respond to the following questions if they are applicable to you:
What is your HIV serostatus? Asymptomatic / Symptomatic / AIDS converted
In what year did you first test positive for HIV? _____________________________________
In what year do you think you were infected? _____________________________________
How do you believe you were infected with HIV? (circle one only):
Sex with a man / Sex with a woman / Injecting drugs / Blood products / Other (specify)

Instructions
This assessment asks how you feel about your quality of life, health, or other areas of
your life. Please, answer all the questions. If you are unsure about which response to
give to a question, please choose the one that appears most appropriate. This can often
be your first response. Please keep in mind your standards, hopes, pleasures and
concerns. We ask that you think about your life in the last two weeks. For example,
thinking about the last two weeks, a question might ask:
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How well are you able to concentrate?

Not at
all

A little

A
moderate
amount

Very
much

Extremely

1

2

3

4

5

You should circle the number that best fits how well are you able to concentrate over the
last two weeks. So you would circle the number 4 if you were able to concentrate very
much. You would circle number 1 if you were not able to concentrate at all in the last two
weeks.
Please read each question, assess your feelings, and circle the number on the scale
for each question that gives the best answer for you.
Very poor

Poor

Neither poor
nor

Good

Very
good

good
1(G1) How would you rate your
quality of life?

2(G4) How satisfied are you with
your health?

1

2

3

4

5

Very
dissatisfied

Dissatisfied

Neither
satisfied nor
dissatisfied

Satisfied

Very
satisfied

1

2

3

4

5

The following questions ask about how much you have experienced certain things in the
last two weeks.
Not at all
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A little

A moderate
Amount

Very
much

An
extreme
amount

3(F1.4)

To what extent do you feel
that physical pain prevents
you from doing what you
need to do?

1

2

3

4

5

4(F1.4)

How much are you bothered
by any physical problems
related to your HIV
infection?

1

2

3

4

5

5(F1.4)

How much do you need any
medical treatment to
function in your daily life?

1

2

3

4

5

6(F1.4)

How much do you enjoy
life?

1

2

3

4

5

7(F1.4)

To what extent do you feel
your life to be meaningful?

1

2

3

4

5

8(F1.4)

What extent are you
bothered by people blaming
you for your HIV status?

1

2

3

4

5

9(F1.4)

How much do you fear the
future?

1

2

3

4

5

10(F1.4)

How much do you worry
about death?

1

2

3

4

5

Not at all

A little

A moderate
Amount

Very
much

An
extreme
amount

1

2

3

4

5

11(F5.3)

How well are you able to
concentrate??
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12(F16.1)

How safe do you feel in
your daily life?

1

2

3

4

5

13(F22.1)

How healthy is your
physical environment?

1

2

3

4

5

The following questions ask about how completely you experience or were able to do
certain things in the last two weeks.

Not at all

A little

Moderately

Mostly

Completely

14(F2.1)

Do you have enough
energy for everyday life?

1

2

3

4

5

15(F7.1)

Are you able to accept your 1
bodily appearance?

2

3

4

5

16(F18.1)

Have you enough money to 1
meet your needs?

2

3

4

5

17(F51.1)

To what extent do you feel
accepted by the people you
know?

1

2

3

4

5

18(F20.1)

How available to you is the
information that you need
in your day-to-day life?

1

2

3

4

5

19(F21.1)

To what extent do you
have the opportunity for
leisure activities?

1

2

3

4

5

Not at all

A little

Moderately

Mostly

Completely
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20(F9.1)

How well are you able to
get around?

1

2

3

4

5

The following questions ask you how good or satisfied you have felt about various
aspects of your life over the last two weeks.

Very
dissatisfied

Dissatisfied

Neither
satisfied nor
dissatisfied

satisfied

Very
satisfied

21(F3.3)

How satisfied are you with
your sleep?

1

2

3

4

5

22(F10.3)

How satisfied are you with
your ability to perform
your daily living activities?

1

2

3

4

5

23(F12.4)

How satisfied are you with
your capacity for work?

1

2

3

4

5

24(F6.3)

How satisfied are you with
yourself?

1

2

3

4

5

25(F13.3)

How satisfied are you with
your personal
relationships?

1

2

3

4

5

26(F15.3)

How satisfied are you with
your sex life?

1

2

3

4

5

27(F14.4)

How satisfied are you with
the support you get from
your friends?

1

2

3

4

5

28(F17.3)

How satisfied are you with
the conditions of your
living place?

1

2

3

4

5
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29(19.3)

How satisfied are you with
your access to health
services?

1

2

3

4

5

30(F23.3)

How satisfied are you with
your transport

1

2

3

4

5

The following question refers to how often you have felt or experienced certain things in
the last two weeks

31(F8.1)

How often do you have
negative feelings such as
blue mood, despair, anxiety,
depression?

Never

Seldom

Quite often

Very
often

Always

1

2

3

4

5

Did someone help you to fill out this form?___________________________________
How long did it take to fill this form out? _____________________________________
Do you have any comments about the questionnaire?
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
THANK YOU FOR YOUR TIME AND HELP

Source: (WHO, 2012). Retrieved from
http://www.who.int/mental_health/publications/whoqol_hiv_bref.pdf
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